Conditions: COVID-19
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 104
Healthy volunteers: no

Brief summary:
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.

Detailed description:

Arms:
arm 1: Participants will receive AT-527-matched placebo twice a day (BID) on Days 1-5. arm 2: Participants will receive 550 mg AT-527 (1x550 mg) twice a day (BID) on Days 1-5. arm 3: Participants will receive 1100 mg AT-527 (4x275 mg) twice a day (BID) on Days 1-5.

Interventions: intervention 1: AT-527 intervention 2: Placebo
Intervention descriptions: intervention 1: Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg. intervention 2: The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.

Protocol document:
Prot_000.pdf: 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
2/Protocol WV43042, Version 6
PROTOCOL HISTORY
Protocol
Associated Country-Specific Protocol
Version
Date Final
Country
Version
Date Final
6
See electronic date 
stamp on the title page



5
13 May 2021



4
24 February 2021
Ireland
5
21 April 2021
2
10 December 2020
Ireland
3
5 February 2021
1
23 November 2020





RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
3/Protocol WV43042, Version 6
PROTOCOL AMENDMENT, VERSION 6:
RATIONALE
Protocol WV43042 has been amended primarily to enable further evaluation of the 
antiviral efficacy and safety of RO7496998 (AT-527) using the dose regimen selected 
from previous cohorts. Changes to the protocol, along with a rationale for each change, 
are summarized below:

In order to perform this evaluation Cohort E has been modified to increase
enrollment and the Day 14 telephone visit has been changed to an in-person visit to 
allow for a nasopharyngeal swab to be collected. Relevant changes have been 
incorporated throughout the protocol including an updated statistical analysis and a 
cohort specific schedule of activities (Sections 3.1, 3.2, 4.1, 4.2.1, 4.3.1.1, 6 ,
Figure 1, and Appendix 3)
Additionally, the following changes have been incorporated

Additional background has been provided regarding the need for COVID-19 
treatment options despite new therapies and availability of vaccines (Section 1.1, 
3.3.2, 3.3.3).

New data from the ongoing Phase 1 and Phase 2 studies have been added and the 
rationales for dose regimen and patient population have been updated accordingly 
(Sections 1.2, 1.3, 3.3.1.1 , 3.3.1.2, 3.3.2, 5.1.1, and 6)

A new secondary efficacy endpoint has been added to evaluate the frequency of all 
cause hospitalizations and death to capture these important outcomes of COVID-19 
(Sections 2 and 6.4.2).

Based on the data from the most recent drugdrug interaction studies the 
requirement to supplement hormonal contraceptive methods with a barrier method 
has been removed (Section 4.1.1).

It has been clarified that the pregnancy test at screening may be performed from 
urine or serum sample (Sections 4.1.2, 4.5.5, Appendices 13)

It has been clarified that the Cockcroft-Gault formula will be used to calculate 
creatine clearance as this is standard practice (Sections 4.1.2, 4.5.5, 
Appendices 13)

The reference to the introduction of the 275 mg tablets after an approved IMPD has 
been deleted from Section 4.3.1.1 as an IMPD for this formulation has now been 
approved and the 275 mg has been introduced.

It has been clarified that paracetamol and non-steroidal anti-inflammatory drugs 
taken for other reasons other than for COVID-19 symptoms are permitted 
(Section 4.4.1) 

The cautionary and prohibited therapy sections have been updated with data from 
recently completed drugdrug interaction studies (Sections 4.4.2, 4.4.3, and 
Appendix 6).  


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
4/Protocol WV43042, Version 6
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics [note: italics not used in Figure 1 or 
Appendix 3 for readability].  This amendment represents cumulative changes to the 
original protocol.




RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
6/Protocol WV43042, Version 6
4.3.2
Study Treatment Dosage, Administration, and 
Compliance............................................................................ 40
4.3.3
Investigational Medicinal Product Handling and 
Accountability ........................................................................ 41
4.3.4
Continued Access to AT-527................................................. 42
4.4
Concomitant Therapy ............................................................ 42
4.4.1
Permitted Therapy................................................................. 42
4.4.2
Cautionary Therapy ............................................................... 42
4.4.2.1
Herbal Therapies ................................................................... 42
4.4.2.2
Effects of Co-administered Therapies on AT-511 
and Metabolites ..................................................................... 42
4.4.2.3
Effects of AT-511 on Co-administered Therapies .................. 43
4.4.3
Prohibited Therapy ................................................................ 43
4.5
Study Assessments ............................................................... 44
4.5.1
Informed Consent Forms and Screening Log........................ 44
4.5.2
Medical History, Baseline Conditions, 
Concomitant Medication, and Demographic Data ................. 44
4.5.3
Physical Examinations........................................................... 45
4.5.4
Vital Signs.............................................................................. 45
4.5.5
Laboratory, Biomarker, and Other Biological 
Samples................................................................................. 45
4.5.6
Electrocardiograms................................................................ 47
4.5.7
Clinical Outcome Assessments ............................................. 48
4.5.7.1
Data Collection Methods for Clinical Outcome 
Assessments ......................................................................... 48
4.5.7.2
Description of Clinical Outcome Assessment 
Instruments............................................................................ 48
4.5.8
Optional Blood Samples for Whole Genome 
Sequencing (Patients at Participating Sites).......................... 49
4.6
Treatment, Patient, Study, and Site 
Discontinuation...................................................................... 50
4.6.1
Study Treatment Discontinuation........................................... 50
4.6.2
Patient Discontinuation from the Study.................................. 50
4.6.3
Study Discontinuation............................................................ 51
4.6.4
Site Discontinuation............................................................... 51


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
7/Protocol WV43042, Version 6
5.
ASSESSMENT OF SAFETY....................................................................... 51
5.1
Safety Plan ............................................................................ 51
5.1.1
Risks Associated with AT-527 ............................................... 52
5.1.2
Management of Patients Who Experience 
Adverse Events ..................................................................... 53
5.1.2.1
Dose Modifications ................................................................ 53
5.1.2.2
Treatment Interruption ........................................................... 53
5.1.2.3
Management of Increases in QT Interval............................... 53
5.2
Safety Parameters and Definitions ........................................ 53
5.2.1
Adverse Events ..................................................................... 53
5.2.2
Serious Adverse Events (Immediately Reportable 
to the Sponsor)...................................................................... 54
5.2.3
Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor).................................................... 55
5.3
Methods and Timing for Capturing and 
Assessing Safety Parameters................................................ 55
5.3.1
Adverse Event Reporting Period ........................................... 55
5.3.2
Eliciting Adverse Event Information....................................... 56
5.3.3
Assessment of Severity of Adverse Events ........................... 56
5.3.4
Assessment of Causality of Adverse Events ......................... 57
5.3.5
Procedures for Recording Adverse Events............................ 57
5.3.5.1
Diagnosis versus Signs and Symptoms................................. 57
5.3.5.2
Adverse Events that Are Secondary to Other 
Events.................................................................................... 58
5.3.5.3
Persistent or Recurrent Adverse Events................................ 58
5.3.5.4
Abnormal Laboratory Values ................................................. 59
5.3.5.5
Abnormal Vital Sign Values ................................................... 59
5.3.5.6
Abnormal Liver Function Tests.............................................. 60
5.3.5.7
Deaths ................................................................................... 60
5.3.5.8
Preexisting Medical Conditions.............................................. 61
5.3.5.9
Lack of Efficacy or Worsening of COVID-19.......................... 61
5.3.5.10
Hospitalization or Prolonged Hospitalization.......................... 61
5.3.5.11
Cases of Overdose, Medication Error, Drug 
Abuse, or Drug Misuse .......................................................... 62
5.3.5.12
Patient-Reported Outcome Data ........................................... 64


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
8/Protocol WV43042, Version 6
5.4
Immediate Reporting Requirements from 
Investigator to Sponsor.......................................................... 64
5.4.1
Medical Monitors and Emergency Medical 
Contacts ................................................................................ 64
5.4.2
Reporting Requirements for Serious Adverse 
Events and Adverse Events of Special Interest..................... 65
5.4.2.1
Events That Occur prior to Study Drug Initiation.................... 65
5.4.2.2
Events That Occur after Study Drug Initiation........................ 65
5.4.3
Reporting Requirements for Pregnancies.............................. 65
5.4.3.1
Pregnancies in Female Patients............................................ 65
5.4.3.2
Abortions ............................................................................... 66
5.4.3.3
Congenital Anomalies/Birth Defects ...................................... 66
5.5
Follow-Up of Patients after Adverse Events .......................... 66
5.5.1
Investigator Follow-Up........................................................... 66
5.5.2
Sponsor Follow-Up ................................................................ 67
5.6
Adverse Events That Occur after the Adverse 
Event Reporting Period.......................................................... 67
5.7
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, 
and Ethics Committees.......................................................... 67
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN....................... 68
6.1
Determination of Sample Size ............................................... 69
6.2
Summaries of Conduct of Study............................................ 69
6.3
Summaries of Demographic and Baseline 
Characteristics....................................................................... 69
6.4
Virology and Efficacy Analyses.............................................. 70
6.4.1
Primary Virology Endpoint ..................................................... 70
6.4.2
Secondary Virology and Efficacy Endpoints .......................... 71
6.4.2.1
Secondary Virology Endpoints............................................... 71
6.4.2.2
Secondary Efficacy Endpoints............................................... 71
6.4.3
Exploratory Virology Endpoints.............................................. 73
6.4.4
Exploratory Patient Global Impression of Severity 
Endpoint ................................................................................ 73
6.5
Safety Analyses..................................................................... 73
6.6
Pharmacokinetic Analyses..................................................... 74


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
9/Protocol WV43042, Version 6
6.7
Biomarker Analyses............................................................... 75
6.8
Interim Analyses .................................................................... 75
6.8.1
Planned Interim Analyses...................................................... 75
6.8.2
Optional Interim Analysis....................................................... 75
7.
DATA COLLECTION AND MANAGEMENT ............................................... 75
7.1
Data Quality Assurance......................................................... 75
7.2
Electronic Case Report Forms............................................... 76
7.3
Source Data Documentation.................................................. 76
7.4
Use of Computerized Systems .............................................. 77
7.5
Retention of Records............................................................. 77
8.
ETHICAL CONSIDERATIONS.................................................................... 77
8.1
Compliance with Laws and Regulations ................................ 77
8.2
Informed Consent.................................................................. 78
8.3
Institutional Review Board or Ethics Committee.................... 79
8.4
Confidentiality........................................................................ 79
8.5
Financial Disclosure .............................................................. 80
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ..................................................................................... 80
9.1
Study Documentation ............................................................ 80
9.2
Protocol Deviations................................................................ 80
9.3
Management of Study Quality ............................................... 80
9.4
Site Inspections ..................................................................... 81
9.5
Administrative Structure......................................................... 81
9.6
Dissemination of Data and Protection of Trade 
Secrets .................................................................................. 81
9.7
Protocol Amendments ........................................................... 82
10. REFERENCES ........................................................................................... 83


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
10/Protocol WV43042, Version 6
LIST OF TABLES
Table 1
Objectives and Corresponding Endpoints................................... 27
Table 2
Predicted Rat and Non-Human Primate Exposure Multiples 
for AT-511 (Free Base Form of AT-527) and Its Major 
Metabolites AT-551, AT-229 and AT-273 at a Human Dose 
of AT-527 1100 mg BID .............................................................. 35
Table 3
Adverse Event Severity Grading Scale for Events Not 
Specifically Listed in NCI CTCAE ............................................... 56
Table 4
Causal Attribution Guidance ....................................................... 57
LIST OF FIGURES
Figure 1
Study Schema............................................................................. 32
LIST OF APPENDICES
Appendix 1
Schedule of Activities for Cohort A.............................................. 85
Appendix 2
Schedule of Activities for Cohorts BD ....................................... 89
Appendix 3
Schedule of Activities for Cohorts E ........................................... 93
Appendix 4
Schedule of Pharmacokinetic Samples....................................... 97
Appendix 5
COVID-19 Symptom Diary and Patient Global Impression of 
Severity....................................................................................... 98
Appendix 6
Update on AT-527 Reproductive Toxicity, In Vitro and 
Clinical DrugDrug Interaction Data......................................... 100


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
11/Protocol WV43042, Version 6
PROTOCOL AMENDMENT ACCEPTANCE FORM
TITLE:
A PHASE II RANDOMIZED, DOUBLE-BLIND, 
PLACEBO-CONTROLLED STUDY TO EVALUATE 
THE ANTIVIRAL ACTIVITY, SAFETY,
PHARMACOKINETICS, AND EFFICACY OF 
RO7496998 (AT-527) IN NON-HOSPITALIZED 
ADULT PATIENTS WITH MILD OR MODERATE 
COVID-19
PROTOCOL NUMBER:
WV43042
VERSION NUMBER:
6
EUDRACT NUMBER:
2020-005366-34
IND NUMBER:
To be determined
NCT NUMBER:
NCT04709835
TEST PRODUCT:
RO7496998 (AT-527)
MEDICAL MONITOR:
, M.D.
SPONSOR:
F. Hoffmann-La Roche Ltd (Ex-United States)
Atea Pharmaceuticals, Inc. (United States)
I agree to conduct the study in accordance with the current protocol.
Principal Investigator's Name  (print)
Principal Investigator's Signature
Date
Please retain the signed original of this form for your study files.  Please return a copy of 
the signed form as instructed by your study monitor.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
12/Protocol WV43042, Version 6
PROTOCOL SYNOPSIS
TITLE:
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL 
ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY 
OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT 
PATIENTS WITH MILD OR MODERATE COVID-19
PROTOCOL NUMBER:
WV43042
VERSION NUMBER:
6
EUDRACT NUMBER:
2020-005366-34
IND NUMBER:
To be determined
NCT NUMBER:
NCT04709835
TEST PRODUCT:
RO7496998 (AT-527)
PHASE:
Phase II
INDICATION:
COVID-19
SPONSOR:
F. Hoffmann-La Roche Ltd (Ex-United States)
Atea Pharmaceuticals, Inc. (United States)
Objectives and Endpoints
This study will evaluate the antiviral activity, safety, pharmacokinetics, and efficacy of 
RO7496998 (AT-527) compared with placebo in non-hospitalized adult patients with mild or 
moderate coronavirus disease 2019 (COVID-19).  Specific objectives and corresponding 
endpoints for the study are outlined are outlined below.
Primary Objective
Corresponding Endpoint
To evaluate the antiviral activity of 
AT-527 compared with placebo
Change from baseline in amount of SARS-CoV-2 virus 
RNA as measured by RT-PCR at specified timepoints
Secondary Objectives
Corresponding Endpoints
To evaluate the antiviral activity of 
AT-527 compared with placebo
Time to cessation of SARS-CoV-2 viral shedding as 
measured by RT-PCR
Time to sustained non-detectable SARS-CoV-2 virus 
RNA
Proportion of patients positive for SARS-CoV-2 virus 
RNA by RT-PCR at specified timepoints
Area under the curve in the amount of SARS-CoV-2 
virus RNA as measured by RT-PCR
RT-PCRreverse- transcription polymerase chain reaction; SARS-CoV-2severe acute 
respiratory syndrome coronavirus-2.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
13/Protocol WV43042, Version 6
Secondary Objectives (cont.)
Corresponding Endpoints
To evaluate the safety of AT-527 
compared with placebo
Incidence and severity of adverse events, with severity 
determined according to NCI CTCAE v5.0
Change from baseline in targeted vital signs, including 
SpO2
Change from baseline in targeted clinical laboratory test 
results
To characterize the PK profile of 
AT-511 (free base form of AT-527)
and its major metabolites 
Plasma concentration of AT-511, AT-551, AT-229, and 
AT-273 (surrogate for the intracellular concentration of 
the active triphosphate metabolite AT-9010) at specified 
timepoints
To evaluate the efficacy of AT-527 
compared with placebo 
The time to alleviation or improvement of COVID-19 
symptoms (Items 112 of the COVID-19 Symptom 
Diary) maintained for a duration of 21.5 hours, defined 
as follows:
For new symptoms:  time from start of treatment to the 
alleviation of COVID-19 symptoms (i.e., a score of 
0 [none] or 1 [mild] on the COVID-19 Symptom Diary)
For preexisting symptoms:  time from start of 
treatment to when a patient’s symptoms have been 
maintained or improved (Note:  Improved requires at 
least a single category improvement from baseline on 
the Likert scale.)
The time to alleviation or improvement of COVID-19 
symptoms (Items 112 of the COVID-19 symptom diary) 
maintained for a duration of 43 hours, defined as follows:
For new symptoms:  time from start of treatment to the 
alleviation of COVID-19 symptoms (i.e., a score of 
0 [none] or 1 [mild] on the COVID-19 Symptom Diary)
For preexisting symptoms:  time from start of 
treatment to when a patient’s symptoms have been 
maintained or improved (Note:  Improved requires at 
least a single category improvement from baseline on 
the Likert scale.)
Time to alleviation of COVID-19 symptoms, defined as 
the length of time taken from start of treatment to the 
point at which the following criterion is met and 
maintained for at least 21.5 hours:  Score of 0 or 1 on 
Items 112 of the COVID-19 Symptom Diary (without 
consideration for presence of pre-existing symptoms)
COVID-19coronavirus disease 2019; NCI CTCAENational Cancer Institute Common 
Terminology Criteria for Adverse Events; PKpharmacokinetic; 
SARS-CoV-2severe acute respiratory syndrome coronavirus-2; SpO2 peripheral capillary 
oxygen saturation.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
14/Protocol WV43042, Version 6
Secondary Objectives (cont.)
Corresponding Endpoints
To evaluate the efficacy of AT-527 
compared with placebo (cont.)
Time to alleviation of COVID-19 symptoms, defined as 
the length of time taken from start of treatment to the 
point at which the following criterion is met and 
maintained for at least 43 hours:  Score of 0 or 1 on 
Items 112 of the COVID-19 Symptom Diary (without 
consideration for presence of pre-existing symptoms)
Duration of fever, defined as the time to return to an 
afebrile state (temperature 37.5°C) maintained for at 
least 21.5 hours
Frequency of COVID-19related complications (death, 
hospitalization, radiologically confirmed pneumonia, 
acute respiratory failure, sepsis, coagulopathy, 
pericarditis, myocarditis, cardiac failure)
Frequency of hospitalizations and death (all cause)
Time to alleviation of an individual symptom, defined as 
the time taken from the start of treatment to the point at 
which the following criterion is met and maintained (for 
each individual symptom) for at least 21.5 hours:  
–
Score of 0 or 1 for Items 112 of the COVID-19 
Symptom Diary
–
Score of 0 for Items 13 and 14 of the COVID-19 
Symptom Diary
Exploratory Objectives
Corresponding Endpoints
To evaluate the antiviral activity of 
AT-527 compared with placebo
Treatment-emergent amino acid substitutions in SARS-
CoV-2 viral genes (nsp12 and potentially other genes)
AntiSARS-CoV-2 antibody status/titer at specified 
timepoints
Change from baseline in SARS-CoV-2 virus titer at 
specified timepoints
Time to cessation of SARS-CoV-2 viral shedding as 
measured by virus titer
Proportion of patients with positive SARS-CoV-2 virus 
titer at specified timepoints
Area under the curve of SARS-CoV-2 virus titer
Drug susceptibility in patients with evaluable virus at 
specified timepoints
To evaluate the relationship 
between drug exposure and 
antiviral activity of AT-527
Relationship between plasma concentration of AT-273 
and anti-viral activity.
To evaluate patient-reported 
COVID-19 symptom severity
Patient’s global impression of severity of COVID-19 
symptoms as assessed through the use of PGIS at Day 
14 and Day 28
COVID-19coronavirus disease 2019; PGISPatient Global Impression of Severity; 
PKpharmacokinetic; 
SARS-CoV-2severe acute respiratory syndrome coronavirus-2.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
15/Protocol WV43042, Version 6
Exploratory Objectives (cont)
Corresponding Endpoints
To identify and/or evaluate 
biomarkers that are predictive of 
response to AT-527
(i.e., predictive biomarkers), are 
early surrogates of efficacy, are 
associated with progression to a 
more severe disease state 
(i.e., prognostic biomarkers), can 
provide evidence of AT-527
activity (i.e., pharmacodynamic 
biomarkers), or can increase the 
knowledge and understanding of 
disease biology and drug safety
Relationship between biomarkers in blood, saliva, 
nasopharyngeal swab,  and nasosorption samples and 
efficacy, safety, PK, or other biomarker endpoints
PKpharmacokinetic.
Study Design
Description of Study
This is a Phase II, randomized, double-blind, placebo-controlled study to evaluate the 
antiviral activity, safety, pharmacokinetics, and efficacy of selected dose regimens of AT-527 
compared with placebo in non-hospitalized adult patients with mild or moderate COVID-19.  If 
all potential cohorts are fully enrolled, the study will enroll up to approximately 404patients 
globally.
Patients will be screened up to 72 hours prior to randomization.  Patients who do not meet the 
criteria for participation in this study (screen failure) cannot be re-screened.  The investigator 
will record reasons for screen failure in the screening log.  
Eligible patients will be enrolled sequentially into one of up to five possible treatment cohorts 
(Cohorts AE).  Sixty patients will be enrolled into Cohort A; Cohorts BD will enroll 40 patients 
each, and Cohort E will enroll approximately 224 patients.
Patients who withdraw from the study or who discontinue study treatment will not be replaced.  
However, patients who withdraw from the study after screening, but before receiving the first 
dose, will be replaced.  
In Cohort A, patients will be randomized in a 1:1 ratio to receive either AT-527 550 mg (or 
placebo) twice a day (BID) on Days 15, with assessment visits on Days 3, 5, and 7.  After 
30 patients (50% enrollment) in Cohort A have completed assessments through Day 10, an 
interim review of safety data will be conducted to determine the AT-527 dose and regimen for 
Cohort B.  
In Cohorts BD, patients will be randomized in a 3:1 ratio to receive either AT-527 or placebo
on Days 1–5, with assessment visits on Days 3, 5 and 7.  Dose regimen decisions for Cohorts 
CD will be made by the Sponsor study team following unblinded review of safety data by an 
Internal Monitoring Committee (IMC) after 20 patients (approximately 15 active and 5 placebo) 
enrolled in the previous cohort have completed assessments through Day 10.  The maximum 
dose to be tested in the study will not exceed AT-527 1100 mg BID for 5 days.  Depending on 
emerging data, the Sponsor may also evaluate regimens with doses of AT-527 lower than 
550 mg BID. Cohorts that evaluate regimens with AT-527 doses lower than a previously 
tested dose regimen will not require IMC oversight.
In Cohort E, patients will be randomized in a 1:1 ratio to receive either AT-527 (or placebo) 
BID on Days 15, with assessment visits on Days 3, 5, 7 and 14.  Cohort E may be initiated 
prior to the completion of all four prior cohorts, and will utilize a dose regimen selected from 
a previous cohort. As  Cohort E dose regimen will have been previously tested, this cohort 
does not require an IMC. 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
16/Protocol WV43042, Version 6
For all cohorts, visits may be conducted in clinic or by mobile nursing.  Where local policies and 
local site logistics permit, patients may also be confined in clinic during Days 17. Where 
treatment occurs in the inpatient setting, the purpose of hospitalization must not be for severe 
COVID-19 requiring inpatient treatment. An end of study safety follow-up telephone call on 
Day 33.  The total study duration for each patient will be 33 days.
For all cohorts, a selection of different samples will be collected to assess severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) viral status at various timepoints.  To 
evaluate the PK properties of AT-527, PK samples will be collected at various timepoints.  
Patients will be closely monitored for COVID-19 signs and symptoms and adverse events; 
adverse events will be graded according to National Cancer Institute Common Terminology 
Criteria for Adverse Events v5.0.
During Cohorts BD, an IMC will provide additional safety oversight for cohorts evaluating 
regimens with AT-527 doses higher than 550 mg BID.  The IMC will include representatives 
from Clinical Science and Clinical Safety who are independent of the Sponsor study team and 
a Biostatistician who does not have regular contact with the sites.  In addition to the ongoing 
assessment of the incidence, nature, and severity of adverse events, serious adverse events, 
deaths, and vital sign and laboratory abnormalities performed by the Medical Monitor, the IMC 
will review safety data through Day 10 for the first 20 patients enrolled in those cohorts.  
The IMC will pause further enrollment in the study to conduct a comprehensive safety 
assessment of all cumulative data if any of the following criteria are met.

Death in any patient for which the cause of death is judged by the investigator to have a 
reasonable possibility of relatedness to the study drug

Occurrence in any patient of a life-threatening serious adverse event for which the causal 
relationship is judged by the investigator to have a reasonable possibility of relatedness to 
the study drug

20% of the enrolled patients in any cohort experience clinically significant Grade 3 or 4 
adverse events judged by the investigator to have a reasonable possibility of relatedness to 
the study drug
The IMC will make recommendations as to the further conduct of the study as outlined in the 
IMC Charter.  Other specific operational details such as the IMC's composition, frequency and 
timing of meetings, and members' roles and responsibilities will be detailed in the IMC Charter.  
Cohorts evaluating regimens with AT-527 doses lower than a previously tested dose regimen 
will not require additional IMC oversight..
Number of Patients
Up to approximately 404 non-hospitalized adult patients with mild or moderate COVID-19 will be 
enrolled in this study.
Target Population
Inclusion Criteria
Patients must meet the following criteria for study entry:

Signed Informed Consent Form

Age ≥18 years at time of signing Informed Consent Form

Willing and able to comply with the study protocol and all study procedures, in the opinion of 
the investigator

Positive SARS-CoV-2 diagnostic test (reverse transcription polymerase chain reaction 
[RT-PCR] or rapid antigen test) at screening

Has symptoms consistent with mild or moderate COVID-19, as determined by the 
investigator, with onset 5 days prior to randomization

For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use adequate contraception during the treatment period and 
for 30 days after the final dose of study drug.
A woman is considered to be of childbearing potential if she is postmenarchal, has not 
reached a postmenopausal state (12 continuous months of amenorrhea with no 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
17/Protocol WV43042, Version 6
identified cause other than menopause), and is not permanently infertile due to surgery 
(i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined 
by the investigator (e.g., Müllerian agenesis).  The definition of childbearing potential 
may be adapted for alignment with local guidelines or regulations. Women of 
childbearing potential must be established on their chosen method of contraception at 
screening.
The following are examples of adequate contraceptive methods:  with a bilateral tubal 
ligation, male sterilization, hormonal contraceptives, hormone-releasing intrauterine 
devices, and copper intrauterine devices; male or female condom with or without 
spermicide; and cap, diaphragm, or sponge with spermicide.
The reliability of sexual abstinence should be evaluated in relation to the duration of the 
clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal 
are not adequate methods of contraception.  If required per local guidelines or 
regulations, locally recognized adequate methods of contraception and information 
about the reliability of abstinence will be described in the local Informed Consent Form.
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:

Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as any of the 
following:  shortness of breath at rest, respiratory rate 30, heart rate 125, peripheral 
capillary oxygen saturation 93% on room air

Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited to, other 
direct-acting antivirals, convalescent plasma, monoclonal antibodies against SARS-CoV-2, 
or intravenous immunoglobulin within 3 months or less than 5 drug-elimination half-lives 
(whichever is longer) prior to screening

Requirement, in the opinion of the investigator, for any of the prohibited medications during 
the study

Use of hydroxychloroquine or amiodarone within 3 months of screening

Pregnant or breastfeeding, or intending to become pregnant during the study or within 
30 days after the final dose of study drug.  Women of childbearing potential must have a 
negative pregnancy test result at screening

Abnormal laboratory test results at screening, defined as meeting any of the following sets 
of criteria:
–
ALT or AST 5 upper limit of normal (ULN)
–
Total bilirubin 1.5 ULN, unless the patient has known Gilbert disease
–
Creatinine clearance 60 mL/min (Cockcroft-Gault formula)
–
Total WBC 2,500/mm3 or ANC 800/mm3
–
Platelet count 80 109/L

Clinically significant abnormal ECG, as determined by the Investigator, at screening

Planned procedure or surgery during the study

Known allergy or hypersensitivity to study drug or drug product excipients

Substance abuse, as determined by the investigator, within 12 months prior to screening

Poor peripheral venous access

Malabsorption syndrome or other condition that would interfere with enteral absorption

Any clinically significant history of epistaxis within the last 3 months and/or history of being 
hospitalized due to epistaxis of any previous occasion 

History of anaphylaxis


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
18/Protocol WV43042, Version 6

Any uncontrolled serious medical condition or other clinically significant abnormality in 
clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe 
participation in and completion of the study
End of Study
The end of this study is defined as the date when the last patient, last visit (i.e., safety follow-up 
telephone call), occurs or the date at which the last data point required for statistical analysis or 
safety follow-up is received from the last patient whichever occurs later.  The end of the study is 
expected to occur 33 days after the last patient has been enrolled.
In addition, the Sponsor may decide to terminate the study at any time.
Length of Study
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 12 months 
Investigational Medicinal Products
The investigational medicinal product for this study is RO7496998 (AT-527) or matching 
placebo
Test Product (Investigational Drug)
In Cohort A, patients randomized to receive study drug will receive AT-527 550 mg BID on 
Days 15.  AT-527 dose and regimen for Cohort B will be determined following an interim safety 
review after 30 patients (50% enrollment) in Cohort A have completed assessments through 
Day 10.  Dose regimen decisions for Cohorts CD will be made by the Sponsor study team
following unblinded review of safety data by the IMC after 20 patients approximately 15 active 
and 5 placebo) enrolled in the previous cohort have completed assessments through Day 10.  
Cohort E may be initiated prior to the completion of all four prior cohorts, and will utilize a 
dose regimen selected from a previous cohort.
Comparator
For patients randomized to receive placebo, placebo will be administered as aligned with the 
applicable study drug regimen for each cohort.
Non-Investigational Medicinal Products
There are no non-investigational medicinal products for this study.
Statistical Methods
Primary Analysis
The primary objective of this study is to evaluate the antiviral activity of AT-527 compared with 
placebo on the basis of the change from baseline in amount of SARS-CoV-2 virus RNA as 
measured by RT-PCR and based on the log-10 scale at specified timepoints.
The change from baseline in the amount of SARS-CoV-2 virus RNA will be compared between 
each AT-527 group and a combined placebo group at Days 3, 5, and 7 using Analysis of 
Covariance (ANCOVA) with baseline virus RNA as a covariate. The treatment group least 
squares mean (LSM) changes, difference in LSM changes, 80% CI and p-value will be 
presented for each comparison.  Additionally, descriptive summaries for the change from 
baseline will also be presented by treatment group. 
If the data are not normally distributed, a non-parametric alternative method will be used 
(e.g., Mann-Whitney U test) to compare distributions.
Determination of Sample Size  
Approximately 60 patients will be randomized in a 1:1 ratio in Cohort A to receive AT-527 or 
placebo.  Cohorts BD will enroll approximately 40 patients in a 3:1 ratio to receive AT-527 or 
placebo, respectively.  Cohort E will enroll approximately to 224 patients in a 1:1 ratio to 
receive AT-527 or placebo, respectively. 
The sample size for Cohort AD is based on the primary endpoint of change from baseline in 
SARS-CoV-2 virus RNA measured by RT-PCR at a single timepoint.  A sample size of 27 
patients per arm (active or placebo) in the modified intent-to-treatinfected population will result 
in at least 80% power to detect a mean reduction in change from baseline of between 0.7 and 
1.1 log10 copies using a two-sample t-test for comparison of means, assuming a standard 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
19/Protocol WV43042, Version 6
deviation of between 1.2 and 1.85 and based on a 1-sided 10% alpha.  The sample size has 
been adjusted to 30 patients per arm to account for an estimated 90% SARS-CoV-2 positive 
rate and is based on a single-cohort comparison of AT-527 versus placebo.
For Cohort E, a sample size of 100 patients per arm (active or placebo) in the mITTi 
population will result in at least 80% power to detect a mean reduction in change from 
baseline of 0.5 log10 copies using a two-sample t-test for comparison of means, assuming a 
standard deviation of 1.25 (deemed appropriate based on current data from WV43042) and 
based on a 1-sided 2.5% alpha.  The sample size for Cohort E has been adjusted to 112 
patients per arm to account for an estimated 90% SARS-CoV-2 positive rate. Based on 
emerging external data on direct acting antivirals in COVID-19 (Fischer et al 2021), a lower 
mean reduction in change from baseline of 0.5 log10 copies has been utilized in Cohort E.   A 
lower alpha level has also been selected to reduce the likelihood of a false positive result and 
enable a more robust evaluation of the antiviral activity of AT-527 at the selected dose 
regimen.  This sample size also allows for a better characterization of the secondary 
endpoints.
Interim Analyses
Planned Interim Analyses
An interim safety analysis is planned for Cohort A after the first 30 patients have completed 
assessments through Day 10.  
Optional Interim Analysis
Given the hypothesis-generating nature of this study, the Sponsor may choose to conduct 
additional interim analyses (i.e., beyond what is specified in the protocol).  The decision to 
conduct an optional interim analysis and the timing of the analysis will be documented in the 
Sponsor's trial master file prior to the conduct of the interim analysis.  The interim analysis will 
be performed and interpreted by members of the Sponsor study team and appropriate senior 
management personnel, who will be unblinded at the treatment group level.  Access to 
treatment assignment information will follow the Sponsor's standard procedures.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
20/Protocol WV43042, Version 6
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation
Definition
ANCOVA
Analysis of Covariance
AUC
area under the curve
AUC,ss
area under the concentrationtime curve over the 
dosing interval at steady state
BID
twice a day
BCRP
Breast Cancer Resistance Protein
C12 hr
concentration at 12 hours 
CDC
Centers for Disease Control and Prevention
Cmax
maximum concentration 
COVID-19
coronavirus disease 2019
CoV
coronavirus
CYP
Cytochrome P450
EC
Ethics Committee
EC90
90% effective concentration
eCRF
electronic Case Report Form
EDC
electronic data capture
EUA
emergency use authorization
FDA
Food and Drug Administration
HCV
hepatitis C virus
ICH
International Council for Harmonisation
IMC
Internal Monitoring Committee
IMP
investigational medicinal product
IND
Investigational New Drug (Application)
IRB
Institutional Review Board
IxRS
interactive voice or web-based response system
LLOQ
lower limit of quantification
LSM
least square means
mITTi
modified intent-to-treat infected 
MN
mobile nursing
NCI CTCAE
National Cancer Institute Common Terminology Criteria 
for Adverse Events
NGS
next-generation sequencing
NLME
non-linear mixed effects
NOAEL
no-observed-adverse-effect level
OAT
Organic Anion Transporter
PBMC
peripheral blood mononuclear cell


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
21/Protocol WV43042, Version 6
Abbreviation
Definition
PD
pharmacodynamic
PGIS
Patient Global Impression of Severity
P-gp
P-glycoprotein
PK
pharmacokinetic
PRO
patient-reported outcome
QD
once a day
QTcF
QT interval corrected through use of Fridericia's 
formula
RT-PCR
reverse-transcription polymerase chain reaction
SAP
Statistical Analysis Plan
SARS
severe acute respiratory syndrome
SARS-CoV-2
SARS coronavirus-2
SpO2
peripheral capillary oxygen saturation
ULN
upper limit of normal
WGS
whole genome sequencing 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
22/Protocol WV43042, Version 6
1.
BACKGROUND
1.1
BACKGROUND ON COVID-19
Coronaviruses are positive-sense, single-stranded RNA viruses, named for the 
crown-like appearance of their spike glycoproteins on the virus envelope.  They are a 
large family of viruses that can cause illness ranging from the common cold to more 
severe diseases such as Middle East respiratory syndrome (MERS) and severe acute 
respiratory syndrome (SARS). An epidemic of cases with unexplained lower respiratory 
tract infections was first detected in Wuhan, the largest metropolitan area in China’s 
Hubei province, and was reported to the WHO Country Office in China on 31 December 
2019.  The WHO subsequently declared a pandemic on 11 March 2020.  This infectious 
disease, named coronavirus disease 2019 (COVID-19) by the WHO, is caused by a 
novel coronavirus strain SARS coronavirus-2 (SARS-CoV-2).  As of 5 September 2021, 
more than 220 million confirmed cases of COVID-19 and over 4.5 million COVID-
19related deaths have been reported globally (WHO 2021).
Infection with SARS-CoV-2 may be asymptomatic, or it may cause a wide spectrum of 
illness, ranging from a mild upper respiratory tract infection to severe life-threatening 
sepsis and multiorgan failure (Wiersinga et al. 2020). Commonly reported symptoms 
include fever, cough, shortness of breath, loss of taste or smell, sore throat, fatigue, 
headaches, muscle aches, and gastrointestinal disturbance. Symptoms are typically 
thought to last 23 weeks, but it is increasingly recognized that many patients continue 
to experience symptoms for many weeksthe so-called "long COVID" (NIHR 2020).
Around 10% of non-hospitalized mild COVID-19 patients report symptoms lasting more 
than 4 weeks and up to 87% of hospitalized patients continue to experience symptoms
2 months after the onset of their illness. COVID-19 affects people of all ages; however,
people who are immunocompromised, elderly, or have certain underlying medical 
conditions (e.g., chronic heart, lung and kidney disease; diabetes, obesity, cancer) are at 
increased risk of poor outcomes (Carfi et al. 2020; CDC 2020; PHE 2020).
Prevention and control of SARS-CoV-2 infection have focused on public health 
measures to slow transmission, such as social distancing, the use of face masks, and 
national or regional lockdowns. The first of several effective COVID-19 vaccines was 
authorized in December 2020.  However, despite large multi-national vaccination 
campaigns, as of September 2021, only 41.1% of the global population (1.9% of the 
population in low-income countries) have received at least one dose of vaccine 
(Mathieu et al. 2020).  Furthermore, the duration of protection afforded by these 
vaccines is currently unknown and there are increasing reports of breakthrough 
infections, including among fully vaccinated individuals, partly driven by the 
emergence of SARS CoV-2 variants (Hacisuleyman et al. 2021).  Additionally, there 
remains a subset of the population who refuse to be vaccinated, who may not respond to 
the available vaccines, or who have a contraindication to vaccination. Intravenous 
remdesivir, an inhibitor of RNA-dependent RNA polymerase, and dexamethasone have 
shown benefit in hospitalized patients with severe COVID-19.  However, in patients with 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
23/Protocol WV43042, Version 6
moderate COVID-19, dexamethasone is not efficacious (and may be harmful) and the 
use of remdesivir is not approved for non-hospitalized patients (Gandhi et al. 2020).
Neutralizing monoclonal antibody cocktail therapies such as bamlanivimab plus 
etesevimab, and casirivimab plus imdevimab, have been approved or granted 
emergency use authorization (EUA) in some countries for the treatment of mild to 
moderate COVID-19 in adults and pediatric patients (12 years and older weighing at 
least 40 kilograms) with positive results of direct SARS-CoV-2 viral testing and who are 
at high risk for progressing to severe COVID-19 and/or hospitalization. However, the risk 
of emergence of SARS-CoV-2 variants with resistance to monoclonal antibodies 
threatens the efficacy of these therapies as seen recently with bamlanivimab plus 
etesevimab, which was shown to have reduced in vitro activity against the gamma and 
beta variants, leading the United States government to temporarily pause distribution 
of this antibody cocktail with the US FDA recommending that healthcare providers use 
alternative authorized monoclonal antibodies (PHE 2021). Additionally, the risk of viral 
variants to which available vaccines may offer insufficient protection further underscores 
the need for treatment options.
Therefore, there remains a significant and urgent unmet medical need for an orally 
administered, direct-acting antiviral drug with broad utility for the treatment of COVID-19.
This will remain the case despite the availability of vaccinations and current treatments.  
An antiviral therapeutic that could be administered to ambulatory, non-hospitalized 
patients has the potential to significantly reduce the burden of disease and reduce the 
deterioration of these patients, thereby preventing progression of disease or 
hospitalization, and will have a significant impact on the pandemic and public health 
systems globally. 
1.2
BACKGROUND ON AT-527
AT-527 (RO7496998) is a phosphoramidate prodrug of a unique, 6-modified purine 
nucleotide prodrug discovered by Atea Pharmaceuticals Inc. In laboratory studies,
AT-527 potently inhibits the RNA-dependent RNA polymerase of several single-stranded 
RNA viruses. AT-527 is converted to its active intracellular triphosphate form (AT-9010) 
through a series of intermediate metabolites. AT-527 has demonstrated sub-micromolar 
potency against a range of coronaviruses, including SARS-CoV-1 (90% effective
concentration [EC90]0.34 M) and SARS-CoV-2 (mean EC90 [SD] 0.42 [0.18] M). 
AT-527 has been evaluated in two completed clinical studies in healthy volunteers and 
patients infected with hepatitis C virus (HCV). In the completed Phase II study 
AT-01B-002 in HCV-infected patients, AT-527 was well-tolerated for durations up to 
12 weeks and achieved a high rate of antiviral efficacy with no safety issues. 
AT-527 is administered orally as tablets.  In healthy volunteers and HCV-infected 
patients, AT-527 exhibited a linear pharmacokinetic and pharmacodynamic (PK/PD) 
profile associated with the observed antiviral efficacy in HCV-infected patients. This 
supportive human PK profile is likely to be observed with dosing of patients with COVID-


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
24/Protocol WV43042, Version 6
19 and is expected to be sufficient for achieving antiviral efficacy, based on the sub-
micromolar EC90 for the active triphosphate of AT-527 against SARS-CoV-2 virus 
replication in laboratory studies.
The safety and efficacy of AT-527 in hospitalized patients aged 18 years with moderate 
COVID-19 who have risk factors for poor outcome is currently being evaluated in a 
Phase II study (AT-03A-001). The safety and pharmacokinetics of AT-527 is also being 
evaluated in healthy volunteers (AT-03A-002).  Summaries from these studies are briefly 
outlined below.
AT-03A-002
The ongoing Phase I Study AT-03A-002 is a randomized (1:1), double-blind, placebo 
controlled study to assess the safety and PK of multiple doses of AT-527 in healthy 
subjects.  In Cohort 1, 20 subjects received 550 mg AT-527 (as 1 550 mg tablet) or 
matching placebo BID for 5 days.  In Cohort 2, 10 subjects received a single dose of 
550 mg AT-527 (as 2 275 mg tablets) or matching placebo.  In Cohort 3, 11 subjects 
received 825 mg AT-527 (as 3 275 mg tablets) or matching placebo BID for 10 days. 
Two additional cohorts are planned to further evaluate the PK and safety of AT-527 at 
different dose regimens.
Preliminary safety data from 41 subjects in the completed Cohorts 13 show no 
premature discontinuations due to AT-527-related AEs, no SAEs, and no patterns with 
regards to laboratory-, ECG-, or vital sign abnormalities.
AT-03A-001
This ongoing Phase II study is randomized (1:1), double blind, placebo-controlled study 
to evaluate the safety and efficacy of AT-527 in hospitalized patients with moderate 
COVID-19 and risk factors for poor outcomes. The study targets enrollment of 
190 patients. 
An interim analysis was performed after the first 70 patients completed assessments 
through Day 14. Interim virology results based on 62 patients who were evaluable for 
virology analysis indicated that AT-527 rapidly reduced viral load levels.  At Day 2, a 
0.7 log10 greater mean reduction from baseline viral load was observed in patients who 
received AT-527 compared to placebo.  A sustained difference in viral load reduction 
was maintained through Day 8.  
AT-527 was generally well tolerated.  In this hospitalized study, there were no drug-
related serious adverse events.  Non-serious adverse events were equally distributed 
across treatment arms.  Most were mild-to-moderate in severity and assessed as not 
related to the study drug by the investigator.  No safety concerns or newly determined 
risks were identified.
Refer to the AT-527 Investigator's Brochure for details on nonclinical and clinical studies.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
25/Protocol WV43042, Version 6
1.3
STUDY RATIONALE AND BENEFIT-RISK ASSESSMENT
Despite the recent approval of vaccines for the prevention of SARS-CoV-2 infection and 
the recent approvals and EUA for monoclonal antibody therapies for mild to moderate 
COVID-19, there remains a significant and urgent unmet medical need to develop new 
therapies for COVID-19. Logistical challenges to widespread vaccination globally are 
likely to remain in the near future and there will be populations who cannot be safely 
vaccinated or for whom vaccination may offer insufficient protection. Currently available 
treatments, remdesivir and dexamethasone, have demonstrated benefit only in 
hospitalized patients with COVID-19, and the recently authorized monoclonal antibody 
therapies for mild to moderate COVID-19 have to be administered by the parenteral 
route and in a healthcare setting due to the risk of hypersensitivity reactions, making 
them unsuitable for use in the outpatient setting. There remains, therefore, an urgent 
unmet medical need to develop new therapies for COVID-19. 
Extensive nonclinical safety data, Phase I and Phase II clinical safety data in healthy 
volunteers, HCV-infected and COVID-19 patients, the favorable human PK data, and 
the potent in vitro antiviral activity of AT-527 against SARS-CoV-2 replication support 
further clinical evaluation of AT-527 in patients with COVID-19.  The main objective of 
the current study is to evaluate the antiviral activity and PK of AT-527 in patients with 
mild or moderate COVID-19 and to obtain early proof of concept to support further 
development of AT-527 in this patient population. 
Nonclinical and clinical safety studies have not revealed any pattern of drug-attributable 
adverse effects or any consistent clinically significant laboratory abnormalities related 
to any body system.  Repeat-dose toxicity studies of up to 13 weeks duration in rats and 
monkeys did not show target-organ toxicity up to the highest tested dose levels.  In 
rats, the no-observed-adverse-effect level (NOAEL) was the highest tested dose of 
1000 mg/kg/day in these studies.  In monkeys, the NOAEL in a 7-day study was 
1000 mg/kg/day, a dose that was reduced to 650 mg/kg/day on Day 8 of a 14-day study 
due to loose stools, emesis, inappetence, and weight loss.  650 mg/kg/day was the 
NOAEL and the highest tested dose in the subsequent 13-week monkey toxicity study.
As detailed in Section 3.3.1, the highest AT-527 dose that may be evaluated in this study 
is 1100 mg, administered twice a day (BID) for 5 days.  While this dose has not 
previously been tested in humans, the plasma exposures achieved in the repeat-dose
toxicity studies either exceed or approximate the anticipated clinical exposures for the 
unchanged drug and different metabolites in one or both species, depending on the 
metabolite.  The potential for reproductive toxicity was assessed in dose rangefinding 
and pivotal GLP-compliant embryofetal development studies in rats and rabbits and in a 
GLP-compliant fertility study in the rat.  These studies have not revealed a concern for 
reproductive toxicity and achieved exposures exceeded the anticipated clinical 
exposures (see Appendix 6).  Thus, the nonclinical safety data are considered to be 
supportive of the intended clinical dose levels and regimens and consistent with 
international guidelines, ICH Topic M3 (R2) and associated question and answer 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
26/Protocol WV43042, Version 6
document (ICH 2008; ICH 2012).  The potential for gastrointestinal effects in humans will 
be monitored through medical data review and safety review on an ongoing basis in this 
study.
Some nucleoside analogs have been associated with mitochondrial toxicity, resulting in 
damage to the liver, muscles, heart, nerve, pancreas and other organs.  Nephrotoxicity 
has also been associated with the use of some nucleoside analogs (e.g., tenofovir), but 
this is not a broad class effect.  The completed nonclinical assessments of AT-527
indicate no potential for mitochondrial toxicity.  The active triphosphate of AT-527, 
AT-9010, did not inhibit the in vitro enzyme activities of human cellular DNA-dependent 
DNA polymerases (, , or ) and was poorly incorporated by human mitochondrial RNA 
polymerase.  Additionally, using cell-based assays, AT-527 had no effect on 
mitochondrial cell membrane integrity, mitochondrial-dependent ATP production, or 
mitochondrial biogenesis.  To date, there have been no clinical signs of adverse effects 
suggesting mitochondrial toxicity for AT-527 in animal toxicology studies or in completed 
clinical studies. 
AT-527 has not been associated with hepatotoxicity in nonclinical or clinical experience 
to date.  As of 28 May 2021, a total of 164 subjects have received unblinded AT-527
(82 healthy volunteers, 82 patients with HCV , including patients with cirrhosis) and 
80 subjects have received blinded AT-527 (28 healthy volunteers, 52 patients with 
COVID-19) at various dose levels in clinical studies.  In HCV-infected patients, liver 
function test values tend to normalize with AT-527 treatment.  No hepatotoxicity was 
observed in animal models (multiple species).    
Patients in this study will be monitored closely for any adverse events through regular 
clinical assessments and safety laboratory monitoring. The inclusion and exclusion 
criteria have been designed to exclude patients who may be at risk of toxicity. Although 
it is reasonable to expect that a SARS-CoV-2 direct-acting antiviral with potent in vitro 
antiviral activity will result in clinical benefit in SARS-CoV-2 infected patients, AT-527
has not yet been proven to be efficacious in patients with COVID-19.  Thus, it is possible 
that patients will not receive any benefit from participation in this study.  However, the 
high unmet medical need for the treatment of COVID-19, the nonclinical and clinical data 
for AT-527, and the risk mitigation outlined for this study support the conduct of a 
placebo-controlled study to evaluate the antiviral activity of AT-527 in non-hospitalized 
adult patients with mild or moderate COVID-19.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
27/Protocol WV43042, Version 6
2.
OBJECTIVES AND ENDPOINTS
This study will evaluate the antiviral activity, safety, pharmacokinetics, and efficacy of 
AT-527 compared with placebo in non-hospitalized adult patients with mild or moderate 
COVID-19.  Specific objectives and corresponding endpoints for the study are outlined in 
Table 1.
Table 1
Objectives and Corresponding Endpoints
Primary Objective
Corresponding Endpoint
To evaluate the antiviral
activity of AT-527
compared with placebo
Change from baseline in amount of SARS-CoV-2 virus RNA as 
measured by RT-PCR at specified timepoints
Secondary Objectives
Corresponding Endpoints
To evaluate the antiviral
activity of AT-527
compared with placebo
Time to cessation of SARS-CoV-2 viral shedding as measured 
by RT-PCR
Time to sustained non-detectable SARS-CoV-2 virus RNA
Proportion of patients positive for SARS-CoV-2 virus RNA by 
RT-PCR at specified timepoints
Area under the curve in the amount of SARS-CoV-2 virus RNA 
as measured by RT-PCR
To evaluate the safety of 
AT-527 compared with 
placebo
Incidence and severity of adverse events, with severity 
determined according to NCI CTCAE v5.0
Change from baseline in targeted vital signs, including SpO2
Change from baseline in targeted clinical laboratory test results
To characterize the 
PK profile of AT-511 
(free base form of 
AT-527) and its major 
metabolites 
Plasma concentration of AT-511, AT-551, AT-229, and AT-273 
(surrogate for the intracellular concentration of the active 
triphosphate metabolite AT-9010) at specified timepoints
NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events;
RT-PCR reverse-transcription polymerase chain reaction; PKpharmacokinetic; SARS-CoV-2 severe 
acute respiratory syndrome coronavirus-2; SpO2peripheral capillary oxygen saturation


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
28/Protocol WV43042, Version 6
Table 1
Objectives and Corresponding Endpoints (cont.)
Secondary Objectives
(cont.)
Corresponding Endpoints
To evaluate the 
efficacy of AT-527
compared with placebo
The time to alleviation or improvement of COVID-19 symptoms 
(Items 112 of the COVID-19 Symptom Diary) maintained for a 
duration of 21.5 hours, defined as follows:
For new symptoms:  time from start of treatment to the 
alleviation of COVID-19 symptoms (i.e., a score of 0 [none] or 
1 [mild] on the COVID-19 Symptom Diary)
For preexisting symptoms:  time from start of treatment to when 
a patient’s symptoms have been maintained or improved (Note:  
Improved requires at least a single category improvement from 
baseline on the Likert scale.)
The time to alleviation or improvement of COVID-19 symptoms 
(Items 112 of the COVID-19 symptom diary) maintained for a 
duration of 43 hours, defined as follows:
For new symptoms:  time from start of treatment to the 
alleviation of COVID-19 symptoms (i.e., a score of 0 [none] or 
1 [mild] on the COVID-19 Symptom Diary)
For preexisting symptoms:  time from start of treatment to when 
a patient’s symptoms have been maintained or improved (Note:  
Improved requires at least a single category improvement from 
baseline on the Likert scale.)
Time to alleviation of COVID-19 symptoms, defined as the length 
of time taken from start of treatment to the point at which the 
following criterion is met and maintained for at least 21.5 hours:  
Score of 0 or 1 on Items 112 of the COVID-19 Symptom Diary 
(without consideration for presence of pre-existing symptoms)
Time to alleviation of COVID-19 symptoms, defined as the length 
of time taken from start of treatment to the point at which the 
following criterion is met and maintained for at least 43 hours:  
Score of 0 or 1 on Items 112 of the COVID-19 Symptom Diary 
(without consideration for presence of pre-existing symptoms)
Duration of fever, defined as the time to return to an afebrile state 
(temperature 37.5°C) maintained for at least 21.5 hours
Frequency of COVID-19related complications (death, 
hospitalization, radiologically confirmed pneumonia, acute 
respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, 
cardiac failure)
Frequency of hospitalizations and death (all cause)
Time to alleviation of an individual symptom, defined as the time 
taken from the start of treatment to the point at which the following 
criterion is met and maintained (for each individual symptom) for 
at least 21.5 hours:  
–
Score of 0 or 1 for Items 112 of the COVID-19 Symptom 
Diary
– Score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary
COVID-19 coronavirus disease 2019; NCI CTCAE National Cancer Institute Common Terminology 
Criteria for Adverse Events; PK pharmacokinetic; SARS-CoV-2 severe acute respiratory syndrome


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
29/Protocol WV43042, Version 6
Table 1
Objectives and Corresponding Endpoints (cont.)
Exploratory Objectives
Corresponding Endpoints
To evaluate the antiviral
activity of AT-527 compared 
with placebo
Treatment-emergent amino acid substitutions in SARS-CoV-
2 viral genes (nsp12 and potentially other genes)
AntiSARS-CoV-2 antibody status/titer at specified 
timepoints
Change from baseline in SARS-CoV-2 virus titer at specified 
timepoints
Time to cessation of SARS-CoV-2 viral shedding as 
measured by virus titer
Proportion of patients with positive SARS-CoV-2 virus titer at 
specified timepoints
Area under the curve of SARS-CoV-2 virus titer
Drug susceptibility in patients with evaluable virus at 
specified timepoints
To evaluate the relationship 
between drug exposure and 
antiviral activity of 
AT-527
Relationship between plasma concentration of AT-273 and 
anti-viral activity
To evaluate patient-reported 
COVID-19 symptom severity
Patient’s global impression of severity of COVID-19 
symptoms as assessed through the use of PGIS at Day 14 
and Day 28
To identify and/or evaluate 
biomarkers that are 
predictive of response to AT-
527 (i.e., predictive 
biomarkers), are early 
surrogates of efficacy, are 
associated with progression 
to a more severe disease 
state (i.e., prognostic 
biomarkers), can provide 
evidence of AT-527 activity 
(i.e., pharmacodynamic 
biomarkers), or can increase 
the knowledge and 
understanding of disease 
biology and drug safety
Relationship between biomarkers in blood, saliva, 
nasopharyngeal swab, and nasosorption samples (listed in 
Section 4.5.5) and efficacy, safety, PK, or other biomarker 
endpoints
COVID-19 coronavirus disease 2019; PGIS Patient Global Impression of Severity; 
PK pharmacokinetic SARS-CoV-2 severe acute respiratory syndrome coronavirus-2


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
30/Protocol WV43042, Version 6
3.
STUDY DESIGN
3.1
DESCRIPTION OF THE STUDY
This is a Phase II, randomized, double-blind, placebo-controlled study to evaluate the 
antiviral activity, safety, pharmacokinetics, and efficacy of selected dose regimens of 
AT-527 compared with placebo in non-hospitalized adult patients with mild or moderate 
COVID-19. If all potential cohorts are fully enrolled, the study will enroll up to 
approximately 404 patients globally.
Patients will be screened up to 72 hours prior to randomization.  Patients who do not 
meet the criteria for participation in this study (screen failure) cannot be re-screened.  
The investigator will record reasons for screen failure in the screening log. 
Eligible patients will be enrolled sequentially into one of up to five possible treatment 
cohorts (Cohorts AE).  Sixty patients will be enrolled into Cohort A; Cohorts BD will 
enroll 40 patients each, and Cohort E will enroll approximately 224 patients.
Patients who withdraw from the study or who discontinue study treatment will not be 
replaced.  However, patients who withdraw from the study after screening, but before
receiving the first dose, will be replaced.  
In Cohort A, patients will be randomized in a 1:1 ratio to receive either AT-527 550 mg 
(or placebo) BID on Days 15, with assessment visits on Days 3, 5, and 7.  After 
30 patients (50% enrollment) in Cohort A have completed assessments through Day 10, 
an interim review of safety data will be conducted to determine the AT-527 dose and 
regimen for Cohort B.  
In Cohorts BD, patients will be randomized in a 3:1 ratio to receive either AT-527 or 
placebo on Days 1–5, with assessment visits on Days 3, 5 and 7. Dose regimen
decisions for Cohorts CD will be made by the Sponsor study team following unblinded 
review of safety data by an Internal Monitoring Committee (IMC) after 20 patients 
(approximately 15 active and 5 placebo) enrolled in the previous cohort have completed 
assessments through Day 10.  The maximum dose to be tested in the study will not 
exceed AT-527 1100 mg BID for 5 days.  Depending on emerging data, the Sponsor 
may also evaluate regimens with doses of AT-527 lower than 550 mg BID. Cohorts that
evaluate regimens with AT-527 doses lower than a previously tested dose regimen will 
not require IMC oversight.
In Cohort E, patients will be randomized in a 1:1 ratio to receive either AT-527 (or 
placebo) BID on Days 15, with assessment visits on Days 3, 5, 7 and 14. Cohort E 
may be initiated prior to the completion of all four prior cohorts, and will utilize a dose 
regimen selected from a previous cohort. As Cohort E dose regimen will have been 
previously tested, this cohort does not require an IMC. 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
31/Protocol WV43042, Version 6
For all cohorts, visits may be conducted in clinic or by mobile nursing. Where local 
policies and local site logistics permit, patients may also be confined in clinic during
Days 17.  Where treatment occurs in the inpatient setting, the purpose of 
hospitalization must not be for severe COVID-19 requiring inpatient treatment. An end 
of study safety follow-up telephone call on Day 33.  The total study duration for each 
patient will be 33 days.
For all cohorts, a selection of different samples will be collected to assess SARS-CoV-2 
viral status at various timepoints.  To evaluate the PK properties of AT-527, PK samples 
will be collected at various timepoints. Patients will be closely monitored for COVID-19 
signs and symptoms and adverse events; adverse events will be graded according to 
National Cancer Institute Common Terminology Criteria for Adverse Events (NCI 
CTCAE) v5.0.
During Cohorts BD, an IMC will provide additional safety oversight for cohorts 
evaluating regimens with AT-527 doses higher than 550 mg BID. The IMC will include 
representatives from Clinical Science and Clinical Safety who are independent of the 
Sponsor study team, and a Biostatistician who does not have regular contact with the 
sites. In addition to the ongoing assessment of the incidence, nature, and severity of
adverse events, serious adverse events, deaths, and vital sign and laboratory 
abnormalities performed by the Medical Monitor, the IMC will review safety data through 
Day 10 for the first 20 patients enrolled in those cohorts.  
The IMC will pause further enrollment in the study to conduct a comprehensive safety 
assessment of all cumulative data if any of the following criteria are met.

Death in any patient for which the cause of death is judged by the investigator to 
have a reasonable possibility of relatedness to the study drug

Occurrence in any patient of a life-threatening serious adverse event for which the 
causal relationship is judged by the investigator to have a reasonable possibility of 
relatedness to the study drug

20% of the enrolled patients in any cohort experience clinically significant Grade 3 
or 4 adverse events judged by the investigator to have a reasonable possibility of 
relatedness to the study drug
The IMC will make recommendations as to the further conduct of the study as outlined in
the IMC Charter.  Other specific operational details such as the IMC's composition, 
frequency and timing of meetings, and members' roles and responsibilities will be 
detailed in the IMC Charter. Cohorts evaluating regimens with AT-527 doses lower than 
a previously tested dose regimen will not require additional IMC oversight..
Figure 1 presents an overview of the study design.  Schedule of activities are provided in 
Appendix 1, Appendix 2, and Appendix 3.




RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
33/Protocol WV43042, Version 6
3.3
RATIONALE FOR STUDY DESIGN
3.3.1
Rationale for AT-527 Dose and Schedule
In healthy volunteers and HCV-infected patients, the pharmacokinetics of AT-511 (the 
free base form of AT-527), AT-551, AT-229, and AT-273 (a major nucleoside metabolite 
of AT-511 and a surrogate for the intracellular concentration of the active triphosphate 
metabolite AT-9010) were comparable.  AT-511 metabolites exhibited dose-related 
plasma exposure in both populations. The PK parameters of AT-511 and its metabolites 
AT-551, AT-229, and AT-273 were also comparable between non-cirrhotic and cirrhotic 
HCV-infected patients.  Similar disposition characteristics of AT-527 are assumed in 
non-hospitalized adult patients with mild or moderate COVID-19.
3.3.1.1
Rationale for AT-527 550 mg BID Dose Regimen
The starting dose regimen (Cohort A) for this study is 550 mg AT-527 BID for 5 days.
This regimen is supported by the following data:

Tissue distribution data for the active triphosphate metabolite AT-9010 in 
non-human primate and production rates of AT-9010 in human and cynomolgus 
monkey hepatocytes incubated with 10 M AT-511 (see details in the AT-527 
Investigator's Brochure, Section 4.2.2.2 and Table 6-1)

Predicted PK profiles for AT-9010 in the lung at the proposed 550 mg BID regimen 
(see details in the AT-527 Investigator's Brochure, in Figure 6-1)
At steady state, the 550 mg BID regimen is predicted to deliver the following values:

Mean trough AT-9010 (the active triphosphate metabolite) concentrations at 
12 hours (C12 hr) in the lung at about 0.9 M, 2.1-fold higher than the mean EC90 of 
0.42 M determined for the free base AT-511 in an in vitro antiviral activity assay in 
SARS-CoV-2infected human airway epithelial cells (AT-527 Investigator's 
Brochure)

Mean maximum lung AT-9010 concentrations at about 1.5 M (time to maximum 
concentration at about 4 hours postdose), 3.6-fold higher than the mean EC90 of 
0.42 M.
The 550 mg BID regimen has been evaluated in the ongoing phase I Study AT-03A-002;
20 healthy subjects (blinded, 1:1 randomization active vs. placebo) were enrolled and 
have completed dosing and no safety concerns were identified. In the ongoing Phase II 
study AT-03A-001 using the 550 mg BID regimen in hospitalized patients with moderate 
COVID-19 and risk factors for poor outcomes (blinded, 1:1 randomization active vs. 
placebo), an interim analysis after the first 70 patients have not revealed any safety 
concerns. Furthermore, a planned interim safety analysis was performed after 
30 patients (50% enrollment) in Cohort A (550 mg BID regimen) of the current study 
had completed assessments through Day 10, and no safety concerns were identified.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
34/Protocol WV43042, Version 6
Data for AT-527 550 mg once a day (QD) combined with daclatasvir 60 mg QD in 
HCV-infected patients is available from the recently completed 12-week study 
(AT-01B-002). In that study, most patients received a cumulative total dose of 
AT-527 30800 mg.  Safety and tolerability data from the study provide a safety margin of 
5.6-fold for a 5-day (5500 mg cumulative dose) treatment regimen for COVID-19 
patients.  
The animal and human systemic exposure parameters summarized in Table 6-2 of the 
AT-527 Investigator's Brochure indicate that the steady-state exposures of AT-511 and 
its metabolites achieved at the NOAEL doses in the 13-week toxicology studies exceed 
or approximate unity for the AT-527 550 mg BID dose in the target population of this 
study.
These considerations support an expected favorable safety profile for the evaluation of 
the 550 mg BID dose regimen in the target population. 
Depending on emerging data, subsequent cohorts may evaluate doses higher or lower 
than 550 mg BID.
3.3.1.2
Rationale for Higher AT-527 Dose Regimens
The available nonclinical and clinical evidence supports the proposed starting regimen of 
550 mg BID.  However, AT-527 dose regimens higher than the starting regimen (550 mg 
BID) may be selected to further explore the dose-exposure-response profile for AT-527 
and delineate the relationship between plasma concentration of AT-273, a surrogate for 
the intracellular concentration of the active triphosphate metabolite AT-9010, and 
antiviral activity.
The maximum dose regimen tested will not exceed 1100 mg BID for five days. At 
steady state, this regimen is predicted to achieve the following values:

Mean trough AT-9010 concentrations at 12 hours (C12 hr) in the lung at about 1.8 
M, 4.3-fold higher than the mean EC90 of 0.42 M determined for AT-511 in the in 
vitro antiviral activity assay in SARS-CoV-2-infected human airway epithelial cells

Mean maximum AT-9010 concentrations in the lung at about 3.0 M, 7.1-fold higher 
than the mean EC90 of 0.42 M
Exposure multiples for the maximum concentration (Cmax) and the area under the 
concentrationtime curve over the dosing interval at steady state (AUC,ss) of AT-511, 
AT-551, AT-229, and AT-273 in plasma at the highest planned AT-527 dose in this study 
(1100 mg BID) are presented in Table 2.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
35/Protocol WV43042, Version 6
Plasma exposures achieved in the repeat-dose toxicity studies in the rat and the 
non-human primate either exceed or approximate the anticipated clinical exposures for 
the different metabolites in one or both species, depending on the metabolite, and are 
consistent with the International Council for Harmonisation (ICH) document on 
metabolite coverage including prodrug approaches (ICH 2008).
Table 2
Predicted Rat and Non-Human Primate Exposure Multiples for 
AT-511 (Free Base Form of AT-527) and Its Major Metabolites 
AT-551, AT-229 and AT-273 at a Human Dose of AT-527 1100 mg 
BID 
Monkey: Day 5
1000 mg/kg
Monkey: 13-wk
650 mg/kg
Rat: 13-wk
1000 mg/kg
Males
Females
Males
Females
Males
Females
Cmax
AT-511
1.6
1.2
2.0
1.0
0.01
0.04
AT-551
8.0
17.5
5.5
3.2
15.1
27.8
AT-229
2.1
2.0
1.0
0.8
2.0
4.3
AT-273
0.4
1.1
0.7
0.6
1.1
1.5
AUC,ss
AT-511
2.9
1.0
1.3
1.5
0.01
0.02
AT-551
8.0
11.4
4.2
2.4
6.0
6.6
AT-229
1.6
0.9
0.6
0.7
1.7
2.8
AT-273
0.3
0.5
0.4
0.4
0.8
1.1
AUC,ssarea under the concentration–time curve during the dosing interval at steady state; 
Cmaxmaximum concentration.
3.3.2
Rationale for Patient Population
Despite the recent approval and EUA of monoclonal antibody therapies for patients with 
mild to moderate COVID-19, the utility of these treatments in this patient population is 
limited by the requirement for parenteral administration within a healthcare setting. An 
antiviral therapeutic that could be administered orally to ambulatory non-hospitalized 
patients with mild to moderate COVID-19 has the potential to significantly reduce their 
viral load and symptoms which may in turn reduce the risk of deterioration of these 
patients, preventing progression of disease or hospitalization, and will have a significant 
impact on the pandemic and public health systems globally. Moreover, together with 
vaccines, safe, effective oral antivirals are expected to form the mainstay of routine 
patient management for COVID-19 in the years to come. Given the acceptable safety 
profile so far in the ongoing Phase I and Phase II studies, this study is justified to confirm 
the antiviral activity, safety, and pharmacokinetics of AT-527 to inform further 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
36/Protocol WV43042, Version 6
development and selection of the appropriate dosing regimen of AT-527 in this patient 
population. 
3.3.3
Rationale for Control Group
A placebo-controlled study design is essential for the evaluation of antiviral activity of 
AT-527 given the visit-by-visit reduction in SARS-CoV-2 viral load that is expected in the 
natural course of a generally self-limiting infection. The use of a placebo control will also 
allow unbiased evaluation of the safety and efficacy of AT-527.  Although new 
monoclonal antibody therapies have recently been approved or authorized for use in this 
patient population, their use is currently limited and supportive or symptomatic treatment 
remains the mainstay of treatment for this patient population. Participants in this study 
will be allowed to use appropriate symptomatic treatment at the investigator’s discretion
as detailed in Section 4.4.  Therefore, a placebo control is considered appropriate in this 
study.
3.3.4
Rationale for Biomarker Assessments
COVID-19 is a heterogeneous disease, and expression of certain biomarkers has been
shown to vary among patients, especially those that are hospitalized (Arunachalam et al. 
2020).  Biomarker expression has also been shown to vary significantly among patients
with mild or moderate disease. Therefore, all patients may not be equally likely to 
benefit from treatment.  Predictive biomarker samples collected prior to dosing will be 
assessed in an effort to identify those patients with COVID-19driven pathogenesis who 
are most likely to respond to AT-527.  PD biomarkers will be assessed to demonstrate 
evidence of biologic activity of AT-527 in patients, to support selection of a 
recommended dose and dosing regimen, and to inform potential revisions to the PK 
sample collection schedule. As these biomarkers may also have prognostic value, their 
potential association with disease progression will also be explored.
3.3.5
Rationale for Non-Standard Clinical Outcome Assessments
At the onset of the COVID-19 pandemic, there was limited understanding of what 
constituted disease progression in COVID-19 and how the symptoms were manifested 
and impacted patients' lives. Given the heterogeneous nature of COVID-19related 
symptoms in outpatients, key COVID-19related symptoms should be assessed 
systematically to provide an accurate evaluation. Currently, there are no validated 
patient-reported outcome (PRO) tools for the assessment of COVID-19 symptoms. This 
study will utilize a PRO instrument based on the example U.S. Food and Drug 
Administration (FDA) COVID-19 PRO instrument that assesses 14 of the most common 
COVID-19 symptoms (FDA 2020). The symptom items used in this PRO are derived
from information provided by the Centers for Disease Control and Prevention (CDC) as 
of 28 August 2020.  


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
37/Protocol WV43042, Version 6
4.
MATERIALS AND METHODS
4.1
PATIENTS
Up to approximately 404 non-hospitalized adult patients with mild or moderate 
COVID-19 will be enrolled in this study.
4.1.1
Inclusion Criteria
Patients must meet the following criteria for study entry:

Signed Informed Consent Form

Age ≥18 years at time of signing Informed Consent Form

Willing and able to comply with the study protocol and all study procedures, in the 
opinion of the investigator

Positive SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test) at screening

Has symptoms consistent with mild or moderate COVID-19, as determined by the 
investigator, with onset 5 days prior to randomization

For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use adequate contraception during the treatment 
period and for 30 days after the final dose of study drug.
A woman is considered to be of childbearing potential if she is postmenarchal, 
has not reached a postmenopausal state (12 continuous months of 
amenorrhea with no identified cause other than menopause), and is not 
permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, 
and/or uterus) or another cause as determined by the investigator 
(e.g., Müllerian agenesis).  The definition of childbearing potential may be 
adapted for alignment with local guidelines or regulations. Women of 
childbearing potential must be established on their chosen method of 
contraception at screening.
The following are examples of adequate contraceptive methods:  bilateral tubal 
ligation; male sterilization; hormonal contraceptives; hormone-releasing 
intrauterine devices; copper intrauterine devices; male or female condom with 
or without spermicide; and cap, diaphragm, or sponge with spermicide.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not adequate methods of contraception.  
If required per local guidelines or regulations, locally recognized adequate 
methods of contraception and information about the reliability of abstinence will 
be described in the local Informed Consent Form. 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
38/Protocol WV43042, Version 6
4.1.2
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:

Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as any
of the following: shortness of breath at rest, respiratory rate 30, heart rate 125, 
peripheral capillary oxygen saturation (SpO2) 93% on room air

Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited 
to, other direct-acting antivirals, convalescent plasma, monoclonal antibodies 
against SARS-CoV-2, or intravenous immunoglobulin within 3 months or less than 
5 drug-elimination half-lives (whichever is longer) prior to screening

Requirement, in the opinion of the investigator, for any of the prohibited medications 
during the study

Use of hydroxychloroquine or amiodarone within 3 months of screening

Pregnant or breastfeeding, or intending to become pregnant during the study or 
within 30 days after the final dose of study drug.  Women of childbearing potential
must have a negative pregnancy test result at screening

Abnormal laboratory test results at screening, defined as meeting any of the 
following sets of criteria:
–
ALT or AST 5 upper limit of normal (ULN)
–
Total bilirubin 1.5 ULN, unless the patient has known Gilbert disease
–
Creatinine clearance 60 mL/min (Cockcroft-Gault formula)
–
Total WBC 2,500/mm3 or ANC 800/mm3
–
Platelet count 80 109/L

Clinically significant abnormal ECG, as determined by the Investigator, at screening

Planned procedure or surgery during the study

Known allergy or hypersensitivity to study drug or drug product excipients

Substance abuse, as determined by the investigator, within 12 months prior to 
screening

Poor peripheral venous access

Malabsorption syndrome or other condition that would interfere with 
enteral absorption

Any clinically significant history of epistaxis within the last 3 months and/or history of 
being hospitalized due to epistaxis of any previous occasion 

History of anaphylaxis

Any uncontrolled serious medical condition or other clinically significant abnormality 
in laboratory tests that, in the investigator's judgment, precludes the patient's safe 
participation in and completion of the study


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
39/Protocol WV43042, Version 6
4.2
METHOD OF TREATMENT ASSIGNMENT AND BLINDING 
4.2.1
Treatment Assignment
This is a randomized, double-blind study.  After initial written or electronic informed 
consent has been obtained, all screening procedures and assessments have been 
completed, and eligibility has been established for a patient, the study site will obtain the 
patient's identification number and treatment assignment from an interactive voice or 
web-based response system (IxRS).
In Cohort A and Cohort E, patients will be randomly assigned to receive AT-527 or 
placebo in a 1:1 ratio.  In Cohorts BD, patients will be randomized to receive AT-527 or 
placebo in a 3:1 ratio. A permuted-block randomization method will be utilized to ensure 
a balanced assignment to each treatment arm (see Section 3.1 for details).
4.2.2
Blinding
Study site personnel and patients will be blinded to treatment assignment during the 
study. Following interim analyses, the Sponsor study team and appropriate senior 
management personnel will be unblinded at a treatment group level, however the 
Sponsor and its agents will be blinded to individual treatment assignment, with the 
exception of individuals who require access to patient treatment assignments to fulfill 
their job roles during a clinical trial. These roles include the unblinding group 
responsible, clinical supply chain managers, sample handling staff, operational assay 
group personnel, IxRS service provider, and IMC members. Supporting biometrics staff 
will have access to the unblinded data to allow for data transfer, unblinding, and 
summarizing of interim analyses and IMC review.
While PK samples must be collected from patients assigned to the placebo arm to 
maintain the blinding of treatment assignment, PK assay results for these patients are 
generally not needed for the safe conduct or proper interpretation of the study data.  
Laboratories responsible for performing study drug PK assays will be unblinded to 
patient treatment assignments to identify appropriate samples for analysis.  PK samples 
from patients assigned to the placebo arm will not be analyzed for study drug PK 
concentration except by request (e.g., to evaluate a possible error in dosing).  
If unblinding is necessary for a medical emergency (e.g., in the case of a serious 
adverse event for which patient management might be affected by knowledge of 
treatment assignment), the investigator will be able to break the treatment code by 
contacting the IxRS.  The treatment code should not be broken except in emergency 
situations.  The investigator is not required to contact the Medical Monitor prior to 
breaking the treatment code.  However, the investigator should contact the Medical 
Monitor to discuss emergency unblinding after the treatment code has been broken.
If the investigator wishes to know the identity of the study drug for any reason other than 
a medical emergency, he or she should contact the Medical Monitor directly.  The 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
40/Protocol WV43042, Version 6
investigator should document and provide an explanation for any non-emergency 
unblinding.  If the Medical Monitor agrees to patient unblinding, the investigator will be 
able to break the treatment code by contacting the IxRS.
As per health authority reporting requirements, the Sponsor's Drug Safety representative
will break the treatment code for all serious, unexpected suspected adverse reactions 
(see Section 5.7) that are considered by the investigator or Sponsor to be related to an 
investigational medicinal product (IMP); defined in Section 4.3).  The patient may 
continue to receive treatment, and the investigator, patient, and Sponsor personnel, with 
the exception of the Drug Safety representative and personnel who must have access to 
patient treatment assignments to fulfill their roles (as defined above), will remain blinded 
to treatment assignment.
4.3
STUDY TREATMENT AND OTHER TREATMENTS RELEVANT 
TO THE STUDY DESIGN
The investigational medicinal product for this study is RO7496998 (AT-527) or matching 
placebo.
4.3.1
Study Treatment Formulation and Packaging
4.3.1.1
AT-527 and Placebo
AT-527 and matching placebo will be supplied by the Sponsor as 275 mg or 550 mg 
tablets. For information on the AT-527 formulation, see the pharmacy manual or AT-527
Investigator's Brochure.
4.3.2
Study Treatment Dosage, Administration, and Compliance
The treatment regimens are summarized in Section 3.1.
Patients in Cohort A will self-administer AT-527 (or placebo) tablets at a dose of 550 mg 
orally BID on Days 15.  AT-527 (or placebo) tablets should be taken approximately 
12 hours apart. If the first dose is taken after 4 p.m. (16:00 hours) on Day 1, the next 
dose will be taken the morning of Day 2. For these patients, the tenth dose will be taken 
on the morning of Day 6. If the first dose is taken prior to 4 p.m. (16:00 hours) on Day 1, 
the next dose should be taken in the evening of the same day (i.e., prior to midnight on 
the same calendar day with a minimum of 8 hours between doses). For these patients, 
the tenth dose will be taken in the evening of Day 5. AT-527 (or placebo) may be taken 
with or without a meal.  AT-527 (or placebo) tablets should be swallowed whole with a 
glass of water and should not be chewed, cut, or crushed.  If a dose of AT-527 (or 
placebo) is missed (i.e., not taken within 12 hours after the scheduled dosing time), the 
patient should resume dosing with the next scheduled dose.  If a patient vomits after 
taking a dose, a replacement tablet should not be taken, dosing should resume with the 
next scheduled dose.  To assess patient compliance with self-administration of AT-527
(or placebo), patients will be required to record the time and date they took each dose in 
a medication diary; missed doses will also be recorded.  Patients will be instructed to 
bring their bottles of AT-527 (or placebo) and their medication diaries to each study visit. 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
41/Protocol WV43042, Version 6
If a BID regimen is selected for Cohorts BE, patients will follow the dose administration 
guidance described above for Cohort A.  For other dose regimens, refer to the pharmacy 
manual for detailed instructions on drug preparation and administration.
Details on treatment administration (e.g., dose and timing) should be noted on the 
Study Drug Administration electronic Case Report Form (eCRF).  Cases of overdose or 
medication error, along with any associated adverse events, should be reported as 
described in Section 5.3.5.11.
Guidelines for dosage modification and treatment interruption or discontinuation for 
patients who experience adverse events are provided in Section 5.1.2.
4.3.3
Investigational Medicinal Product Handling and Accountability
All IMPs required for completion of this study will be provided by the Sponsor.  The study 
site (i.e., investigator or other authorized personnel [e.g., pharmacist or nurse]) is 
responsible for maintaining records of IMP delivery to the site, IMP inventory at the site, 
IMP use by each patient, and disposition or return of unused IMP, thus enabling 
reconciliation of all IMP received, and for ensuring that patients are provided with doses 
specified by the protocol.
The study site should follow all instructions included with each shipment of IMP.  The 
study site will acknowledge receipt of IMPs supplied by the Sponsor, using the IxRS to
confirm the shipment condition and content.  Any damaged shipments will be replaced.  
The investigator or designee must confirm that appropriate temperature conditions have 
been maintained during transit, either by time monitoring (shipment arrival date and 
time) or temperature monitoring, for all IMPs received and that any discrepancies have 
been reported and resolved before use of the IMPs.  All IMPs must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions, with access limited to the investigator 
and authorized staff.
Only patients enrolled in the study may receive IMPs, and only authorized staff may 
supply or administer IMPs.
IMPs will either be disposed of at the study site according to the study site's institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
documentation.  The site's method of destroying Sponsor-supplied IMPs must be agreed 
to by the Sponsor.  The site must obtain written authorization from the Sponsor before 
any Sponsor-supplied IMP is destroyed, and IMP destruction must be documented on 
the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
the study site should be recorded on the drug accountability log.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
42/Protocol WV43042, Version 6
Refer to the pharmacy manual and/or the AT-527 Investigator's Brochure for information 
on IMP handling, including preparation and storage, and accountability. 
4.3.4
Continued Access to AT-527
Currently, the Sponsor does not have any plans to provide IMP (RO7496998 [AT-527]) 
or any other study treatments to patients who have completed the study.  The Sponsor 
may evaluate whether to continue providing AT-527 in accordance with the Roche 
Global Policy on Continued Access to Investigational Medicinal Product, available at the 
following website:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
4.4
CONCOMITANT THERAPY
Concomitant therapy consists of any medication (e.g., prescription drugs, over-the-
counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used 
by a patient in addition to protocol-mandated treatment from 7 days prior to initiation of 
study drug (12 months for COVID-19 vaccines) to the end of study telephone call 
(Day 33).  All such medications should be reported to the investigator and recorded on 
the Concomitant Medications eCRF.
4.4.1
Permitted Therapy 
Patients are permitted to use the following therapies during the study:

Hormonal contraceptives (see Section 4.1.1)

Hormone-replacement therapy

Paracetamol (acetaminophen)

Non-steroidal anti-inflammatory drugs

COVID-19 vaccines are permitted from Day 15 onwards (see Section 4.5.2 for 
documentation requirements pertaining to vaccine type and date of dosing).
–
Patients must have a 40-day window since their last dose of vaccination 
(second dose if applicable) prior to enrollment.
4.4.2
Cautionary Therapy
4.4.2.1
Herbal Therapies
Concomitant use of herbal therapies is not recommended because their 
pharmacokinetics, safety profiles, and potential drugdrug interactions are generally 
unknown.
4.4.2.2
Effects of Co-administered Therapies on AT-511 and 
Metabolites
P-glycoprotein (P-gp) inhibitors

Concomitant use of P-gp inhibitors is permitted but dosing of study drug and 
the P-gp inhibitor must be staggered by 2 hours (with study drug dosed first). 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
43/Protocol WV43042, Version 6
Common examples of P-gp inhibitors include carvedilol, imidazoles, macrolides, 
ritonavir and verapamil. 
For a list of P-gp inhibitors, refer to 
https://go.drugbank.com/categories/DBCAT002667
Breast Cancer Resistance Protein (BCRP) inducers

BCRP inducers may affect plasma levels of AT-229.  However, AT-229 is 
considered an inactive metabolite, and changes in AT-229 PK are not expected to 
affect the antiviral activity of AT-527.  Consider substituting or stopping drugs 
that are major BCRP inducers during study treatment and resume 12 hours after 
the final dose of study drug.  In the event that the BCRP inducers cannot be safely 
discontinued or substituted, they should be used with caution.  Common examples 
of BCRP inducers include venlafaxine.
For a list of BCRP inducers, refer to 
https://go.drugbank.com/categories/DBCAT003986.
Organic Anion Transporter 1 and 3 (OAT1 and OAT3) inhibitors

OAT1 and OAT3 inhibitors may affect plasma levels of AT-273.  However, AT-273 
is considered an inactive metabolite, and changes in AT-273 PK are not expected to 
affect the antiviral activity of AT-527.  Consider stopping drugs that are major 
OAT1/3 inhibitors during study treatment and resume 12 hours after the final dose 
of study drug.  In the event that the OAT1/3 inhibitors cannot be safely 
discontinued or substituted, they should be used with caution.  Common examples 
of OAT1/3 inhibitors include furosemide, losartan and cimetidine.
For a list of OAT1 and OAT3 inhibitors, refer to 
https://go.drugbank.com/categories/DBCAT004041 and 
https://go.drugbank.com/categories/DBCAT003946, respectively.
4.4.2.3
Effects of AT-511 on Co-administered Therapies
P-glycoprotein (P-gp) sensitive substrates

P-gp inhibition: In the event that sensitive substrates of P-gp with a NTI cannot be 
safely discontinued or substituted, they should be dosed 2 hours after study drug 
administration, by which time absorption of AT-511 is considered essentially 
complete. Common examples of P-gp sensitive substrates with NTI include digoxin 
and tamoxifen.
For a list of sensitive P-gp substrates with NTI refer to 
https://go.drugbank.com/categories/DBCAT004027.
4.4.3
Prohibited Therapy
Use of the following concomitant therapies is prohibited from Day 1 until study 
completion or early termination, except as otherwise indicated, as described below:

Investigational therapy (other than protocol-mandated study treatment) is prohibited 
within 90 days prior to initiation of study treatment and during study treatment

Sofosbuvir, for patients with active HCV


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
44/Protocol WV43042, Version 6

Abacavir, for patients with HIV

Hydroxychloroquine or amiodarone within 3 months prior to screening and during 
the study
4.5
STUDY ASSESSMENTS 
The schedules of activities to be performed during the study are provided in 
Appendix 1Appendix 3.  All activities should be performed and documented for each 
patient.  
Patients will be monitored for safety and tolerability throughout the study.  
At applicable sites, informed consent may be obtained and certain study assessments 
may be performed by a mobile nursing (MN) professional at the patient's home to 
improve access and convenience for patients participating in the study.  If participating 
sites cannot provide MN services, the Sponsor will select a healthcare organization that 
will be responsible for providing MN services (the MN vendor).  The site or MN vendor is 
responsible for ensuring that all MN professionals are licensed, qualified, and in good 
standing, as per applicable regulations, and that appropriate background checks have 
been performed.  If the investigator at a participating site determines that MN services 
are appropriate for a patient and the patient gives written or electronic informed consent 
to participate in MN visits, the MN network will communicate with the patient and the 
patient's site.  MN visits will be scheduled on specified visit days, to allow for the relevant 
assessments to be performed by the MN professional.  The schedule of activities will 
specify the assessments that can be performed by an MN professional.
4.5.1
Informed Consent Forms and Screening Log
Written or electronic informed consent for participation in the study must be obtained 
before performing any study-related procedures (including screening evaluations).  
Informed Consent Forms for enrolled patients and for patients who are not subsequently 
enrolled will be maintained at the study site.
All screening evaluations must be completed and reviewed to confirm that patients meet 
all eligibility criteria before enrollment.  The investigator will maintain a screening log to 
record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
4.5.2
Medical History, Baseline Conditions, Concomitant Medication,
and Demographic Data
Medical history, including clinically significant diseases, surgeries, cancer history 
(including prior cancer therapies and procedures), reproductive status, smoking 
history, and use of alcohol and drugs of abuse, will be recorded at baseline.  In addition, 
all medications (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
45/Protocol WV43042, Version 6
homeopathic remedies, nutritional supplements) used by the patient within 7 days prior 
to initiation of study treatment (12 months for COVID-19 vaccines) will be recorded.  At 
the time of each study visit and at the follow-up telephone call (Day 33), an interval 
medical history should be obtained and any changes in medications and allergies should 
be recorded.
Demographic data will include age, sex, and self-reported race/ethnicity.
COVID-19 vaccines should be reported by the brand name or company manufacturer, if 
available (examples:  Pfizer COVID-19 vaccine, Moderna COVID-19 vaccine) and date 
administered if known. If not available, report as COVID-19 vaccine.
4.5.3
Physical Examinations
A complete physical examination, performed at screening and other specified visits, 
should include an evaluation of the head, eyes, ears, nose, and throat, and the 
cardiovascular, dermatologic, musculoskeletal, respiratory, gastrointestinal,
genitourinary, and neurologic systems.  Any abnormality identified at baseline should be 
recorded on the General Medical History and Baseline Conditions eCRF.
Limited, symptom-directed physical examinations should be performed as clinically 
indicated.  Changes from baseline abnormalities should be recorded in patient notes.  
New or worsened clinically significant abnormalities should be recorded as adverse 
events on the Adverse Event eCRF.
4.5.4
Vital Signs
Vital signs will include measurements of respiratory rate, pulse rate, and systolic and 
diastolic blood pressure and SpO2 while the patient is in a supine or seated position, and 
temperature.  Record abnormalities observed at baseline on the General Medical History 
and Baseline Conditions eCRF.  At subsequent visits, record new or worsened clinically 
significant abnormalities on the Adverse Event eCRF.
4.5.5
Laboratory, Biomarker, and Other Biological Samples
At screening only, samples for the following laboratory tests will be sent to the study 
site's local laboratory for analysis:

Pregnancy test (urine or serum)
All women of childbearing potential will have a pregnancy test at screening

SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test) at screening: 
nasopharyngeal swab

Hematology:  WBC count, RBC count, hemoglobin, hematocrit, platelet count, and 
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, 
other cells)

Chemistry panel (serum or plasma): bicarbonate or total carbon dioxide (if 
considered standard of care for the region), sodium, potassium, chloride, glucose, 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
46/Protocol WV43042, Version 6
BUN or urea, creatinine, creatinine clearance (Cockcroft-Gault formula),
total protein, albumin, phosphate, calcium, magnesium, total and direct bilirubin, 
ALP, ALT, AST, triglycerides, cholesterol, amylase and lipase
On all other study days, samples for the following laboratory tests will be sent to 
designated central laboratories for analysis, unless otherwise noted:

Hematology:  WBC count, RBC count, hemoglobin, hematocrit, platelet count, and 
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes, 
other cells)

Chemistry panel (serum or plasma):  bicarbonate or total carbon dioxide (if 
considered standard of care for the region), sodium, potassium, chloride, glucose, 
BUN or urea, creatinine, creatinine clearance (Cockcroft-Gault formula), total
protein, albumin, phosphate, calcium, magnesium, total and direct bilirubin, ALP, 
ALT, AST, urate, CK (isoenzyme analysis if CK is elevated), cardiac troponins, BNP, 
triglycerides, cholesterol, amylase, LDH, PCT, and lipase

Coagulation:  INR, aPTT, PT, D-dimer, and fibrinogen

Plasma samples for PK analysis and exploratory PK research

Serum samples for PD analysis and exploratory biomarker research

Serum samples for SARS-COV-2 antibody titer and serum viral load

Nasopharyngeal swab, saliva, and blood samples for SARS-COV-2 virology tests 
(viral load and exploratory analysis, including sequencing)

Nasopharyngeal swab sample for respiratory pathogen co-infections panel
(multiplex assay)

Nasosorptionsamples for exploratory research on biomarkers

Saliva samples for exploratory research on biomarker (viral) assay development

Blood PAXgene RNA for RNA sequencing or quantitative polymerase chain reaction

Cryopreserved peripheral blood mononuclear cells (PBMCs) for high dimensional 
cytometry analysis 

Plasma obtained during PBMC processing will be retained for further exploratory 
research
Exploratory biomarker research and virologic testing may include, but will not be limited 
to, analysis of inflammatory mediators and/or cytokines, immune cells, serum viral load,
SARS-COV-2 antibody titer, and virus genotypic analysis.  Research may also involve 
extraction of DNA, cell-free DNA, or RNA; analysis of mutations, single nucleotide 
polymorphisms, and other genomic variants; and genomic profiling through use of 
next-generation sequencing of a comprehensive panel of genes. Genomic research will 
be aimed at exploring inherited characteristics.
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
47/Protocol WV43042, Version 6
Biological samples will be destroyed no later than the time of completion of the final 
Clinical Study Report, with the following exceptions:

Plasma samples collected for PK analysis may be needed for additional PK assay 
development and validation; therefore, these samples will be destroyed no later than 
5 years after the final Clinical Study Report has been completed.

Blood (serum, PMBCs, plasma [from PBMC processing]), blood PAXgene RNA,
nasopharyngeal swabs , nasosorption and saliva samples collected for biomarker 
research and biomarker (viral) assay development will be destroyed no later than 15 
years after the final Clinical Study Report has been completed.
When a patient withdraws from the study, samples collected prior to the date of
withdrawal may still be analyzed, unless the patient specifically requests that the 
samples be destroyed or local laws require destruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data.
Data arising from sample analysis, including data on genomic variants, will be subject to 
the confidentiality standards described in Section 8.4.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
4.5.6
Electrocardiograms
Single ECG recordings will be obtained at screening and specified timepoints, as
outlined in the schedule of activities (see Appendix 1Appendix 3), and may be obtained
thereafter at unscheduled timepoints as at the investigator’s discretion.
All ECG recordings must be performed using a standard high-quality, high-fidelity digital 
electrocardiograph machine equipped with computer-based interval measurements. 
Lead placement should be as consistent as possible.  ECG recordings must be 
performed after the patient has been resting for at least 10 minutes.  All ECGs are to be 
obtained prior to other procedures scheduled at that same time (e.g., vital sign 
measurements, blood draws) and should not be obtained within 3 hours after any meal.  
Circumstances that may induce changes in heart rate, including environmental
distractions (e.g., television, radio, conversation) should be avoided during the pre-ECG 
resting period and during ECG recording.
For safety monitoring purposes, the investigator or delegate must review, sign, and date 
all ECG tracings.  Paper copies of ECG tracings will be kept as part of the patient's 
permanent study file at the site.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
48/Protocol WV43042, Version 6
4.5.7
Clinical Outcome Assessments
PRO instruments will be completed to assess the clinical efficacy of AT-527 compared 
with placebo.  In addition, PRO instruments will enable the capture of each patient's 
direct experience with AT-527.
PRO data will be collected through use of the following instruments: COVID-19 
Symptom Diary and Patient Global Impression of Severity (PGIS).
4.5.7.1
Data Collection Methods for Clinical Outcome Assessments
PRO instruments will be self-administered at specified timepoints during the study 
(see the schedules of activities in Appendix 1Appendix 3).  At the clinic, instruments will 
be administered before the patient receives any information on disease status, prior to 
the performance of non-PRO assessments, and prior to the administration of study 
treatment unless otherwise specified.
PRO instruments, translated into the local language as appropriate, will be provided by 
the Sponsor in pre-printed booklets to enable the instrument to be administered.  The 
booklets will be labeled to capture timepoint of administration.
Patients should be given the following instructions for completing PRO instruments at 
home or in the clinic:

Patients should complete the instruments in a quiet area with minimal distractions 
and disruptions.

Patients should answer questions to the best of their ability; there are no right or 
wrong answers.

Patients should not obtain advice or help from others (e.g., family members or
friends) when completing the instruments.
4.5.7.2
Description of Clinical Outcome Assessment Instruments
COVID-19 Symptom Diary
The COVID-19 Symptom Diary (see Appendix 5) is adapted from a general 
influenza-like illness symptom patient diary. The diary will be used to characterize key 
symptoms recognized as attributable to COVID-19 illness per FDA guidance (FDA 2020) 
as well as to document the treatment benefit of AT-527. The COVID-19 Symptom Diary 
is composed of 14 individual symptom item questions, each with a 2- or 4-point Likert 
response option.
As outlined in the schedules of activities (Appendix 1Appendix 3), the COVID-19 
Symptom Diary will be administered on paper and completed in its entirety by the patient 
twice a day (morning and evening) on Days 114 and once a day in the evening on 
Days 1528. Patients will be provided with separate versions of the diary for the 
Days 114 assessments (morning vs. evening) and Days 1528 assessment (evening).


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
49/Protocol WV43042, Version 6
Patient Global Impression of Severity
The PGIS (see Appendix 5) is a single item assessment of a patient’s impression of 
severity of his or her COVID-19 symptoms over the course of the study and is 
administered in conjunction with the COVID-19 Symptom Diary. Change in COVID-19 
symptoms is rated on a 4-point Likert scale from “none” (0) to “severe” (3). 
Additional COVID-19 Related Assessment
Patients will measure their temperature twice a day on Days 114 and once a day on 
Days 1528.  Temperature will be recorded as an additional entry in the COVID-19 
Symptom Diary. 
4.5.8
Optional Blood Samples for Whole Genome Sequencing
(Patients at Participating Sites)
At participating sites, optional blood samples will be collected from consenting patients 
for DNA extraction to enable whole genome sequencing (WGS) to identify variants that 
are predictive of response to study drug, are associated with progression to a more 
severe disease state, are associated with susceptibility to developing adverse events, 
can lead to improved adverse event monitoring or investigation, or can increase the 
knowledge and understanding of disease biology and drug safety. Research will be 
aimed at exploring inherited characteristics. The samples may be sent to one or more 
laboratories for analysis. 
Collection and submission of blood samples for WGS is contingent upon the review and 
approval of the exploratory research by each site's Institutional Review Board/ Ethics 
Committee (IRB/EC) and, if applicable, an appropriate regulatory body. If a site has not 
been granted approval for WGS, this section of the protocol (Section 4.5.8) will not be 
applicable at that site. 
The Informed Consent Form will contain a separate section that addresses optional 
blood samples for WGS. A separate, specific signature will be required to document a 
patient's agreement to provide optional blood samples. The investigator should 
document whether or not the patient has given consent to participate and (if applicable) 
the date(s) of consent, by completing the Optional Whole Genome Sequencing Informed 
Consent/Withdrawal eCRF. 
Genomics is increasingly informing researchers' understanding of disease pathobiology. 
WGS provides a comprehensive characterization of the genome and, along with clinical 
data collected in this study, may increase the opportunity for developing new therapeutic 
approaches or new methods for monitoring efficacy and safety or predicting which 
patients are more likely to respond to a drug or develop adverse events. Data will be 
analyzed in the context of this study but will also be explored in aggregate with data from 
other studies. The availability of a larger dataset will assist in identification and 
characterization of important biomarkers and pathways to support future drug 
development. 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
50/Protocol WV43042, Version 6
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual. 
Blood samples collected for WGS are to be stored until they are no longer needed or 
until they are exhausted. However, the storage period will be in accordance with the 
IRB/ECapproved Informed Consent Form and applicable laws (e.g., health authority 
requirements). 
Refer to Section 4.5.5 for details on use of samples after patient withdrawal, 
confidentiality standards for data, and availability of data from biomarker analyses. 
4.6
TREATMENT, PATIENT, STUDY, AND SITE DISCONTINUATION
4.6.1
Study Treatment Discontinuation
Patients must permanently discontinue study treatment if they experience any of the 
following:

Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient's safety if he or she continues to receive study treatment

Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient

Pregnancy

Any event that meets stopping criteria defined in Section 3.1
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be 
replaced.
Patients who discontinue study drug prematurely will complete assessments as 
indicated in the schedules of activities (see Appendix 1Appendix 3).
Refer to the schedules of activities (see Appendix 1Appendix 3) for details on follow-up 
assessments to be performed for patients who permanently discontinue study treatment.  
If a patient requests to be withdrawn from treatment or follow-up assessments, this 
request must be documented in the source documents and signed by the investigator.
4.6.2
Patient Discontinuation from the Study
Patients who discontinue from study participation will have an early termination visit 
7 (2) days after their final dose of study drug.  Patients who discontinue from the study 
after Day 14 will not be required to complete an early termination visit.
Patients have the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
51/Protocol WV43042, Version 6
Reasons for patient discontinuation from the study may include, but are not limited to, 
the following:

Patient withdrawal of consent

Study termination or site closure

Adverse event

Loss to follow-up

Patient non-compliance, defined as failure to comply with protocol requirements as
determined by the investigator or Sponsor
Every effort should be made to obtain a reason for patient discontinuation from the 
study.  The primary reason for discontinuation from the study should be documented on 
the appropriate eCRF.  If a patient requests to be withdrawn from the study, this request 
must be documented in the source documents and signed by the investigator.  Patients 
who withdraw from the study will not be replaced.
4.6.3
Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:

The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients

Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
4.6.4
Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:

Excessively slow recruitment

Poor protocol adherence

Inaccurate or incomplete data recording

Non-compliance with the ICH guideline for Good Clinical Practice

No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)
5.
ASSESSMENT OF SAFETY
5.1
SAFETY PLAN
AT-527 is not approved, and clinical development is ongoing.  The safety plan for 
patients in this study is based on clinical experience with AT-527 completed and ongoing 
studies.  The anticipated important safety risks for AT-527 are outlined below.  Please 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
52/Protocol WV43042, Version 6
refer to the AT-527 Investigator's Brochure for a complete summary of safety 
information. 
Several measures will be taken to ensure the safety of patients participating in this 
study.  Eligibility criteria have been designed to exclude patients at higher risk for 
toxicities.  Throughout the duration of the study, patients will undergo safety monitoring 
including assessment of the nature, frequency, and severity of adverse events.
5.1.1
Risks Associated with AT-527
AT-527 has been evaluated in two completed clinical studies (AT-01B-001 and AT-01B-
002) in healthy volunteers and HCV-infected patients.  In the first study, 88 subjects 
were dosed with blinded study drug (AT-527 or placebo), with 72 of the 88 subjects
receiving active study drug.  AT-527 was well-tolerated in both healthy volunteers and 
HCV-infected patients as either single or multiple doses (seven daily doses) up to 600 
mg of AT-527 (equivalent to 553 mg AT-511 free base).  In the second study, 10 HCV-
infected patients received AT-527 550 mg in combination with 60 mg daclatasvir QD for 
8-12 weeks. There were no serious adverse events, dose-limiting toxicities, or premature 
discontinuations.  
In the COVID-19 development program, AT-527 is being evaluated in one Phase I 
study (AT-03A-002) in healthy volunteers and two Phase II studies in COVID-19 
patients (AT-03A-001 and WV43042). In the ongoing study AT-03A-002, the 
completed Cohorts 1 and 3 investigated AT-527 doses at 550 mg (as 1 550 mg tablet) 
or placebo BID for 5 days and 825 mg (as 3 275 mg) or placebo BID for 10 days, 
respectively.  The completed Cohort 2 investigated a single dose of 550 mg (as 
2 275 mg tablets).  Preliminary safety data from 41 subjects in the completed 
Cohorts 13 show no premature discontinuations due to AT-527-related AEs, no SAEs, 
and no patterns with regards to laboratory-, ECG-, or vital sign abnormalities. In the 
ongoing study AT-03A-001, AT-527 is being evaluated at a dose of 550 mg BID in 
hospitalized patients with moderate COVID-19 and risk factors for poor outcomes. 
Preliminary results from an interim analysis performed after the first 70 patients show 
that AT-527 was generally well tolerated. There were no drug-related SAEs. Non-
serious AEs were equally distributed across treatment arms.  Most were mild-to-
moderate in severity and assessed as not related to the study drug.  No safety concerns 
or newly determined risks were identified. (see further detail in Section 1.2 and 1.3). 
In the current study (WV43042), a planned interim safety analysis after the first 
30 patients enrolled in Cohort A (dosed at 550 mg BID for 5 days) had completed 
assessments through Day 10, identified no safety concerns. All AEs were Grade 1 or 2 
in severity and no SAEs were reported.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
53/Protocol WV43042, Version 6
Some nucleoside analogs have been associated with mitochondrial toxicity, resulting in 
damage to liver, muscles, heart, nerve, pancreas, and other organs. Nephrotoxicity has 
also been associated with the use of some nucleoside analogs (e.g., tenofovir) but is not 
a broad class effect.  The completed nonclinical assessments suggested no potential for 
mitochondrial toxicity with AT-527.  To date, there have been no clinical signs of adverse 
events suggesting mitochondrial toxicity for AT-527 dosing.
To date, there have been no appreciable patterns of treatment-related or dose-related 
clinical adverse events or laboratory abnormalities from nonclinical or clinical studies.
5.1.2
Management of Patients Who Experience Adverse Events
5.1.2.1
Dose Modifications
There will be no dose modifications for study drug in this study.
5.1.2.2
Treatment Interruption
Treatment interruptions will not be permitted for study drug in this study.
5.1.2.3
Management of Increases in QT Interval
Study drug should be discontinued in patients who develop any of the following, unless 
there is a clear alternative cause for the changes:

Sustained (at least two ECG measurements 30 minutes apart) QTcF that is 
500 ms and 60 ms longer than the baseline value

An episode of torsades de pointes or a new ECG finding of clinical concern
Management of patients with sustained QTcF prolongation should include close 
monitoring, with ECGs repeated at least hourly until two successive ECGs show 
resolution of the findings, correction of any electrolyte abnormalities, and possible 
discontinuation of other concomitant medications that are known to prolong the QT 
interval.  Consultation with a cardiologist or electrophysiologist is recommended, to help 
in the management of such patients.
5.2
SAFETY PARAMETERS AND DEFINITIONS
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest, performing 
protocol-specified safety laboratory assessments, measuring protocol-specified vital 
signs, and conducting other protocol-specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in
Section 5.4.
5.2.1
Adverse Events
According to the ICH guideline for Good Clinical Practice, an adverse event is any 
untoward medical occurrence in a clinical investigation subject administered a 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
54/Protocol WV43042, Version 6
pharmaceutical product, regardless of causal attribution.  An adverse event can 
therefore be any of the following:

Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product

Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition) (see Sections 5.3.5.9
and 5.3.5.10 for more information)

Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline

Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug

Adverse events that are related to a protocol-mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., screening invasive 
procedures such as biopsies)
5.2.2
Serious Adverse Events (Immediately Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:

Is fatal (i.e., the adverse event actually causes or leads to death)

Is life-threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that, had it occurred in a more severe 
form or was allowed to continue, might have caused death.

Requires or prolongs inpatient hospitalization (see Section 5.3.5.11)

Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal life 
functions)

Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug

Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity 
of an adverse event (e.g., rated as mild, moderate, or severe, or according to NCI 
CTCAE; see Section 5.3.3); the event itself may be of relatively minor medical 
significance (such as severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
55/Protocol WV43042, Version 6
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.3
Adverse Events of Special Interest (Immediately Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by the investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
are as follows:

Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by 
Hy's Law (see Section 5.3.5.6)

Suspected transmission of an infectious agent by the study drug, as defined below
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
5.3
METHODS AND TIMING FOR CAPTURING AND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity 
(see Section 5.3.3), and causality (see Section 5.3.4).  
5.3.1
Adverse Event Reporting Period
Investigators will seek information on adverse events at each patient contact.  All 
adverse events, whether reported by the patient or noted by study personnel, will be 
recorded in the patient's medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study drug, all adverse events will be reported until 28 days after the 
final dose of study drug.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
56/Protocol WV43042, Version 6
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.
5.3.2
Eliciting Adverse Event Information
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non-directive 
questions include the following:
"How have you felt since your last clinic visit?"
"Have you had any new or changed health problems since you were last here?" 
5.3.3
Assessment of Severity of Adverse Events
The adverse event severity grading scale for the NCI CTCAE (v5.0) will be used for 
assessing adverse event severity.  Table 3 will be used for assessing severity for 
adverse events that are not specifically listed in the NCI CTCAE.
Table 3
Adverse Event Severity Grading Scale for Events Not Specifically 
Listed in NCI CTCAE
Grade
Severity
1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
or intervention not indicated
2
Moderate; minimal, local, or non-invasive intervention indicated; or limiting 
age-appropriate instrumental activities of daily living a
3
Severe or medically significant, but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; or 
limiting self-care activities of daily living b, c
4
Life-threatening consequences or urgent intervention indicated d
5
Death related to adverse event d
NCI CTCAENational Cancer Institute Common Terminology Criteria for Adverse Events.
Note:  Based on the most recent version of NCI CTCAE (v5.0), which can be found at:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
a Instrumental activities of daily living refer to preparing meals, shopping for groceries or 
clothes, using the telephone, managing money, etc.
b Examples of self-care activities of daily living include bathing, dressing and undressing, 
feeding oneself, using the toilet, and taking medications, as performed by patients who are 
not bedridden.
c If an event is assessed as a "significant medical event," it must be reported as a serious 
adverse event (see Section 5.4.2 for reporting instructions), per the definition of serious
adverse event in Section 5.2.2.
d Grade 4 and 5 events must be reported as serious adverse events (see Section 5.4.2 for 
reporting instructions), per the definition of serious adverse event in Section 5.2.2.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
57/Protocol WV43042, Version 6
5.3.4
Assessment of Causality of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no"
accordingly.  The following guidance should be taken into consideration (see also
Table 4):

Temporal relationship of event onset to the initiation of study drug

Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)

Known association of the event with the study drug or with similar treatments

Known association of the event with the disease under study

Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event

Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event
Table 4
Causal Attribution Guidance
Is the adverse event suspected to be caused by the study drug on the basis of facts, evidence, 
science-based rationales, and clinical judgment?
YES
There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
the patient's clinical state, intercurrent illness, or concomitant therapies; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re-challenge.
NO
An adverse event will be considered related, unless it fulfills the criteria specified below.  
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
or concomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
first dose of study drug).
5.3.5
Procedures for Recording Adverse Events
Investigators should use correct medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.
5.3.5.1
Diagnosis versus Signs and Symptoms
A diagnosis (if known) should be recorded on the Adverse Event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
58/Protocol WV43042, Version 6
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the Adverse Event 
eCRF.  If a diagnosis is subsequently established, all previously reported adverse events 
based on signs and symptoms should be nullified and replaced by one adverse event 
report based on the single diagnosis, with a starting date that corresponds to the starting 
date of the first symptom of the eventual diagnosis.
5.3.5.2
Adverse Events that Are Secondary to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:

If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.

If vomiting results in severe dehydration, both events should be reported separately 
on the eCRF.

If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.

If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.

If neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
5.3.5.3
Persistent or Recurrent Adverse Events
A persistent adverse event is one that extends continuously, without resolution, 
between patient evaluation timepoints.  Such events should only be recorded once on 
the Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should be updated
by changing the event from "non-serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
59/Protocol WV43042, Version 6
5.3.5.4
Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy

Is clinically significant in the investigator's judgment 
It is the investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5ULN associated with cholestasis), only the diagnosis 
(i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for 
details on recording persistent adverse events).
5.3.5.5
Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must
be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention or a change in concomitant therapy

Is clinically significant in the investigator's judgment 
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
60/Protocol WV43042, Version 6
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (e.g., hypertension) should be recorded 
on the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section 5.3.5.3 for 
details on recording persistent adverse events).
5.3.5.6
Abnormal Liver Function Tests
The finding of an elevated ALT or AST (3baseline value) in combination with either 
an elevated total bilirubin (2ULN) or clinical jaundice in the absence of cholestasis or 
other causes of hyperbilirubinemia is considered to be an indicator of severe liver injury
(as defined by Hy's Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:

Treatment-emergent ALT or AST 3baseline value in combination with total 
bilirubin 2ULN (of which 35% is direct bilirubin)

Treatment-emergent ALT or AST 3baseline value in combination with clinical 
jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section 5.3.5.4) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest 
(see Section 5.4.2).
5.3.5.7
Deaths
All deaths that occur during the protocol-specified adverse event reporting period 
(see Section 5.3.1), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2).  This 
includes death attributed to progression of COVID-19.
Death should be considered an outcome and not a distinct event.  The event or condition
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by the established cause of death.  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
61/Protocol WV43042, Version 6
If the death is attributed solely to progression of COVID-19, “coronavirus disease-2019
progression" should be recorded on the Adverse Event eCRF.
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
5.3.5.8
Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  When 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches").
5.3.5.9
Lack of Efficacy or Worsening of COVID-19
Medical occurrences or symptoms of deterioration that are anticipated as part of 
COVID-19, such as fluctuations in symptoms, should not be recorded as adverse 
events. However, deterioration that is judged by the investigator to have unexpectedly 
worsened in severity or frequency or changed in nature at any time during the study
should be recorded as an adverse event.  When recording an unanticipated worsening 
of COVID-19 on the Adverse Event eCRF, it is important to convey the concept that the 
condition has changed by including applicable descriptors (e.g., "accelerated worsening 
of coronavirus disease 2019").
5.3.5.10
Hospitalization or Prolonged Hospitalization
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital)
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2), except as outlined 
below.  
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:

Hospitalization for a preexisting condition, provided that all of the following criteria 
are met:
The hospitalization was planned prior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease
The patient has not experienced an adverse event


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
62/Protocol WV43042, Version 6
An event that leads to hospitalization under the following circumstances is not 
considered to be a serious adverse event, but should be reported as an adverse event 
instead:

Hospitalization that was necessary because of patient requirement for outpatient 
care outside of normal outpatient clinic operating hours
5.3.5.11
Cases of Overdose, Medication Error, Drug Abuse, or Drug 
Misuse
Overdose (accidental or intentional), medication error, drug abuse, and drug misuse
(hereafter collectively referred to as "special situations"), are defined as follows:

Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose

Intentional overdose:  intentional administration of a drug in a quantity that is higher 
than the assigned dose

Medication error:  accidental deviation in the administration of a drug 
In some cases, a medication error may be intercepted prior to administration of 
the drug.

Drug abuse:  intentional excessive use of a drug that may lead to addiction or 
dependence, physical harm, and/or psychological harm

Drug misuse:  intentional deviation in the administration of a drug that does not 
qualify as drug abuse
In cases where drug is to be self-administered by the patient, drug misuse 
could involve the drug being administered to someone other than the patient.
Special situations are not in themselves adverse events, but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria or qualifies as an adverse event of special interest, the event should 
be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2).  For AT-527 (or matching placebo), adverse events 
associated with special situations should be recorded as described below for each 
situation:

Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.

Intentional overdose:  Enter the adverse event term.  Check the "Intentional 
overdose" box.  If drug abuse is suspected, check the "Drug abuse" box.  If drug 
abuse is not suspected, check the "Drug misuse" box.

Medication error that does not qualify as an overdose:  Enter the adverse event 
term.  Check the "Medication error" box.

Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
63/Protocol WV43042, Version 6

Drug abuse that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Drug abuse" box.

Drug abuse that qualifies as an overdose:  Enter the adverse event term.  Check the 
"Intentional overdose" and "Drug abuse" boxes.

Drug misuse that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Drug misuse" box.

Drug misuse that qualifies as an overdose:  Enter the adverse event term.  Check 
the "Intentional overdose" and "Drug misuse" boxes.
In addition, all special situations associated with AT-527 (or matching placebo),
regardless of whether they result in an adverse event, should be recorded on the 
Adverse Event eCRF as described below:

Accidental overdose:  Enter the drug name and "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes.

Intentional overdose:  Enter the drug name and "intentional overdose" as the event 
term.  Check the "Intentional overdose" box.  If drug abuse is suspected, check the 
"Drug abuse" box.  If drug abuse is not suspected, check the "Drug misuse" box.

Medication error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expired drug 
administered) as the event term.  Check the "Medication error" box.

Medication error that qualifies as an overdose:  Enter the drug name and "accidental 
overdose" as the event term.  Check the "Accidental overdose" and "Medication 
error" boxes.  Enter a description of the error in the additional case details.

Intercepted medication error:  Enter the drug name and "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.

Drug abuse that does not qualify as an overdose:  Enter the drug name and "drug 
abuse" as the event term.  Check the "Drug abuse" box.

Drug abuse that qualifies as an overdose:  Enter the drug name and "intentional 
overdose" as the event term.  Check the "Intentional overdose" and "Drug abuse" 
boxes.

Drug misuse that does not qualify as an overdose:  Enter the drug name and "drug 
misuse" as the event term.  Check the "Drug misuse" box.

Drug misuse that qualifies as an overdose:  Enter the drug name and "intentional 
overdose" as the event term.  Check the "Intentional overdose" and "Drug misuse" 
boxes.

Drug administered to someone other than the patient:  Enter the drug name and 
"patient supplied drug to third party" as the event term.  Check the "Drug misuse" 
box.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
64/Protocol WV43042, Version 6
As an example, an accidental overdose that resulted in a headache would require two 
entries on the Adverse Event eCRF, one entry to report the accidental overdose and one 
entry to report the headache.  The "Accidental overdose" and "Medication error" boxes 
would need to be checked for both entries.
5.3.5.12
Patient-Reported Outcome Data
Adverse event reports will not be derived from PRO data by the Sponsor.  Sites are not 
expected to review the PRO data for adverse events.
5.4
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical trial.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the investigator learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:

Serious adverse events (defined in Section 5.2.2; see Section 5.4.2 for details on 
reporting requirements)

Adverse events of special interest (defined in Section 5.2.3; see Section 5.4.2 for 
details on reporting requirements)

Pregnancies (see Section 5.4.3 for details on reporting requirements)
For serious adverse events and adverse events of special interest, the investigator must 
report new significant follow-up information to the Sponsor immediately (i.e., no more 
than 24 hours after becoming aware of the information).  New significant information 
includes the following:

New signs or symptoms or a change in the diagnosis

Significant new diagnostic test results

Change in causality based on new information

Change in the event's outcome, including recovery

Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.1
Medical Monitors and Emergency Medical Contacts
Contact Information for All Sites
Medical Monitor/Emergency Medical Contact:
, M.D.
Telephone No.:


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
65/Protocol WV43042, Version 6
To ensure the safety of study patients, an Emergency Medical Call Center will be 
available 24 hours per day, 7 days per week, in case the above-listed contacts cannot 
be reached.  The Emergency Medical Call Center will connect the investigator with an 
Emergency Medical Contact, provide medical translation service if necessary, and track 
all calls.  Contact information, including toll-free numbers for the Emergency Medical Call 
Center, will be distributed to investigators. 
5.4.2
Reporting Requirements for Serious Adverse Events and 
Adverse Events of Special Interest
5.4.2.1
Events That Occur prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
event), either by faxing or by scanning and emailing the form using the fax number or 
email address provided to investigators.
5.4.2.2
Events That Occur after Study Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until 28 days after the final dose of study drug.  Investigators 
should record all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on the Adverse Event eCRF and submit the report via the 
electronic data capture (EDC) system.  A report will be generated and sent to Roche 
Safety Risk Management by the EDC system.
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by faxing or by scanning and emailing 
the form using the fax number or email address provided to investigators.  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.  
Instructions for reporting serious adverse events that occur 28 days after the final dose 
of study treatment are provided in Section 5.6.
5.4.3
Reporting Requirements for Pregnancies
5.4.3.1
Pregnancies in Female Patients
Female patients of childbearing potential will be instructed through the Informed Consent 
Form to immediately inform the investigator if they become pregnant during the study or 
within 30 days after the final dose of study drug.  A paper Clinical Trial Pregnancy 
Reporting Form should be completed and submitted to the Sponsor or its designee 
immediately (i.e., no more than 24 hours after learning of the pregnancy), either by 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
66/Protocol WV43042, Version 6
faxing or by scanning and emailing the form using the fax number or email address 
provided to investigators.  Pregnancy should not be recorded on the Adverse Event 
eCRF.  The investigator should discontinue study drug and counsel the patient, 
discussing the risks of the pregnancy and the possible effects on the fetus.  Monitoring 
of the patient should continue until conclusion of the pregnancy.  Any serious adverse 
events associated with the pregnancy (e.g., an event in the fetus, an event in the mother 
during or after the pregnancy, or a congenital anomaly/birth defect in the child) should be 
reported on the Adverse Event eCRF.  In addition, the investigator will submit a Clinical 
Trial Pregnancy Reporting Form when updated information on the course and outcome 
of the pregnancy becomes available.  
5.4.3.2
Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2).
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).  A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.
5.4.3.3
Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug should be classified as a serious adverse event, recorded on the Adverse Event 
eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after 
learning of the event; see Section 5.4.2).
5.5
FOLLOW-UP OF PATIENTS AFTER ADVERSE EVENTS
5.5.1
Investigator Follow-Up
The investigator should follow each adverse event until the event has resolved to baseline 
grade or better, the event is assessed as stable by the investigator, the patient is lost to 
follow-up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study treatment or trial-related 
procedures until a final outcome can be reported.
During the adverse event reporting period (defined in Section 5.3.1), resolution of adverse 
events (with dates) should be documented on the Adverse Event eCRF and in the patient's 
medical record to facilitate source data verification.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
67/Protocol WV43042, Version 6
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.2
Sponsor Follow-Up
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow up by telephone, fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospital discharge 
summaries, consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.6
ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE 
EVENT REPORTING PERIOD
The Sponsor should be notified if the investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
28 days after the final dose of study drug), if the event is believed to be related to prior 
exposure to study drug.  These events should be reported through use of the Adverse 
Event eCRF.  However, if the EDC system is not available, the investigator should report 
these events directly to the Sponsor or its designee, either by faxing or by scanning and 
emailing the paper Clinical Trial Serious Adverse Event/Adverse Event of Special 
Interest Reporting Form using the fax number or email address provided to investigators.
5.7
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, 
AND ETHICS COMMITTEES
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the document listed below:
Drug
Document
AT-527
AT-527 Investigator's Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed.
An aggregate report of any clinically relevant imbalances that do not favor the test 
product will be submitted to health authorities.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
68/Protocol WV43042, Version 6
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN
All primary and secondary virology and efficacy outcomes will be analyzed in the 
modified intent-to-treat infected (mITTi) population. The mITTi population is defined as 
all patients randomized in the study who received any amount of study drug and had at
least one positive SARS-CoV-2 RT-PCR test result above or equal to the limit of 
quantification (LOQ) during the study, with patients grouped according to the treatment 
assignment at randomization. 
Safety analyses will be performed on the safety evaluable population, which consists of 
all patients who receive any amount of study drug.  In all safety analyses, patients will be 
grouped according to the treatment that the patients actually received rather than the 
treatment assigned at randomization.
For Cohorts AD, the primary virology analysis will be performed as part of a Day 10 
review (accompanied with key safety review if deemed necessary, further details will be 
included in the SAP) which is to be completed after all patients enrolled in the current 
cohort have completed assessments through Day 10. Other endpoints will be analyzed 
at the completion of each full cohort or at the completion of the study.
For Cohorts AD, all analyses at the Day 10 review or at the completion of each cohort
will compare each AT-527 dose group and a combined placebo group, including all 
placebo patients enrolled across cohorts up to the cohort being analyzed, while analyses 
performed at the completion of the study will compare each AT-527 dose group and a 
combined placebo group from Cohorts AD.
For Cohort E, the primary virology analysis will be performed as part of a Day 14 
review (accompanied with key safety review if deemed necessary, further details will be 
included in the SAP) which is to be completed after all patients in Cohort E have 
completed assessments through Day 14. Other endpoints will be analyzed at the 
completion of the cohort.
For Cohort E, all analyses will compare the AT-527 dose group and the placebo group 
from Cohort E only. Data from cohorts with the same dose may be pooled to further 
evaluate the primary endpoint as part of a sensitivity analysis.  Full details of all 
planned tables, listings, graphs, and statistical methods will be provided in a Statistical 
Analysis Plan (SAP), which will be finalized prior to the end of the study.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
69/Protocol WV43042, Version 6
6.1
DETERMINATION OF SAMPLE SIZE
The primary objective of this study is to evaluate the antiviral activity of AT-527
compared with placebo.  Approximately 60 patients will be randomized in a 1:1 ratio in 
Cohort A to receive AT-527 or placebo.  Cohorts BD will enroll approximately 
40 patients in a 3:1 ratio to receive AT-527 or placebo, respectively. Cohort E will 
enroll approximately 224 patients in a 1:1 ratio to receive AT-527 or placebo.
The sample size for Cohort AD is based on the primary endpoint of change from 
baseline in SARS-CoV-2 virus RNA measured by RT-PCR at a single timepoint.  A 
sample size of 27 patients per arm (active or placebo) in the mITTi population will result 
in at least 80% power to detect a mean reduction in change from baseline of between 
0.7 and 1.1 log10 copies using a two-sample t-test for comparison of means, assuming a 
standard deviation of between 1.2 and 1.85 (Regeneron 2020) and based on a 1-sided 
10% alpha.  The sample size has been adjusted to 30 patients per arm to account for an 
estimated 90% SARS-CoV-2 positive rate and is based on a single-cohort comparison of 
AT-527 versus placebo.
For Cohort E, a sample size of 100 patients per arm (active or placebo) in the mITTi
population will result in at least 80% power to detect a mean reduction in change from 
baseline of 0.5 log10 copies using a two-sample t-test for comparison of means, 
assuming a standard deviation of 1.25 (deemed appropriate based on current data from 
WV43042) and based on a 1-sided 2.5% alpha. The sample size for Cohort E has been 
adjusted to 112 patients per arm to account for an estimated 90% SARS-CoV-2 positive
rate. Based on emerging external data on direct acting antivirals in COVID-19 (Fischer 
et al 2021), a lower mean reduction in change from baseline of 0.5 log10 copies has been 
utilized in Cohort E. A lower alpha level has also been selected to reduce the likelihood 
of a false positive result and enable a more robust evaluation of the antiviral activity of 
AT-527 at the selected dose regimen.  This sample size also allows for a better 
characterization of the secondary endpoints.
6.2
SUMMARIES OF CONDUCT OF STUDY
The number of patients who are randomized, enroll, discontinue, or complete the study 
will be summarized. Reasons for premature study discontinuation will be listed and 
summarized. 
Eligibility criteria and other major protocol deviations will be listed and summarized by 
treatment group.
6.3
SUMMARIES OF DEMOGRAPHIC AND BASELINE 
CHARACTERISTICS
Demographic and baseline characteristics (including, but not limited to, age, sex, race, 
onset of symptoms, baseline symptom severity, presence of underlying health 
conditions, pre-existing symptoms) will be summarized using means, standard 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
70/Protocol WV43042, Version 6
deviations, medians, and ranges for continuous variables and proportions for categorical 
variables, as appropriate. Summaries will be presented by treatment group and will be 
presented for the mITTi population and may, in addition, be presented for the safety 
population. 
Medical history data, including surgery and procedures, and baseline conditions, will be 
summarized descriptively by treatment group using the safety population. Previous and 
concomitant treatments will be summarized descriptively by treatment group. Exposure 
to study drug will be summarized, including number of doses. A listing of patients by 
treatment group, detailing dosing of study drug will be prepared.
6.4
VIROLOGY AND EFFICACY ANALYSES
All virology and efficacy analyses will be performed on the mITTi population. 
Sensitivity analyses to evaluate the robustness of results to the primary analysis 
methods (e.g., handling of dropouts) may be conducted and will be described in the 
SAP. 
No alpha adjustments for multiple comparisons are planned.
6.4.1
Primary Virology Endpoint
The primary objective of this study is to evaluate the antiviral activity of AT-527
compared with placebo on the basis of the change from baseline in amount of 
SARS-CoV-2 virus RNA as measured by RT-PCR and based on the log-10 scale at 
specified timepoints.
In Cohorts A-D, the change from baseline in the amount of SARS-CoV-2 virus RNA will 
be compared between each AT-527 group and a combined placebo group at Days 3, 5, 
and 7 using Analysis of Covariance (ANCOVA) with baseline virus RNA as a covariate. 
The treatment group least squares mean (LSM) changes, difference in LSM changes, 
80% CI and p-value will be presented for each comparison. Additionally, descriptive
summaries for the change from baseline will also be presented by treatment group.
In Cohort E, the change from baseline in the amount of SARS-CoV-2 virus RNA will be 
compared between the AT-527 group and a placebo group containing only patients from 
Cohort E (unpooled) at Days 3, 5, 7, and 14 using Analysis of Covariance (ANCOVA) 
with baseline virus RNA as a covariate.  The treatment group least squares mean 
(LSM) changes, difference in LSM changes, 95% CI and p-value will be presented for 
each comparison. Additionally, descriptive summaries for the change from baseline will 
also be presented by treatment group.
If the data are not normally distributed, a non-parametric alternative method will be used 
(e.g., Mann-Whitney U test) to compare distributions.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
71/Protocol WV43042, Version 6
Further details of the primary endpoint analysis will be included in the SAP, including 
details of any missing data handling rules for the primary endpoint.
6.4.2
Secondary Virology and Efficacy Endpoints
The following virology and efficacy secondary endpoints will be compared between each 
AT-527 dose group and the pooled placebo group for Cohorts AD and an unpooled 
placebo group for Cohort E:
6.4.2.1
Secondary Virology Endpoints

Time to cessation of SARS-CoV-2 viral shedding as measured by RT-PCR

Time to sustained non-detectable SARS-CoV-2 virus RNA

Proportion of patients positive for SARS-CoV-2 virus RNA by RT-PCR at specified 
timepoints

Area under the curve in the amount of SARS-CoV-2 virus RNA as measured by 
RT-PCR
6.4.2.2
Secondary Efficacy Endpoints

Time to alleviation or improvement of COVID-19 symptoms (Items 112 of the 
COVID-19 Symptom Diary) maintained for a duration of 21.5 hours (24 hours minus 
10%, to allow some flexibility in the timing of assessments), defined as follows:
–
For new symptoms:  time from start of treatment to the alleviation of COVID-19 
symptoms (i.e., a score of 0 [none] or 1 [mild] on the COVID-19 Symptom 
Diary) 
–
For pre-existing symptoms:  time from start of treatment to when a patient’s 
symptoms have been maintained or improved (note improved requires at least 
a single category improvement from baseline on the Likert scale)
The efficacy endpoint definition includes both alleviation of new COVID-19 symptoms 
and maintenance/improvement of pre-existing COVID-19 symptoms to allow for the 
possibility that some patients may have underlying health conditions with symptoms 
similar to those observed with COVID-19 (e.g., cough in a patient with chronic 
obstructive pulmonary disease).  At screening, patients will be assessed with a 14-item 
COVID-19 symptom severity assessment to identify pre-existing symptoms (within the 
prior 30 days), and assess if they worsened due to COVID-19.  Symptoms that are not 
pre-existing are considered to be new symptoms and need to achieve sustained 
alleviation (score of 0 or 1) to meet the endpoint. 
If a symptom is pre-existing, the patient is asked if the severity at screening is worse 
than what was experienced within the last 30 days prior to COVID-19:
–
If the severity is not worse, the symptom must be maintained (no worsening) or 
improved to meet the endpoint.
–
If the severity is worse, then a sustained improvement of at least one grade 
must be achieved to meet the endpoint.  For example, a symptom classed as 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
72/Protocol WV43042, Version 6
severe at screening must improve to moderate, mild, or none, and a symptom 
classed as moderate at screening must improve to mild or none.

The time to alleviation or improvement of COVID-19 symptoms (Items 112 of the 
COVID-19 Symptom Diary) maintained for a duration of 43 hours, defined as 
follows:
–
For new symptoms:  time from start of treatment to the alleviation of COVID-19 
symptoms (i.e., a score of 0 [none] or 1 [mild] on the COVID-19 Symptom 
Diary) 
–
For preexisting symptoms:  time from start of treatment to when a patient’s 
symptoms have been maintained or improved (Note:  Improved requires at 
least a single category improvement from baseline on the Likert scale.)

Time to alleviation of COVID-19 symptoms, defined as the length of time taken from 
start of treatment to the point at which the following criterion is met and maintained 
for at least 21.5 hours:  Score of 0 or 1 on Items 112 of the COVID-19 Symptom 
Diary (without consideration for presence of pre-existing symptoms)

Time to alleviation of COVID-19 symptoms, defined as the length of time taken from 
start of treatment to the point at which the following criterion is met and maintained 
for at least 43 hours:  Score of 0 or 1 on Items 112 of the COVID-19 Symptom 
Diary (without consideration for presence of pre-existing symptoms)

Duration of fever, defined as the time to return to an afebrile state (temperature 
37.5°C) maintained for at least 21.5 hours

Frequency of COVID-19related complications (death, hospitalization, radiologically 
confirmed pneumonia , acute respiratory failure, sepsis, coagulopathy, pericarditis, 
myocarditis, cardiac failure)

Frequency of hospitalizations and death (all cause)

Time to alleviation of an individual symptom, defined as the time taken from the start 
of treatment to the point at which the following criterion is met and maintained (for 
each individual symptom) for at least 21.5 hours:
–
Score of 0 or 1 for Items 112 of the COVID-19 Symptom Diary
–
Score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary
All secondary endpoints will be analyzed descriptively and summary statistics will be 
presented.  For time to event endpoints, a Kaplan-Meier plot and the median time to 
response will be presented along with CIs.  For proportion, frequency and incidence 
endpoints, the number, proportion and difference in proportions along with CIs will be 
presented.  For area under the curve (AUC) endpoints, summary statistics will be 
presented.  Any exploratory statistical testing will be specified in the SAP as appropriate.
Rules for missing data will be specified in the SAP.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
73/Protocol WV43042, Version 6
6.4.3
Exploratory Virology Endpoints
The following virology exploratory endpoints will be compared between each AT-527
dose group and the pooled placebo group for Cohorts AD and an unpooled placebo 
group for Cohort E:

Treatment-emergent amino acid substitutions in SARS-CoV-2 viral genes (nsp12 
and potentially other genes)

Anti-SARS-CoV-2 antibody status/titer at specified timepoints

Change from baseline in SARS-CoV-2 virus titer at specified timepoints

Time to cessation of SARS-CoV-2 viral shedding as measured by virus titer

Proportion of patients with positive SARS-CoV-2 virus titer at specified timepoints

AUC of SARS-CoV-2 virus titer

Drug susceptibility in patients with evaluable virus at specified timepoints
All endpoints will be summarized using descriptive statistics as specified for the 
secondary endpoints.  Any exploratory statistical testing will be specified in the SAP.
6.4.4
Exploratory Patient Global Impression of Severity Endpoint
The exploratory endpoint to evaluate patients’ self-assessment of COVID-19 symptom 
severity as assessed by PGIS at Days 14 and 28 will be summarized using descriptive 
statistics as specified for the secondary endpoints.
6.5
SAFETY ANALYSES
The safety analysis population will consist of all randomized patients who received any 
amount of study drug, with patients grouped according to treatment received.
Safety analyses will be presented by each AT-527 dose and the combined placebo 
group for Cohorts AD and an unpooled placebo group for Cohort E.
Safety will be assessed through summaries of exposure to study treatment, adverse 
events, changes in laboratory test results, and changes in vital signs and ECGs.
Study treatment exposure (such as treatment duration and total dose received) will be 
summarized with descriptive statistics.
All verbatim adverse event terms will be mapped to Medical Dictionary for Regulatory 
Activities thesaurus terms, and adverse event severity will be graded according to NCI 
CTCAE v5.0.  All adverse events, serious adverse events, adverse events leading to 
death, adverse events of special interest, and adverse events leading to study treatment 
discontinuation that occur on or after the first dose of study treatment will be summarized 
by mapped term, appropriate thesaurus level, and severity grade.  For events of varying 
severity, the highest grade will be used in the summaries.  Deaths and cause of death 
will be summarized.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
74/Protocol WV43042, Version 6
Relevant laboratory and vital sign (pulse rate, respiratory rate, blood pressure, SpO2, 
and temperature), data will be displayed by time, with grades identified where 
appropriate.  Additionally, a shift table of selected laboratory tests will be used to 
summarize the baseline and maximum postbaseline severity grade.  Changes in vital 
signs and ECGs will be summarized. 
6.6
PHARMACOKINETIC ANALYSES
The PK analysis population will consist of patients with sufficient data to enable 
estimation of key parameters (including, but not limited to Cmax, and minimum 
concentration), with patients grouped according to treatment received.  Due to sparse 
sampling, non-compartmental analysis will not be performed.
Samples taken for pharmacokinetic analysis will be processed to plasma and 
concentrations of AT-511 (free base form of AT-527) and its major metabolites AT-551, 
AT-229, and AT-273, will be quantified by a validated liquid chromatography-tandem 
mass spectrometry method.
Descriptive summary statistics for PK concentration data will be provided by cohort and 
visit/sampling time point. Concentrations below the lower limit of quantification (LLOQ)
will be reported as zero. Summary statistics will include mean (arithmetic and 
geometric), SD, CV (arithmetic and geometric), median, minimum, and maximum. 
Concentrations below LLOQ will be treated as zero in summary statistics and for PK 
parameter calculations.
Nonlinear mixed effects (NLME) modeling may be used to analyze the dose-
concentration-time data of AT-511 and AT-273 in plasma. Population and individual PK
parameters (e.g., CL/F and Vss/F) will be estimated and the influence of various 
covariates (such as age, gender and body weight) on these parameters will be 
investigated. The data collected during this study may be pooled with data collected in 
other clinical studies (previous Phase I and/or Phase II study in healthy volunteers and 
HCV-infected patients) as appropriate to build the pharmacokinetic model. Secondary 
PK parameters such as AUC and Cmax may be derived from the individual post-hoc 
predictions.  Results of the NLME PK analysis will be reported in a standalone document 
separate from the Clinical Study Report.
The exposure-response profile of AT-511 and its major metabolites will be explored 
(e.g., relationship between plasma concentration of AT-273 and antiviral activity) and will 
be reported in a standalone document separate from the Clinical Study Report.
Additional PK analyses may be conducted as appropriate. The PK data and parameters 
derived from these analyses may be used for exploratory graphical analyses of the PD 
data and parameters.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
75/Protocol WV43042, Version 6
6.7
BIOMARKER ANALYSES
Although no formal statistical analysis of exploratory biomarkers will be performed, data 
may be analyzed in the context of this study and in aggregate with data from other 
studies.  
6.8
INTERIM ANALYSES
6.8.1
Planned Interim Analyses
An interim safety analysis is planned for Cohort A after the first 30 patients have 
completed assessments through Day 10.
6.8.2
Optional Interim Analysis
Given the hypothesis-generating nature of this study, the Sponsor may choose to 
conduct additional interim analyses (i.e., beyond what is specified in Section 6.8.1).  The 
decision to conduct an optional interim analysis and the timing of the analysis will be 
documented in the Sponsor's trial master file prior to the conduct of the interim analysis.  
The interim analysis will be performed and interpreted by members of the Sponsor study 
team and appropriate senior management personnel, who will be unblinded at the 
treatment group level. Access to treatment assignment information will follow the 
Sponsor's standard procedures.
7.
DATA COLLECTION AND MANAGEMENT
7.1
DATA QUALITY ASSURANCE
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data and IxRS data will 
be sent directly to the Sponsor, using the Sponsor's standard procedures to handle and 
process the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system's audit trail.  
System backups for data stored by the Sponsor and records retention for the study data 
will be consistent with the Sponsor's standard procedures.
PRO data will be collected on paper questionnaires.  The data from the questionnaires 
will be entered into the EDC system by site staff.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
76/Protocol WV43042, Version 6
7.2
ELECTRONIC CASE REPORT FORMS 
eCRFs are to be completed through use of a Sponsor-designated EDC system.  Sites 
will receive training and have access to a manual for appropriate eCRF completion.  
eCRFs will be submitted electronically to the Sponsor and should be handled in 
accordance with instructions from the Sponsor.
All eCRFs should be completed by designated, trained site staff.  eCRFs should be 
reviewed and electronically signed and dated by the investigator or a designee.
At the end of the study, the investigator will receive patient data for his or her site in a 
readable format that must be kept with the study records.  Acknowledgement of receipt 
of the data is required.
7.3
SOURCE DATA DOCUMENTATION
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by authorized site 
personnel are accurate, complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, patient-reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies of transcriptions that are certified after verification as being accurate 
and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, 
patient files, and records kept at pharmacies, laboratories, and medico-technical 
departments involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.5.
To facilitate source data verification and review, the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by applicable health authorities.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
77/Protocol WV43042, Version 6
7.4
USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name of the person 
making the change, and date of the change.
7.5
RETENTION OF RECORDS
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, electronic or paper PRO data (if applicable), Informed Consent 
Forms, laboratory test results, and medication inventory records, and images, must be 
retained by the Principal Investigator for 15 years after completion or discontinuation of 
the study or for the length of time required by relevant national or local health authorities, 
whichever is longer.  After that period of time, the documents may be destroyed, subject 
to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
The Sponsor will retain study data for 25 years after the final study results have been 
reported or for the length of time required by relevant national or local health authorities, 
whichever is longer.
8.
ETHICAL CONSIDERATIONS
8.1
COMPLIANCE WITH LAWS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the country in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the United States or under a U.S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Trial Directive (2001/20/EC)
and applicable local, regional, and national laws.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
78/Protocol WV43042, Version 6
8.2
INFORMED CONSENT
The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms such as a Mobile Nursing Informed Consent Form, if applicable) will be provided 
to each site.  If applicable, it will be provided in a certified translation of the local 
language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample Informed Consent Forms or any alternate consent 
forms proposed by the site (collectively, the "Consent Forms") before IRB/EC 
submission.  The final IRB/ECapproved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local requirements.
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature will be required to 
document a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.
The Consent Forms must be signed and dated by the patient or the patient's legally 
authorized representative before his or her participation in the study.  The case history or 
clinical records for each patient shall document the informed consent process and that 
written or electronic informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/ECapproved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
If the Consent Forms are revised (through an amendment or an addendum) to 
communicate information that might affect a patient's willingness to continue in the 
study, the patient or a legally authorized representative must re-consent by signing the 
most current version of the Consent Forms or the addendum, in accordance with 
applicable laws and IRB/EC policy.  For any updated or revised Consent Forms, the 
case history or clinical records for each patient shall document the informed consent 
process and that written or electronic informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the patient or the patient's
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and must be available for verification by study 
monitors at any time.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
79/Protocol WV43042, Version 6
8.3
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE
This protocol, the Informed Consent Forms, any information to be given to the patient, 
and relevant supporting information must be submitted to the IRB/EC by the Principal 
Investigator and reviewed and approved by the IRB/EC before the study is initiated.  
In addition, any patient recruitment materials must be approved by the IRB/EC. 
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the 
requirements, policies, and procedures established by the IRB/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments (see
Section 9.7).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety-related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their IRB/EC, and 
archived in the site's study file. 
8.4
CONFIDENTIALITY
The Sponsor maintains confidentiality standards by coding each patient enrolled in the 
study through assignment of a unique patient identification number.  This means that 
patient names are not included in data sets that are transmitted to any Sponsor location.
Patient medical information obtained by this study is confidential and may be disclosed 
to third parties only as permitted by the Informed Consent Form (or separate 
authorization for use and disclosure of personal health information) signed by the 
patient, unless permitted or required by law.
Medical information may be given to a patient's personal physician or other appropriate 
medical personnel responsible for the patient's welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by law.  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.6).
Data generated by this study must be available for inspection upon request by 
representatives of national and local health authorities, Sponsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
80/Protocol WV43042, Version 6
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
participating in this study.  These data may be combined with or linked to other data and 
used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease.  In 
addition, redacted Clinical Study Reports and other summary reports will be provided 
upon request (see Section 9.6).
8.5
FINANCIAL DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section 3.2).
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION
9.1
STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.
9.2
PROTOCOL DEVIATIONS
The investigator should document and explain any protocol deviations. The investigator 
should promptly report any deviations that might have an impact on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3
MANAGEMENT OF STUDY QUALITY
The Sponsor has implemented a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient safety and data integrity. Prior 
to study initiation, the Sponsor identified potential risks associated with critical trial 
processes and data and implemented plans for evaluating and controlling these risks. 
Risk evaluation and control included the selection of risk-based parameters 


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
81/Protocol WV43042, Version 6
(e.g., adverse event rate, protocol deviation rate) and the establishment of quality 
tolerance limits for these parameters prior to study initiation. Detection of deviations 
from quality tolerance limits will trigger an evaluation to determine if action is needed. 
Details on the establishment and monitoring of quality tolerance limits are provided in a 
Quality Tolerance Limit Management Plan.
9.4
SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, patients' medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.5
ADMINISTRATIVE STRUCTURE
This trial will be sponsored and managed by F. Hoffmann-La Roche Ltd (outside the 
United States) and Atea Pharmaceuticals, Inc. (in the United States).  F. Hoffmann-La 
Roche Ltd will provide clinical operations management and data management, and both, 
F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc. will provide medical 
monitoring.
Up to approximately 220 patients will be enrolled across approximately 52 sites globally.  
Enrollment will occur through an IxRS.  
Central facilities will be used for certain study assessments throughout the study 
(e.g., specified laboratory tests, biomarker and PK analyses), as specified in Section 4.5.  
Accredited local laboratories will be used for assessing eligibility at screening and
routine monitoring if required; local laboratory ranges will be collected.
An IMC will be employed to monitor and evaluate patient safety as specified in
Section 3.1.
9.6
DISSEMINATION OF DATA AND PROTECTION OF TRADE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer-reviewed journals. The Sponsor will 
comply with all requirements for publication of study results.  Study data may be shared 
with others who are not participating in this study (see Section 8.4 for details), and 
redacted Clinical Study Reports and other summary reports will be made available upon 
request.  For more information, refer to the Roche Global Policy on Sharing of Clinical
Study Information at the following website:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
82/Protocol WV43042, Version 6
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
the respective Clinical Study Report.  In addition, for all clinical trials in patients involving 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound.
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator will be designated by mutual agreement.
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.7
PROTOCOL AMENDMENTS
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information).


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
83/Protocol WV43042, Version 6
10.
REFERENCES
Arunachalam PS, Wimmers F, Mok CKP, et al. Systems biological assessment of 
immunity to mild versus severe COVID-19 infection in humans. Science 
2020;369:121020.
Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute 
COVID-19. JAMA 2020;324:6035.
[CDC] Centers for Disease Control and Prevention. People with certain medical 
conditions [resource on the internet]. 2020 [updated 16 October 2020; cited 
1 November 2020]. Available from: https://www.cdc.gov/coronavirus/2019-
ncov/need-extra-precautions/people-with-medical-conditions.html.
[FDA] U.S. Food and Drug Administration. Assessing COVID-19related symptoms in 
outpatient adult and adolescent subjects in clinical trials of drugs and biological 
products for COVID-19 prevention or treatment: guidance for industry [resource on 
the Internet]. 2020 [published September 2020; cited 1 November 2020]. Available 
from: https://www.fda.gov/regulatory-information/search-fda-guidance-
documents/assessing-covid-19-related-symptoms-outpatient-adult-and-
adolescent-subjects-clinical-trials-drugs. 
Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for 
COVID-19. medRxiv [Preprint]. 2021 June 17.
Gandhi RT, Lynch JB, Del Rio C. Mild to moderate Covid-19. N Engl J Med 
2020;383:175766.
[ICH] International Council for Harmonisation Topic M3 (R2) Non-clinical safety studies 
for the conduct of human clinical trials and marketing authorization for 
pharmaceuticals [resource on the Internet]. 2008 [published July 2008; cited 
9 November 2020]. Available from: 
https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m-3-r2-non-
clinical-safety-studies-conduct-human-clinical-trials-marketing-
authorization_en.pdf.
[ICH] International Council for Harmonisation guideline M3 (R2)questions and answers 
[resource on the Internet]. 2012 [published May 2012; cited 9 November 2020]. 
Available from: https://www.ema.europa.eu/en/documents/other/international-
conference-harmonisation-technical-requirements-registration-pharmaceuticals-
human-use_en.pdf.
Mathieu E, Ritchie H, Ortiz-Ospina E, et al.  A global database of COVID-19 
vaccinations.[resource on the Internet] Nat Hum Behav (2021).  Accessed 
10 September 2021.  Available from:  https://ourworldindata.org/coronavirus.
[NIHR] National Institute for Health Research. Living with Covid19 [resource on the 
Internet]. 2020 [published 15 October 2020; cited 1 November 2020]. Available 
from: https://evidence.nihr.ac.uk/themedreview/living-with-covid19/#Ref.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
84/Protocol WV43042, Version 6
[PHE] Public Health England. Guidance: COVID-19: long-term health effects [resource 
on the Internet]. 2020 [published 7 September 2020; cited 1 November 2020]. 
Available from: https://www.gov.uk/government/publications/covid-19-long-term-
health-effects/covid-19-long-term-health-effects. 
[PHE] Public Health England. Pause in the distribution of bamlanivimab/etesevimab 
[resource on the Internet]. 2021 [published 25 June 2021; cited 10 September 
2020]. Available from: 
https://www.phe.gov/emergency/events/COVID19/investigation-
MCM/Bamlanivimab-etesevimab/Pages/bamlanivimab-etesevimab-distribution-
pause.aspx. 
[Regeneron] Regeneron Pharmaceuticals, Inc. REGN-COV2 antibody cocktail program 
update: September 29, 2020. Accessed: 16 November 2020. Available from: 
https://investor.regeneron.com/static-files/a596a85e-e72d-4529-8eb5-
d52d87a99070).
[WHO] World Health Organization. Weekly operational update on 
COVID-1907 September 2021 [resource on the Internet]. 2021 [published 
07 September 2021; cited: 10 September 2021]. Available from: 
https://www.who.int/publications/m/item/weekly-epidemiological-update-on-
covid-19---7-september-2021.
Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, 
and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 
2020;324:78293.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
85/Protocol WV43042, Version 6
Appendix 1
Schedule of Activities for Cohort A
Screening a
Treatment
Monitoring
UV b
ET c
Follow-Up
Day
–3 to 1
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Informed consent
x e. f
Demographic data f
x
Medical history and 
baseline conditions f
x
Pre-existing symptoms
assessment
x
COVID-19 Symptom Diary g
x
x
x
x
x
x
x
x g
x g
x g, h
Vital signs, including 
oxygen saturation f, i
x
x
x
x
x
x
x
Weight f
x
Height f
x
Complete physical 
examination f, j
x
x
Limited physical 
examination f, k,
As clinically indicated
x
Single ECG
x
x
x
Hematology f, l
x
x
x
x
x
Chemistry f, m
x
x
x
x
x
Pregnancy test f, n
x


Appendix 1: Schedule of Activities for Cohort A
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
86/Protocol WV43042, Version 6
Screening a
Treatment
Monitoring
UV b
ET c
Follow-Up
Day
–3 to 1
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Nasopharyngeal swab
sample
for COVID-19 virology f, o
x
x p
x
x
x
x
x
Nasosorptionsample for 
biomarkers f
x
x
x
x
Serum sample for 
biomarkers, anti-SARS-
COV-2 antibodies, and viral 
RNA f
x p
x
Randomization q
x
AT-527 (or placebo) 
administration
x r
x
x
x
x
Telephone call
x
x
Concomitant medications f, s
x
x
x
x
x
Adverse events f, t
x
x
x
x
x


Appendix 1: Schedule of Activities for Cohort A
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
87/Protocol WV43042, Version 6
COVID-19coronavirus disease 2019; ET early termination; PKpharmacokinetic; RT-PCRreverse-transcription polymerase chain reaction; 
SARS-CoV-2severe acute respiratory syndrome coronavirus-2; PROpatient-reported outcome; UVunscheduled visit.
Notes: On treatment days (Days 15), all assessments should be performed prior to dosing, unless otherwise specified.
a Screening assessments may be performed up to 72 hours prior to Day 1 or on Day 1.
b An unscheduled visit represents a visit that is not specified by the protocol but is determined to be necessary by the investigator or Sponsor 
(e.g., for evaluation of an adverse event).  Assessments (including PK sample collection) should be performed as clinically indicated.  For 
unscheduled visits occurring after Day 7, PK sample collection is not required.
c Patients who discontinue study drug prematurely will continue to complete assessments as indicated until the end of the study.  Patients who 
discontinue from study participation will have an early termination visit 7 (2) days after their final dose of study drug.  Patients who discontinue 
from the study after Day 14 will not be required to complete an early termination visit.
d Required follow-up information will be collected via telephone call at Day 14 (2 days) and Day 33 (3 days).
e Informed consent must be documented before any study-specific screening procedure is performed.
f
For patients at participating sites who have provided written or electronic informed consent to participate in mobile nursing visits, this assessment 
or procedure may be performed by a trained nursing professional at the patient's home.
g COVID-19 Symptom Diary includes questions regarding symptoms (Items 114) and the Patient Global Impression of Severity.  On assessment
visit days, questionnaires will be self-administered before the patient receives any information on disease status, prior to the performance of non-
PRO assessments, and prior to the administration of study treatment.  On Day 1, the first diary questionnaire should be completed prior to the 
first dose.  On Days 114, the questionnaire (including recording of temperature) should be completed twice a day (morning and evening) at the 
same time each day.  
h On Days 1528, the questionnaire (including recording of temperature) should be completed once a day in the evening at the same time each 
day.
i
Includes oxygen saturation (pulse oximetry), respiratory rate, pulse rate, and systolic and diastolic blood pressure while the patient is in a supine 
or seated position, and temperature. 
j
Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, 
gastrointestinal, genitourinary, and neurologic systems.  
k Perform a limited, symptom-directed examination as clinically indicated.
l
Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes, other cells).
m Chemistry panel (serum or plasma) at screening includes bicarbonate or total carbon dioxide (if considered standard of care for the region), 
sodium, potassium, chloride, glucose, BUN or urea, creatinine, creatinine clearance (Cockcroft-Gault formula), total protein, albumin, 
phosphate, calcium, magnesium, total and direct bilirubin, ALP, ALT, AST, triglycerides, cholesterol, amylase and lipase. On all other study days, 


Appendix 1: Schedule of Activities for Cohort A
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
88/Protocol WV43042, Version 6
chemistry panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, 
potassium, chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphate, calcium, magnesium, total and direct bilirubin, ALP, 
ALT, AST, urate, CK (isoenzyme analysis if CK elevated), cardiac troponins, BNP, triglycerides, cholesterol, amylase, LDH, PCT, and lipase.
n All women of childbearing potential will have a pregnancy test (urine or serum) at screening.
o Nasopharyngeal swab samples should be collected at screening and once per day  on Days 1, 3, 5, and 7.  Swab samples should be collected
from both nostrils at all timepoints.  Screening samples will be used for point-of-care RT-PCR or rapid antigen testing to determine eligibility.
p  Sample must be collected prior to dosing.
q Randomization will be performed as soon as possible after screening and within 72 hours.
r
First dose on Day 1 must be administered as soon as possible after randomization and within 24 hours. AT-527 (or placebo), should be taken 
approximately 12 hours apart. If the first dose is taken after 4 pm (16:00 hours) on Day 1, the next dose will be taken in the morning of Day 2. 
For these patients, the 10th dose will be taken on the morning of Day 6. If the first dose is taken prior to 4 pm (16:00 hours) on Day 1, the next 
dose should be taken in the evening of the same day (i.e., prior to midnight on the same calendar day with a minimum of 8 hours between 
doses). For these patients, the 10th dose will be taken in the evening of Day 5.  
s Medication (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol-mandated treatment from 7 days prior to initiation of study drug until the end of study follow-up telephone call on 
Day 33.
t
After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until the end of study follow-up telephone call on
Day 33.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
89/Protocol WV43042, Version 6
Appendix 2
Schedule of Activities for Cohorts BD
Day
Screening a
Treatment
Monitoring
UV b
ET c
Follow-up
3 to 1 
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Informed consent
x e, f
Demographic data f
x
Medical history and baseline 
conditions f
x
Pre-existing symptoms assessment
x
COVID-19 Symptom Diary g
x
x
x
x
x
x
x
x 
x 
x h
Vital signs, including oxygen
saturation f, i
x
x
x
x
x
x
x
Weight f
x
Height f
x
Complete physical examination f, j
x
x
Limited physical examination f, k
As clinically indicated
x
Single ECG 
x
x
x
Hematology f, l
x
x
x 
x 
x
Chemistry f, m
x
x
x 
x 
x
Coagulation (INR, aPTT, PT, D-
dimer, and fibrinogen)
x
x 
x 
Pregnancy test f, n
x
Nasopharyngeal swab sample
for COVID-19 virology f, o
x
x p
x
x
x
x
x


Appendix 2: Schedule of Activities for Cohorts BD
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
90/Protocol WV43042, Version 6
Day
Screening a
Treatment
Monitoring
UV b
ET c
Follow-up
3 to 1 
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Nasosorptionsample for 
biomarkers f
x
x
x
x
Saliva sample for COVID-19 virology 
f
x p
x
x
x
x
x
Serum sample for biomarkers, 
anti-SARS-COV-2 antibodies, and 
viral RNA f
x p
x
x
x
x
x
Blood sample for cryopreserved 
PBMCs f, q
x
x
x
Blood sample for RNA analysis f, r
x
x
x
x
Blood sample for WGS (optional) f, s
x
Randomization t
x
AT-527 (or placebo) administration u
x
x
x
x
x
Telephone Call
x
x
Concomitant medications f, v
x
x
x
x
x
Adverse events f, w
x
x
x
x
x
COVID-19coronavirus disease 2019; ET early termination; PBMCperipheral blood mononuclear cell; PK pharmacokinetic; PRO patient-
reported outcome; RT-PCRreverse-transcription polymerase chain reaction; SARS-CoV-2severe acute respiratory syndrome coronavirus-2; 
UVunscheduled visit; WGSwhole genome sequencing.
Notes:  On treatment days (Days 15), all assessments should be performed prior to dosing, unless otherwise specified.  


Appendix 2: Schedule of Activities for Cohorts BD
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
91/Protocol WV43042, Version 6
a Screening assessments may be performed up to 72 hours prior to Day 1 or on Day 1.
b An unscheduled visit represents a visit that is not specified by the protocol but is determined to be necessary by the investigator or Sponsor 
(e.g., for evaluation of an adverse event).  Assessments (including PK sample collection) should be performed as clinically indicated.  For 
unscheduled visits occurring after Day 7, PK sample collection is not required.
c Patients who discontinue study drug prematurely will continue to complete assessments as indicated until the end of the study.  Patients who 
discontinue from study participation will have an early termination visit 7 (2) days after their final dose of study drug.  Patients who discontinue 
from the study after Day 14 will not be required to complete an early termination visit.
d Required follow-up information will be collected via telephone call at Day 14 (2 days) and Day 33 (3 days).
e Informed consent must be documented before any study-specific screening procedure is performed.
f
For patients at participating sites who have provided written or electronic informed consent to participate in mobile nursing visits, this assessment 
or procedure may be performed by a trained nursing professional at the patient's home.
g COVID-19 Symptom Diary includes questions regarding symptoms (Items 114) and the Patient Global Impression of Severity.  Questionnaires 
will be self-administered before the patient receives any information on disease status, prior to the performance of non-PRO assessments, and 
prior to the administration of study treatment.  On Day 1, the first diary questionnaire should be completed prior to the first dose.  On Days 114, 
the questionnaire (including recording of temperature) should be administered twice a day (morning and evening) at the same time each day.  
h On Days 1528, the questionnaire (including recording of temperature) should be completed once a day in the evening at the same time each 
day.
i
Includes oxygen saturation (pulse oximetry), respiratory rate, pulse rate, and systolic and diastolic blood pressure while the patient is in a supine
or seated position, and temperature. 
j
Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, 
gastrointestinal, genitourinary, and neurologic systems. 
k Perform a limited, symptom-directed examination as clinically indicated.
l
Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes, other cells).
m Chemistry panel (serum or plasma) at screening includes bicarbonate or total carbon dioxide (if considered standard of care for the region), 
sodium, potassium, chloride, glucose, BUN or urea, creatinine, creatine clearance (Cockcroft-Gault formula), total protein, albumin, phosphate, 
calcium, magnesium, total and direct bilirubin, ALP, ALT, AST, triglycerides, cholesterol, amylase and lipase. On all other study days, chemistry 
panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphate, calcium, magnesium, total and direct bilirubin, ALP, ALT, AST, urate, CK 
(isoenzyme analysis if CK elevated), cardiac troponins, BNP, triglycerides, cholesterol, amylase, LDH, PCT, and lipase.
n All women of childbearing potential will have a pregnancy test (urine or serum) at screening.


Appendix 2: Schedule of Activities for Cohorts BD
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
92/Protocol WV43042, Version 6
o Nasopharyngeal swab samples should be collected at screening and once per day  on Days 1, 3, 5, and 7.  Swab samples should be collected 
from both nostrils at all timepoints.  Screening samples will be used for point-of-care RT-PCR or rapid antigen testing to determine eligibility.
p
Sample must be collected prior to dosing.
q Samples for PBMC may not be collected at some timepoints if sample stability requirements for processing will not be met. Please refer to the 
laboratory manual for more detail. A plasma sample will be generated from the blood sample obtained following PBMC processing and will be 
stored for biomarker research.  No additional blood draw is needed.
r
Collection of blood sample for RNA analysis using PAXgene tubes.
s Not applicable for a site that has not been granted approval for WGS. If the sample is not collected on Day 1 for any reason, it may be collected 
at any later timepoint.
t
Randomization will be performed as soon as possible after screening and within 72 hours.
u First dose on Day 1 must be administered as soon as possible after randomization and within 24 hours. For BID regimens, AT-527 (or placebo), 
should be taken approximately 12 hours apart. If the first dose is taken after 4 pm (16:00 hours) on Day 1, the next dose will be taken in the 
morning of Day 2. For these patients, the 10th dose will be taken on the morning of Day 6. If the first dose is taken prior to 4 pm (16:00 hours) on 
Day 1, the next dose should be taken in the evening of the same day (i.e., prior to midnight on the same calendar day with a minimum of 8 hours 
between doses). For these patients, the 10th dose will be taken in the evening of Day 5. For other dose regimens see Pharmacy manual for 
details of dosing instruction.
v Medication (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol-mandated treatment from 7 days (12 months for COVID-19 vaccines) prior to initiation of study drug until the end of 
study follow-up telephone call on Day 33.
w After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until the end of study follow-up telephone call on 
Day 33.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
93/Protocol WV43042, Version 6
Appendix 3
Schedule of Activities for Cohorts E
Day
Screening a
Treatment
Monitoring
UV b
ET c
Follow-up
3 to 1 
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Informed consent
x e, f
Demographic data f
x
Medical history and baseline 
conditions f
x
Pre-existing symptoms assessment
x
COVID-19 Symptom Diary g
x
x
x
x
x
x
x
x 
x 
x h
Vital signs, including oxygen
saturation f, i
x
x
x
x
x
x
x
x
Weight f
x
Height f
x
Complete physical examination f, j
x
x
Limited physical examination f, k
As clinically indicated
x
Single ECG 
x
x
x
Hematology f, l
x
x
x 
x 
x
Chemistry f, m
x
x
x 
x 
x
Coagulation (INR, aPTT, PT, D-
dimer, and fibrinogen)
x
x 
x 
Pregnancy test f, n
x
Nasopharyngeal swab sample
for COVID-19 virology f, o
x
x p
x
x
x
x
x
x


Appendix 3: Schedule of Activities for Cohort E
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
94/Protocol WV43042, Version 6
Day
Screening a
Treatment
Monitoring
UV b
ET c
Follow-up
3 to 1 
1
2
3
4
5
6
7
813
14 d
1528
33 d
(3)
Nasosorptionsample for 
biomarkers f
x
x
x
x
x
Saliva sample for COVID-19 virology 
f
x p
x
x
x
x
x
x
Serum sample for biomarkers, 
anti-SARS-COV-2 antibodies, and 
viral RNA f
x p
x
x
x
x
Blood sample for cryopreserved 
PBMCs f, q
x
x
Blood sample for RNA analysis f, r
x
x
Blood sample for WGS (optional) f, s
x
Randomization t
x
AT-527 (or placebo) administration u
x
x
x
x
x
Telephone Call
x
Concomitant medications f, v
x
x
x
x
x
Adverse events f, w
x
x
x
x
x
COVID-19coronavirus disease 2019; ET early termination; PBMCperipheral blood mononuclear cell; PK pharmacokinetic; PRO patient-
reported outcome; RT-PCRreverse-transcription polymerase chain reaction; SARS-CoV-2severe acute respiratory syndrome coronavirus-2; 
UVunscheduled visit; WGSwhole genome sequencing.
Notes:  On treatment days (Days 15), all assessments should be performed prior to dosing, unless otherwise specified.  


Appendix 3: Schedule of Activities for Cohort E
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
95/Protocol WV43042, Version 6
a Screening assessments may be performed up to 72 hours prior to Day 1 or on Day 1.
b An unscheduled visit represents a visit that is not specified by the protocol but is determined to be necessary by the investigator or Sponsor 
(e.g., for evaluation of an adverse event).  Assessments (including PK sample collection) should be performed as clinically indicated.  For 
unscheduled visits occurring after Day 7, PK sample collection is not required.
c Patients who discontinue study drug prematurely will continue to complete assessments as indicated until the end of the study.  Patients who 
discontinue from study participation will have an early termination visit 7 (2) days after their final dose of study drug.  Patients who discontinue 
from the study after Day 14 will not be required to complete an early termination visit.
d Required follow-up information will be collected at Day 14 (2 days). and Day 33 (3 days).  Patients in Cohort E are required to have an in-
person visit for nasopharyngeal swab collection.
e Informed consent must be documented before any study-specific screening procedure is performed.
f
For patients at participating sites who have provided written or electronic informed consent to participate in mobile nursing visits, this assessment 
or procedure may be performed by a trained nursing professional at the patient's home.
g COVID-19 Symptom Diary includes questions regarding symptoms (Items 114) and the Patient Global Impression of Severity.  Questionnaires 
will be self-administered before the patient receives any information on disease status, prior to the performance of non-PRO assessments, and 
prior to the administration of study treatment.  On Day 1, the first diary questionnaire should be completed prior to the first dose.  On Days 114, 
the questionnaire (including recording of temperature) should be administered twice a day (morning and evening) at the same time each day.  
h On Days 1528, the questionnaire (including recording of temperature) should be completed once a day in the evening at the same time each 
day.
i
Includes oxygen saturation (pulse oximetry), respiratory rate, pulse rate, and systolic and diastolic blood pressure while the patient is in a supine
or seated position, and temperature. 
j
Includes evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, 
gastrointestinal, genitourinary, and neurologic systems.  
k Perform a limited, symptom-directed examination as clinically indicated.
l
Hematology includes WBC count, RBC count, hemoglobin, hematocrit, platelet count, and differential count (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes, other cells).
m Chemistry panel (serum or plasma) at screening includes bicarbonate or total carbon dioxide (if considered standard of care for the region), 
sodium, potassium, chloride, glucose, BUN or urea, creatinine, creatinine clearance (Cockcroft-Gault formula), total protein, albumin, phosphate, 
calcium, magnesium, total and direct bilirubin, ALP, ALT, AST, triglycerides, cholesterol, amylase and lipase. On all other study days, chemistry 
panel (serum or plasma) includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphate, calcium, magnesium, total and direct bilirubin, ALP, ALT, AST, urate, CK 
(isoenzyme analysis if CK elevated), cardiac troponins, BNP, triglycerides, cholesterol, amylase, LDH, PCT, and lipase.


Appendix 3: Schedule of Activities for Cohort E
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
96/Protocol WV43042, Version 6
n All women of childbearing potential will have a pregnancy test (urine or serum) at screening.
o Nasopharyngeal swab samples should be collected at screening and once per day  on Days 1, 3, 5, and 7.  Swab samples should be collected 
from both nostrils at all timepoints.  Screening samples will be used for point-of-care RT-PCR or rapid antigen testing to determine eligibility.
p
Sample must be collected prior to dosing.
q Samples for PBMC may not be collected at some timepoints if sample stability requirements for processing will not be met. Please refer to the 
laboratory manual for more detail. A plasma sample will be generated from the blood sample obtained following PBMC processing and will be 
stored for biomarker research.  No additional blood draw is needed.
r
Collection of blood sample for RNA analysis using PAXgene tubes.
s Not applicable for a site that has not been granted approval for WGS. If the sample is not collected on Day 1 for any reason, it may be collected 
at any later timepoint.
t
Randomization will be performed as soon as possible after screening and within 72 hours.
u First dose on Day 1 must be administered as soon as possible after randomization and within 24 hours. For BID regimens, AT-527 (or placebo), 
should be taken approximately 12 hours apart. If the first dose is taken after 4 pm (16:00 hours) on Day 1, the next dose will be taken in the 
morning of Day 2. For these patients, the 10th dose will be taken on the morning of Day 6. If the first dose is taken prior to 4 pm (16:00 hours) on 
Day 1, the next dose should be taken in the evening of the same day (i.e., prior to midnight on the same calendar day with a minimum of 8 hours 
between doses). For these patients, the 10th dose will be taken in the evening of Day 5. For other dose regimens see Pharmacy manual for 
details of dosing instruction.
v Medication (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol-mandated treatment from 7 days (12 months for COVID-19 vaccines) prior to initiation of study drug until the end of 
study follow-up telephone call on Day 33.
w After informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until the end of study follow-up telephone call on 
Day 33.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
97/Protocol WV43042, Version 6
Appendix 4
Schedule of Pharmacokinetic Samples
Cohort A
Cohorts BE
BID Regimen
BID Regimen
TID Regimen
QD Regimen
Day 1
Predose a, c
Predose a, c
Predose a, c
Predose a, c
1 and 3 hours
postdose b, c
1 and 4 hours
postdose b, c
1 hour postdose b, c
1 and 4 hours
postdose b, c
Predose
[with reference to second 
dose of the day] a, c
Day 3
Predose a, c
Predose a, c
Predose a, c
Predose a, c
Day 5
Predose a, c
and 3 hours 
postdose b, c
Predose a,  c
Predose a, c
Predose a, c
1 and 4 hours
postdose b, c
1 hour postdose b, c
1 and 4 hours 
postdose b, c
Predose
[with reference to second 
dose of the day] a, c
Day 7
48 (1) hours c, e
Anytime c, d
Anytime c, d
Anytime c, d
Early 
termination

Sample to be collected if early termination occurs
on or before Day 7
BIDtwice a day; QDonce a day; TIDthree times a day.
Note:  Unless otherwise specified (TID regimen), all timepoints are in relation to the first dose administered on a 
given day.
a Predose sampling window:  within 30 minutes prior to dose administration. 
b Postdose sampling window:  30 minutes from scheduled sampling time. 
c For patients at participating sites who have provided written or electronic informed consent to participate in 
mobile nursing visits, this assessment or procedure may be performed by a trained nursing professional at the 
patient's home.
d The exact sampling time will be captured in relation to the time of last (10th) dose.
e   In Cohort A, the 48-hour PK sampling on Day 7 is with reference to the first dose on Day 5.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
98/Protocol WV43042, Version 6
Appendix 5
COVID-19 Symptom Diary
and Patient Global Impression of Severity
Do not reproduce or distribute.  The Sponsor will provide sites with 
all instruments to be completed in this study.
Note that the following is a sample.  Sites will be provided with separate versions of the 
diary for Days 114 (morning vs. evening, including recording of temperature) and Days 
1528 (evening, including recording of temperature).
Today's date: ___________  Time completing: ___________
COVID-19 Evening Symptom Diary
This diary will keep track of your COVID-19 symptoms and temperature during the study. 
Please complete this diary before you go to bed each evening. For each symptom, 
please tick the box that best describes your experience.
Please rate the severity of each symptom at its worst since you got up this morning.
None
Mild
Moderate
Severe
1. 
Nasal congestion or runny 
nose
2. 
Sore throat
3. 
Cough
4. 
Shortness of breath
(difficulty breathing)
5. 
Aches and pains
6. 
Fatigue (tiredness)
7. 
Headache
8. 
Chills/Sweats 
9. 
Feeling hot or feverish
10. Nausea (wanting to throw up)
11.
Vomiting (thrown up)
12. Diarrhea (mostly or completely 
liquid bowel movements)


Appendix 5: COVID-19 Symptom Diary and Patient Global Impression of Severity
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
99/Protocol WV43042, Version 6
Patient Global Impression of Severity
Please rate your overall COVID-19 symptoms at their worst since you got up this 
morning.
☐None
☐Mild
☐Moderate 
☐Severe 
Same as usual / no 
change 
Not as good as usual 
/ no sense
13. Rate your sense of smell
since you got up this morning.
14. Rate your sense of taste
since you got up this morning.


RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
100/Protocol WV43042, Version 6
Appendix 6
Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical
DrugDrug Interaction Data
New data from reproductive toxicity studies have become available since the release of 
the AT-527 Investigator's Brochure Version 7.  The new data are summarized below.
Overall, these new data did not provide new safety concerns and support further 
development including the planned Phase 3 clinical trial.
In vitro drug-drug interaction (DDI) flags for AT-527 with potential clinical relevance as 
well as preliminary data from clinical DDI studies were taken into account in the 
concomitant therapy section.
REPRODUCTIVE TOXICITY
The potential for reproductive toxicity was assessed in dose range-finding and pivotal 
Good Laboratory Practice (GLP)-compliant embryofetal development studies in rats and 
rabbits and in a GLP-compliant fertility study in the rat. 
EMBRYOFETAL DEVELOPMENT
Definitive GLP-compliant embryofetal development (EFD) studies did not reveal 
evidence of teratogenicity or embryofetal toxicity up to the highest maternal dose level 
tested of 1000 mg/kg/day in rats and 100 mg/kg/day in rabbits.
Administration of AT-527 by oral gavage to female rats at dose levels of 250, 500, and 
1000 mg/kg/day once daily from gestation day (GD) 7 to GD17 in an initial dose range-
finding study and in a subsequent definitive study induced no maternal or developmental 
toxicity at any dose level. 
In a dose range finding EFD study in pregnant rabbits, the two highest dose groups of 
500 and 250 mg/kg/day were terminated prematurely due to severe maternal toxicity. 
The low dose level of 125 mg/kg/day was tolerated, but induced maternal toxicity 
characterized by apparent reductions of food consumption, minimal body weight loss 
and slightly reduced gravid uterine weight. There were no external fetal abnormalities at 
125 mg/kg/day and resorption incidence was not noticeably increased, but fetal weight 
was reduced by 10%, which was secondary to maternal toxicity.
In a definitive GLP-compliant EFD study in pregnant rabbits, AT-527 was administered 
by once daily oral gavage to time-mated female New Zealand White rabbits at 25, 50, or 
100 mg/kg/day from GD 7 through GD 19. The highest dose level of 100 mg/kg/day was 
above the maximum maternal tolerated dose, characterized by marked reductions in 
food consumption, body weight loss in the majority of rabbits and 3 associated abortions. 
Reductions in maternal food consumption and body weight gain were also noted at both 
lower dose levels of 50 and 25 mg/kg/day. Maternal administration of AT-527 did not 
affect embryofetal viability or fetal body weights at any dose level. There were no 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
101/Protocol WV43042, Version 6
AT-527-related fetal abnormalities at any dose level.  Therefore, the developmental no-
adverse-effect level (NOAEL) for AT-527 was 100 mg/kg/day. 
FERTILITY AND EARLY EMBRYONIC DEVELOPMENT (FEED)
In a GLP-compliant FEED study, AT-527 was given to male and female rats by daily oral 
gavage at dose levels of 250, 500 and 1000 mg/kg/day. Males were treated for 4 weeks 
and females for 2 weeks before pairing. For females dosing stopped on GD6 and they 
were submitted to C-section on GD13. Males were dosed for at least 7 weeks prior to 
necropsy. Administration of AT-527 reduced body weights and body weight gains in
males at 1000 mg/kg/day and caused increased incidence of abnormal breathing sounds 
at 500 and 1000 mg/kg/day. There were no AT-527-related effects on mating, fertility, or 
reproductive organ weights in males or females, estrous cycling and ovarian and uterine 
parameters in females, or male reproductive assessments (sperm motility or 
concentration) in males. Therefore, the NOAEL for AT-527 for general toxicity, 
reproductive performance, and early embryonic development was 1000 mg/kg/day, the 
highest dose tested.
Exposures for AT-511 (Free Base Form of AT-527) and Its Major Metabolites 
AT-551, AT-229 and AT-273 at No-Adverse Effect Level Doses from Pivotal 
Reproductive Toxicity Studies
Pivotal EFD rat 1000 mg/kg/day
Pivotal EFD rabbit 100 mg/kg/day
GD17 
AUCtlast
(hr*ng/mL)
Multiple to human for 
550 mg bid/ 1100 mg 
bid
GD19 AUCtlast
(hr*ng/mL)
Multiple to human for 
550 mg bid/ 1100 mg bid
AT-511
145
0.02/0.01
4080
0.5/0.3
AT-551
135000
26/13
33800
7/3
AT-229
160000
10/5
70100
4/2
AT-273
28600
5/2
14300
2/1
AUC area under the concentration–time curve; BID twice a day; EFD embryofetal 
development; GD gestation day.
Anticipated human exposures at 550 mg bid are an AUC of 7503 hr*ng/mL for AT-511, 5134 
hr*ng/mL for AT-551, 16154 hr*ng/mL for AT-229 and 6136 hr*ng/mL for AT-273.
Anticipated human exposures at 1100 mg bid are an AUC of 15006 hr*ng/mL for AT-511, 10268 
hr*ng/mL for AT-551, 32308 hr*ng/mL for AT-229 and 12631 hr*ng/mL for AT-273.
All studies were performed in the United States of America with bioanalysis and 
toxicokinetic evaluations performed in Canada, both countries members of the 
Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
102/Protocol WV43042, Version 6
of Data (MAD) program. All definitive reproductive toxicity studies were performed in 
compliance with OECD GLP Regulations.
IN VITRO DRUG-DRUG INTERACTION 
The parent compound AT-511 and metabolites AT-551, AT-229 and AT-273 were 
characterized in vitro to determine the potential of CYP450 and transporter related victim 
and perpetrator drug-drug interaction (DDI).  In vitro DDI flags with potential clinical 
relevance were taken into account in the concomitant therapy section.
AT-511 as the parent drug is a substrate of P-gp, and likely not a substrate of BCRP. 
The breakdown of AT-511 is not CYP450 dependent, and several 
catabolism/metabolism processes have been postulated and are presented in the most 
recent version of the Investigator Brochure [v7]. 
The metabolites AT-551 and AT-273 are not substrates of P-gp or BCRP, metabolite 
AT-229 is a substrate of BCRP but not P-gp. AT-229 is not a substrate of a renal 
transporter (Organic Anion Transporter 1 [OAT1] and 3 [OAT3], Organic Cation 
Transporter 2 [OCT2], Multidrug and Toxin Extrusion protein 1 [MATE1] and 2-K  
[MATE2-K]) while AT-273 is a substrate of OAT1 and OAT3 but not OCT2, MATE1, 
MATE2-K.
The in vitro potential of the parent drug AT-511 and the metabolites (AT-551, AT-229 
and AT-273) for perpetrator DDI against drug transporters (P-gp, BCRP, Organic Anion 
Transporting Polypeptide 1B1 [OATP1B1] and 1B3 [OATP1B3], OAT1, OAT3, OCT2, 
MATE1 and MATE2-K) and CYP450’s (1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A) has 
been characterized. 
AT-511 is an in vitro inhibitor of P-gp, BCRP and OATP1B1 with IC50 values below the 
estimated gut concentration (550 mg dose/intake water 250 mL) and for which a DDI risk 
may be anticipated.
The in vitro reversible/time-dependent inhibition and induction potential of the parent 
drug AT-511 on CYP3A4 is likely indicated, however, the impact of the perpetrator 
potential on net enzyme DDI effects in liver and intestine remains uncertain. The direct 
inhibition IC50 values of AT-511 on CYP2C8 and CYP2C19 in vitro are much higher 
than the unbound systemic exposure in the historical clinical studies, and no additional 
CYP related in DDI risks were identified. 
For metabolites AT-551, AT-229 and AT-273, no or weak perpetrator DDI risk for 
transporters and CYPs is anticipated based on in vitro data and the static perpetrator 
DDI risk assessment results.


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
103/Protocol WV43042, Version 6
CLINICAL DRUG-DRUG INTERACTION STUDIES
Preliminary data are available from 3 clinical studies, namely AT-03A-004, AT-03A-
005 and AT-03A-009, and are summarized below.
Study AT-03A-004: A Phase 1 Study Assessing the Effect of Carbamazepine, a P-
Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult 
Subjects.
Design elements
This is a single center, open-label DDI study with 3 Periods. In Periods 1 and 2, 
healthy subjects (n20) undergo sequential treatments. Subjects who complete Periods 
1 and 2 are subsequently be randomized to one of two treatments in Period 3.
The below figure presents an overview of the study design.
Period 1 (AT-527) (n=20). Day 1: AT-527 550 mg (1x550 mg tablet) in the morning. Days 2 
to 5: No treatment for 4 days. 
BID:  twice a day, CBZ: Carbamazepine,  PgP: P-Glycoprotein.
Period 2 (dose titration with carbamazepine) (n20). Days 6 to 8 (3 days): 
carbamazepine 100 mg BID (1100 mg tablet BID, in the morning and 12 hours later). 
Days 9 to 11 (3 days): carbamazepine 200 mg BID (2100 mg tablets BID, in the 
morning and 12 hours later). Days 12 to 25 (14 days): carbamazepine 300 mg BID 
(3100 mg tablets BID, in the morning and 12 hours later).
Period 3 (AT-527 carbamazepine). Day 26: AT-527 550 mg (1550 mg tablet, in the 
morning) carbamazepine 300 mg BID (3100 mg tablets BID, in the morning and 
12 hours later) (n10), or Day 26: AT-527 1100 mg (2550 mg tablets, in the morning) 
carbamazepine 300 mg BID (3100 mg tablets BID, in the morning and 12 hours 
later) (n10).


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
104/Protocol WV43042, Version 6
Preliminary results
The below figure presents the changes in pharmacokinetic parameters (Cmax and AUC) 
for AT-511 and metabolites in the presence of the co-administered drug.
Legend to the figure. AUC: area under the plasma concentration-time curve, CI: confidence 
interval, Cmax: maximum plasma concentration, GMR: geometric mean ratio.
On Day 26, when 550 mg AT-527 was co-administered with carbamazepine, the 
exposure of AT-511 and AT-551 was reduced by about 30% and 40%, respectively. The 
exposure of AT-229 and AT-273 was not affected. This indicates that AT-527 can be 
administered with a strong P-gp inducer without dose adjustment.
On Day 26, when 1100 mg AT-527 was co-administered with carbamazepine, the 
exposure of AT-511 and metabolites essentially doubled. A single dose of 1100 mg AT-
527 can mitigate the DDI risk associated with Pgp induction and can be administered 
with a strong Pgp inducer without dose adjustment.


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
105/Protocol WV43042, Version 6
Study AT-03A-005: A Phase 1, Randomized, Open-Label Study to Evaluate the 
Effect of Cyclosporine on the Plasma Pharmacokinetics of AT-527 in Healthy 
Adult Male Subjects.
Design elements
This is a single center, open-label, 2-arm study. The below figure presents an overview 
of the study design.
Arm-1 (n12): Simultaneous dosing. Day 1: A single 550 mg dose of AT-527 
(1550 mg tablet) is administered to subjects. Day 7: A single 550 mg dose of AT-527 
(1x550 mg tablet) and a single 600 mg dose of cyclosporine (6100 mg capsules) is co-
administered to subjects.
Arm-2 (n12): Staggered dosing. Day 1: A single 550 mg dose of AT-527 (1550 mg 
tablet) is administered to subjects. Day 7: A single 550 mg dose of AT-527 (1550 mg 
tablet) is administered to subjects. Then, a single 600 mg dose of cyclosporine (6100 
mg capsules) is administered approximately 2 hours later.
Preliminary results
The below figure presents the changes in pharmacokinetic parameters (Cmax and AUC) 
for AT-511 and metabolites in the presence of the co-administered drug (left: 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
106/Protocol WV43042, Version 6
simultaneous dosing of cyclosporine [Arm-1], right: staggered dosing of cyclosporine 
[Arm-2]).
Legend to the figure. AUC: area under the plasma concentration-time curve, CI: confidence 
interval, Cmax: maximum plasma concentration, GMR: geometric mean ratio.
In Arm-1, the Cmax of AT-511 and AT-551 doubled and tripled, respectively. The AUC 
of AT-511 and AT-551 increased by 5-fold and 4-fold, respectively. The exposure of 
AT-229 was not affected, and that of AT-273 increased by 50%.
In Arm-2, a single dose of cyclosporine administered 2 hours after AT-527 did not 
affect the exposure of AT-511 and metabolites.
These data indicate that the substantial DDI risk associated with Pgp inhibition can be  
effectively mitigated by staggered dosing of the inhibitor.


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
107/Protocol WV43042, Version 6
Study AT-03A-009: A Phase 1 Open-Label Study to Evaluate the Interaction 
Potential between AT-527 and Midazolam in Healthy Adult Subjects
Design elements
This is a single center, open-label, 2-arm study. The below figure presents an overview 
of the study design.
MDZ: midazolam
Arm-1 (n12). Day 1: 2 mg midazolam (1 mL) is administered in the morning. Day 3: 
550 mg AT-527 and 2 mg midazolam (1 mL) are co-administered (within 1 minute 
apart) together in the morning and a second 550 mg AT-527 dose is administered in the 
evening, approximately 12 hours after the morning dose. Days 4 to 6: 550 mg AT-527 
is administered to subjects twice daily (BID), once in the morning and once in the 
evening, approximately 12 hours apart. Day 7: 550 mg AT-527 and 2 mg midazolam (1 
mL) are co-administered (within 1 minute apart) in the morning and a second 550 mg 
AT-527 dose is administered in the evening, approximately 12 hours after the morning 
dose.
Arm-2 (n=12). Day 1: 2 mg midazolam (1 mL) is administered in the morning. Day 
3: 550 mg AT-527 is administered in the morning then a 2 mg midazolam dose (1 mL) 
is administered 2 hours (±5 minutes) later (at approximately the same time when 
midazolam was administered in Day 1). A second 550 mg AT-527 dose is administered 
in the evening, approximately 12 hours after the AT-527 morning dose. Days 4 to 6: 
550 mg AT-527 is administered to subjects BID, in the morning and in the evening, 
approximately 12 hours apart. Day 7: 550 mg AT-527 is administered in the morning 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
108/Protocol WV43042, Version 6
then a 2 mg midazolam dose (1 mL) is administered 2 hours (±5 minutes) later (at 
approximately the same time when midazolam was administered in Day 1). A second 
550 mg AT-527 dose is administered in the evening, approximately 12 hours after the 
AT-527 morning dose.
Preliminary results

Assessment 1 (Day 3 is compared to Day 1). The below figure presents the changes 
in pharmacokinetic parameters (Cmax, AUC, and half-life) for midazolam (left) and 
1-hydroxy-midazolam (right) in the presence of AT-527 (single dose of 550 mg). In 
each forest plot, the changes in pharmacokinetic parameters are presented after the 
simultaneous (Arm-1; top) and staggered (Arm-2; bottom) administration of 
midazolam.
Legend to the figure. AUC: area under the plasma concentration-time curve, CI: 
confidence interval, Cmax: maximum plasma concentration, HL: half-life, SD: single dose, 
1-OH midazolam: 1-hydroxy midazolam, GMR: geometric mean ratio.
A single dose of AT-527 increased the exposure of midazolam by 2025% after 
simultaneous or staggered dosing. The exposure of 1-hydroxy midazolam was 
slightly increased by 2530% after simultaneous dosing, and minimally increased 
by 515% after staggered dosing.

Assessment 2 (Day 7 is compared to Day 1). The below figure presents the changes 
in pharmacokinetic parameters (Cmax, AUC, and half-life) for midazolam (left) and 
1-hydroxy-midazolam (right) in the presence of AT-527 (multiple doses of 550 mg). 
In each forest plot, the changes in pharmacokinetic parameters are presented after 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
109/Protocol WV43042, Version 6
the simultaneous (Arm-1; top) and staggered (Arm-2; bottom) administration of 
midazolam.
Legend to the figure. AUC: area under the plasma concentration-time curve, 
CI: confidence interval, Cmax: maximum plasma concentration, HL: half-life, SD: single 
dose, 1-OH midazolam: 1-hydroxy midazolam, GMR: geometric mean ratio.
Multiple doses of AT-527 increased the plasma exposure of midazolam by 90% 
(simultaneous dosing) and by 60% (staggered dosing), and had a slight to minimal 
effect on 1-hydroxy midazolam (an increase of 2025% after simultaneous dosing, 
and an increase of 010% after staggered dosing).

Assessment 3 (Day 7 is compared to Day 3). The below figure presents the changes 
in pharmacokinetic parameters (Cmax, AUC, and half-life) for midazolam (left) and 
1-hydroxy-midazolam (right) in the presence of AT-527 (single dose of AT-527 on 
Day 3, and multiple dose of AT-527 on Day 7). In each forest plot, the changes in 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
110/Protocol WV43042, Version 6
pharmacokinetic parameters are presented after the simultaneous (Arm-1; top) and 
staggered (Arm-2; bottom) administration of midazolam.
Legend to the figure. AUC: area under the plasma concentration-time curve, 
CI: confidence interval, Cmax: maximum plasma concentration, HL: half-life, SD: single 
dose, 1-OH midazolam: 1-hydroxy midazolam, GMR: geometric mean ratio.
After multiple doses of AT-527, the net effect of time dependent inhibition and 
induction (Day 7) over direct competitive inhibition (Day 3) on midazolam 
exposure was increased 4560% (simultaneous dosing) and increased 1535% 
(staggered dosing), and almost absent (05% increase) on 1-hydroxy midazolam.

Assessment 4 (Arm-2 [staggered administration of AT-527] is compared to Arm-1 
[simultaneous administration of AT-527]). The below figure presents the changes 
in pharmacokinetic parameters (Cmax, AUC, and half-life) for midazolam (left) and 


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
111/Protocol WV43042, Version 6
1-hydroxy-midazolam (right) in the absence (Day 1) or in the presence of AT-527 
(single dose of AT-527 on Day 3, and multiple dose of AT-527 on Day 7).
Legend to the figure. AUC: area under the plasma concentration-time curve, 
CI: confidence interval, Cmax: maximum plasma concentration, HL: half-life, SD: single 
dose, 1-OH midazolam: 1-hydroxy midazolam, GMR: geometric mean ratio.
Day 1 (midazolam alone): the exposure of midazolam was slightly lower in Arm 2 
(vs. Arm 1) by 10-20%, and was not changed for 1-hydroxy midazolam.
Day 3 (single dose of AT-527; competitive inhibition): 520% less effect of 
staggered dosing of AT-527 on the exposure of midazolam and 1-hydroxy 
midazolam.
Day 7 (multiple dose of AT-527; competitive plus time dependent inhibition and 
induction): 1530% less effect of staggered dosing of AT-527 on the exposure of 
midazolam and 1-hydroxy midazolam.
Data interpretation
A single dose (simultaneous or staggered) of AT-527 increased the exposure of 
midazolam by 2025%. AT-527 (AT-511) is a weak competitive inhibitor of CYP3A4.


Appendix 6: Update on AT-527 Reproductive Toxicity, In Vitro, and Clinical DrugDrug 
interaction Data
RO7496998 (AT-527)—F. Hoffmann-La Roche Ltd and Atea Pharmaceuticals, Inc.
112/Protocol WV43042, Version 6
Multiple doses of AT-527 increased the exposure of midazolam by 90 and 60% after 
simultaneous and staggered (30% less) dosing, respectively. This is consistent with 
time-dependent inhibition of CYP3A4.
Staggered dosing after single of multiple doses of AT-527 had limited effect on the PK 
parameters of midazolam.
The induction potential of AT-511, while confronted by a more pronounced time-
dependent inhibition effect, is weak and unlikely to affect (reduce) the efficacy of 
hormonal contraceptives that are substrates of CYP3A4.
CYP3A4 substrates can be co-administered with AT-527 without dose adjustment. 
Staggered dosing of AT-527 is not warranted.

SAP_001.pdf: 
S T A TI S TI C A L A N A L Y SI S A M E N D M E N T P L A N A P P R O V A L
S P O N S O R:
L E G A L R E GI S T E R E D 
A D D R E S S:
F. H off m a n n -L a R o c h e Lt d ( E x -U nit e d St at e s)
At e a P h ar m a c e uti c al s, I n c. ( U nit e d St at e s)
Gr e n z a c h er str a s s e 1 2 4
4 0 7 0 B a s el, S wit z erl a n d
1 2 5 S u m m er Str e et, B o st o n,
M a s s a c h u s ett s 0 2 1 1 0, U. S. A
D A T E FI N A L:
S e e el e ctr o ni c d at e st a m p a b o v e 
C O N FI D E N TI A L
T hi s i s a n F. H off m a n n -L a R o c h e Lt d d o c u m e nt t h at c o nt ai n s c o nfi d e nti al i nf or m ati o n.  N ot hi n g 
h er ei n i s t o b e di s cl o s e d wit h o ut writt e n c o n s e nt fr o m F. H off m a n n -L a R o c h e Lt d.
A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
S T A TI S TI C A L A N A L Y SI S P L A N
S T U D Y TI T L E:
A P H A S E II R A N D O MI Z E D, D O U B L E -B LI N D, 
P L A C E B O -C O N T R O L L E D S T U D Y T O E V A L U A T E T H E A N TI VI R A L 
A C TI VI T Y, S A F E T Y, P H A R M A C O KI N E TI C S, A N D E F FI C A C Y O F 
R O 7 4 9 6 9 9 8 ( A T- 5 2 7) I N N O N -H O S PI T A LI Z E D A D U L T P A TI E N T S 
WI T H MI L D O R M O D E R A T E C O VI D -1 9
S T U D Y N U M B E R:
W V 4 3 0 4 2
S T U D Y N A M E: 
M O O N S O N G
V E R SI O N N U M B E R:
4
R O C H E C O M P O U N D:
A T -5 2 7 
( R O 7 4 9 6 9 9 8)
E U D R A C T N U M B E R:
2 0 2 0 -0 0 5 3 6 6 -3 4
N C T N U M B E R:
N C T 0 4 7 0 9 8 3 5
P L A N P R E P A R E D B Y:
, M. S c.
 
D ate a n d Ti me( U T C)         Re as o n f or Si g ni n g                              N a me
C o m pa n y Si g nat or y
0 1- Se p- 2 0 2 1 1 3: 2 1: 2 5


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2
S T A TI S TI C A L A N A L Y SI S P L A N V E R SI O N HI S T O R Y
T hi s S A P w a s d e v el o p e d b a s e d o n R o c h e S A P m o d el d o c u m e nt u p d at e d o n 
2 6 O ct o b er 2 0 2 0.
S A P V er si o n
A p pr o v al D at e
B a s e d o n Pr ot o c ol 
( V er si o n, Ap pr o v al D at e)
4
s e e el e ctr o ni c d at e st a m p 
o n titl e
V er si o n 5, 1 3 M a y 2 0 2 1
3
1 7 J u n e 2 0 2 1
V er si o n 5, 1 3 M a y 2 0 2 1
2
0 4 M ar c h 2 0 2 1
V er si o n 4, 2 4 F e br u ar y 2 0 2 1
1
0 4 F e br u ar y 2 0 2 1
V er si o n 2, 1 0 D e c e m b er 2 0 2 0


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3
S T A TI S TI C A L A N A L Y SI S P L A N A M E N D M E N T R A TI O N A L E
T h e k e y c h a n g e i n t hi s S A P a m e n d m e nt ( v 4) i s a n u p d at e t o h o w vir al R N A n e g ati vit y i s 
d ef i n e d. S a m pl e s t h at ar e b el o w t h e li mit of q u a ntifi c ati o n (B L Q ) ar e n o w t o b e 
c o n si d er e d a s n e g ati v e ( B L Q w a s pr e vi o u sl y c o n si d er e d t o b e p o siti v e). T hi s c h a n g e 
aff e ct s t h e d efi niti o n of t h e m o difi e d i nt e nt -t o-tr e at i nf e ct e d (mI T T i) p o p ul ati o n a n d s o m e 
s e c o n d ar y vir ol o g y e n d p oi nt s. T hi s c h a n g e h a s b e e n d et ail e d i n e a c h of t h e r el e v a nt 
s e cti o n s.
T h e r ati o n al e f or t hi s c h a n g e i s t o ali g n t h e d ef i niti o n of n e g ati vit y wit h ot h er e xt er n al 
d at a ( e. g., Fi s c h er et al . 2 0 2 1 ) t o e n s ur e o ur fi n di n g s ar e c o m p ar a bl e a n d i nt er pr et a bl e .
Pr e vi o u sl y, t h e d ef i niti o n of n e g ati vit y w a s b a s e d o nl y o n t h e q u alit ati v e r e s ult 
d et er mi n e d u si n g c y cl e t hr e s h ol d ( Ct) v al u e s. T h er ef or e, a p arti c ul ar vir al l o a d t hr e s h ol d 
w a s n ot u s e d; to e n s ur e w e h a v e a n u m eri c vir al l o a d t hr e s h ol d t o d efi n e n e g ati vit y , t h e 
li mit of q u a ntifi c ati o n ( 1 2 0 c o pi e s/ m L) i s n o w al s o c o n si d er e d . S a m pl e s t h at ar e 
q u alit ati v el y “ n e g ati v e” or q u a ntit ati v el y “ B L Q” ar e n o w d efi n e d t o b e n e g ati v e.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
4
K e y c h a n g e s t o t h e S A P, al o n g wit h t h e r ati o n al e f or e a c h c h a n g e, ar e s u m m ari z e d 
b el o w.
S e cti o n
D e s cri pti o n of C h a n g e
R ati o n al e f or C h a n g e
4
T h e m o difi e d i nt e nt -t o-tr e at i nf e ct e d (mI T T i)
p o p ul ati o n d efi niti o n w a s u p d at e d t o e n s ur e t h at 
e a c h p ati e nt h a s at l e a st o n e r e v er s e-
tr a n s cri pti o n p ol ym e r a s e c h ai n r e a cti o n (R T -
P C R ) t e st r e s ult a b o v e or e q u al t o t h e li mit of 
q u a ntifi c ati o n ( L O Q)
T o ali g n wit h e xt er n al d at a
5. 3. 5
A d diti o n al s u b gr o u p s of: d a y s fr o m s y m p t o m 
o n s et t o tr e at m e nt ( 3 d a y s, 3 d a y s); a n d a n y 
u n d erl yi n g h e alt h c o n diti o n s ( y e s, n o) h a v e b e e n 
a d d e d f or t h e pri m ar y  e n d p oi nt
T o all o w a n al y s e s of 
a d diti o n al s u b gr o u p s t h at 
m a y b e of i nt er e st a n d/ or 
r el e v a n c e 
5. 4. 2. 1
F or t h e ti m e t o c e s s ati o n of vir al s h e d di n g a n d 
ti me t o s u st ai n e d n o n -d et e ct a bl e vir u s R N A 
e n d p oi nt s, r e c ei vi n g a n e g ati v e r e s ult or a r e s ult 
b el o w t h e li mit of q u a ntifi c ati o n (B L Q ) n o w 
m e et s t h e c o n diti o n f or c e s s ati o n a n d n o n -
d et e ct a bilit y, r e s p e cti v el y
T o ali g n wit h e xt er n al d at a
5. 4 . 2. 1
U p d at e d t h e c e n s ori n g d at e a n d ti m e f or p ati e nt s 
t h at d o n ot m e et t h e ti m e-t o-e v e nt vir ol o g y 
e n d p oi nt s t o t h e fi n al ti m e p oi nt o n D a y 7
T o e n s ur e p ati e nt s r e m ai n
“ at-ri s k” t o a s si st wit h t h e 
i nt er pr et ati o n of t h e 
K a pl a n -M ei er pl ot s at D a y 7
5. 4. 2. 1
F or t h e pr o p orti o n of p ati e nt s p o siti v e e n d p oi nt, 
t h e d efi niti o n of p o siti vit y w a s a m e n d e d t o b e 
a n y R T -P C R t e st r e s ult a b o v e or e q u al t o t h e 
li mit of q u a ntifi c ati o n
T o ali g n wit h e xt er n al d at a
5. 4. 2. 3
M o difi e d t h e c e n s ori n g d at e a n d ti m e f or p ati e nt s 
t h at d o n ot m e et t h e effi c a c y ti m e-t o- e v e nt 
e n d p oi nt s t o t h e fi n al ti m e p oi nt o n D a y 2 8
T o ali g n wit h o ur h a n dli n g 
of ot h er ti m e -t o- e v e nt 
e n d p oi nt s
A d diti o n al mi n or c h a n g e s h a v e b e e n m a d e t hr o u g h o ut t o i m pr o v e cl arit y a n d 
c o n si st e n c y.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
5
T A B L E O F C O N T E N T S
S T A TI S TI C A L A N A L Y SI S P L A N A M E N D M E N T R A TI O N A L E ............................. 3
1.
I N T R O D U C TI O N .......................................................................................... 8
1. 1
O bj e cti v e s a n d E n d p oi nt s ........................................................ 9
1. 2
St u d y D e si g n ......................................................................... 1 1
1. 2. 1 
Tr e at m e nt A s si g n m e nt a n d Bli n di n g ...................................... 1 3
1. 2. 2  
D at a M o nit ori n g ..................................................................... 1 4
2.
S T A TI S TI C A L H Y P O T H E S E S .................................................................... 1 5
3.
S A M P L E SI Z E D E T E R MI N A TI O N .............................................................. 1 5
4.
A N A L Y SI S S E T S ........................................................................................ 1 6
5.
S T A TI S TI C A L A N A L Y S E S ......................................................................... 1 7
5. 1
G e n er al C o n si d er ati o n ........................................................... 1 7
5. 2
P arti ci p a nt Di s p o siti o n ........................................................... 2 0
5. 3
Pri m ar y E n d p oi nt A n al y si s ..................................................... 2 0
5. 3. 1
D efi niti o n of Pri m ar y Vir ol o g y E n d p oi nt ................................. 2 0
5. 3. 2
M ai n A n al yti c al A p pr o a c h f or Pri m ar y Vir ol o g y 
E n d p oi nt ................................................................................ 2 0
5. 3. 3
S e n siti vit y A n al y s e s f or Pri m ar y Vir ol o g y 
E n d p oi nt ................................................................................ 2 1
5. 3. 4
S u p p l e m e nt ar y A n al y s e s f or Pri m ar y Vir ol o g y 
E n d p oi nt ................................................................................ 2 1
5. 3. 5
S u b gr o u p A n al y s e s f or Pri m ar y Vir ol o g y 
E n d p oi nt ................................................................................ 2 2
5. 4
S e c o n d ar y E n d p oi nt s A n al y s e s ............................................. 2 2
5. 4. 1
P ot e nti al F urt h er St ati sti c al A n al y s e s .................................... 2 2
5. 4. 2
S e c o n d ar y E n d p oi nt s ............................................................ 2 2
5. 4. 2. 1
S e c o n d ar y E n d p oi nt s ( Vir ol o g y) ............................................ 2 2
5. 4. 2. 2
S e c o n d ar y E n d p oi nt s ( S af et y) ............................................... 2 5
5. 4. 2. 3
S e c o n d ar y E n d p oi nt s ( Effi c a c y) ............................................. 2 8
5. 4. 2. 4
S e c o n d ar y E n d p oi nt ( P h ar m a c o ki n eti c s) ............................... 3 0
5. 4. 2. 5
S e n siti vit y A n al y s e s f or S e c o n d ar y E n d p oi nt s ....................... 3 1


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
6
5. 5
E x pl or at or y E n d p oi nt s A n al y si s ............................................. 3 2
5. 6
Ot h er S af et y A n al y s e s ........................................................... 3 3
5. 6. 1
E xt e nt of E x p o s u r e ................................................................ 3 3
5. 6. 2
E C G s ..................................................................................... 3 3
5. 7
Ot h er A n al y s e s ...................................................................... 3 3
5. 7. 1
D a y 1 0 R e vi e w ...................................................................... 3 3
5. 7. 2 
S u m m ari e s of C o n d u ct of St u d y ............................................ 3 4
5. 7. 3
S u m m ari e s of D e m o gr a p hi c s a n d B a s eli n e 
C h ar a ct eri sti c s ....................................................................... 3 4
5. 8
I nt eri m A n al y s e s.................................................................... 3 5
5. 8. 1
Pl a n n e d I nt eri m A n al y s e s ...................................................... 3 5
5. 8. 2
O pti o n al I nt eri m A n al y s e s ...................................................... 3 5
6.
S U P P O R TI N G D O C U M E N T A TI O N ............................................................ 3 5
7.
R E F E R E N C E S ........................................................................................... 3 8
LI S T O F T A B L E S
T a bl e 1
O bj e cti v e s a n d C orr e s p o n di n g E n d p oi nt s ..................................... 9
T a bl e 2
A n al y si s S et s .............................................................................. 1 7
T a bl e 3
Diff er e n c e s i n Vir ol o g y S a m pli n g B et w e e n C o h ort s .................... 1 8
T a bl e 4
Vir ol o g y A s s e s s m e nt Ti m e Wi n d o w s .......................................... 1 8
T a bl e 5
Vit al Si g n s (I n cl u di n g O x y g e n S at ur ati o n) Ti m e Wi n d o w s .......... 1 9
T a bl e 6
L a b or at or y ( H e m at ol o g y, C h e mi str y) Ti m e Wi n d o w s .................. 1 9
T a bl e 7 
Vir ol o g y Ti m e t o E v e nt C e n s ori n g ............................................... 2 4
T a bl e 8 
Pr e- s p e cifi e d Tr e at m e nt - E m er g e nt A b n or m al L a b or at or y 
Crit eri a ........................................................................................ 2 7
T a bl e 9
Effi c a c y Ti m e t o E v e nt C e n s ori n g ............................................... 3 0
LI S T O F FI G U R E S
Fi g ur e 1
St u d y S c h e m a ............................................................................. 1 3
LI S T O F A P P E N DI C E S
A p p e n di x 1
C h a n g e s t o Pr ot o c ol -Pl a n n e d A n al y s e s ...................................... 3 5
A p p e n di x 2
C O VI D -1 9 S y m pt o m Di ar y a n d P ati e nt Gl o b al I m pr e s si o n of 
S e v erit y ....................................................................................... 3 6


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
7
LI S T O F A B B R E VI A TI O N S A N D D E FI N I TI O N S O F T E R M S
A b br e vi ati o n or T er m
D e s cri pti o n
A E s
a d v er s e e v e nt s
A E SI
a d v er s e e v e nt s of s p e ci al i nt er e st
A N C O V A
a n al y si s of c o v ari a n c e
A U C
ar e a u n d er t h e c ur v e
BI D
t wi c e a d a y
B L Q
li mit of q u a ntifi c ati o n
B MI
b o d y  m a s s i n d e x
C m a x
m a xi m u m  c o n c e ntr ati o n
C o V
c or o n a vir u s
C O VI D -1 9
c or o n a vir u s di s e a s e 2 0 1 9
C S R
Cli ni c al St u d y R e p ort
E C 9 0
9 0 % eff e cti v e c o n c e ntr ati o n
E U A
e m er g e n c y  u s e a ut h ori z ati o n
H C V 
h e p atiti s C vir u s
I M C
I nt er n al M o nit ori n g C o m mitt e e
I M P
i n v e sti g ati o n al m e di ci n al pr o d u ct
I T T
i nt e nt-t o-tr e at
I x R S
i nt er a cti v e v oi c e or w e b-b a s e d r e s p o n s e s y st e m 
L L O Q
l o w er li mit of q u a ntifi c ati o n
L O Q
li mit of q u a ntifi c ati o n
L S M
l e a st s q u ar e s m e a n
mI T Ti
m o difi e d i nt e nt -t o-tr e at i nf e ct e d
N CI C T C A E
N ati o n al C a n c er I n stit ut e C o m m o n T er mi n ol o g y Crit eri a f or A d v er s e 
E v e nt s
N L M E
n o nli n e ar mi x e d eff e ct s
P D
p h ar m a c o d y n a mi c s
P D s
pr ot o c ol d e vi ati o n s
P GI S
P ati e nt Gl o b al I m pr e s si o n of S e v erit y
P K
p h ar m a c o ki n eti c
P T s
pr ef err e d t er m s
R T -P C R
r e v er s e-tr a n s cri pti o n p ol ym e r a s e c h ai n r e a cti o n
S A R S
s e v er e a c ut e r e s pir at or y s y n dr o m e
S A R S -C o V - 1
s e v er e a c ut e r e s pir at or y s y n dr o m e c or o n a vir u s - 1
S A R S -C o V - 2
S A R S c or o n a vir u s - 2
S E
st a n d ar d err or
S O C
S y st e m  Or g a n C l a s s
S p O 2
p eri p h er al c a pill ar y o x y g e n s at ur ati o n


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
8
1.
I N T R O D U C TI O N
T hi s St ati sti c al A n al y si s Pl a n ( S A P) pr o vi d e s d et ail s of t h e pl a n n e d a n al y s e s a n d
st ati sti c al m et h o d s u s e d t o e v al u at e t h e a nti vir al a cti vit y, s af et y, p h ar m a c o ki n eti c s, a n d 
effi c a c y d at a f or St u d y W V 4 3 0 4 2.
A T -5 2 7 ( R O 7 4 9 6 9 9 8) i s a p h o s p h or a mi d at e pr o dr u g of a u ni q u e, 6 -m o difi e d p uri n e 
n u cl e oti d e pr o dr u g di s c o v er e d b y At e a P h ar m a c e uti c al s , I n c. I n l a b or at or y st u di e s, 
A T -5 2 7 p ot e ntl y i n hi bit s t h e R N A -d e p e n d e nt R N A p ol y m er a s e of s e v er al si n gl e -str a n d e d 
R N A vir u s e s. A T -5 2 7 i s c o n v ert e d t o it s a cti v e i ntr a c ell ul ar tri p h o s p h at e f or m ( A T-9 0 1 0) 
t hr o u g h a s eri e s of i nt er m e di at e m et a b olit e s. A T -5 2 7 h a s d e m o n str at e d s u b -mi cr o m ol ar 
p ot e n c y a g ai n st a r a n g e of c or o n a vir u s e s, i n cl u di n g s e v er e a c ut e r e s pir at or y s y n dr o m e
c or o n a vir u s - 1 (S A R S -C o V - 1) ( 9 0 % eff e cti v e c o n c e ntr ati o n [ E C 9 0 ] 0. 3 4 M) a n d 
S A R S -c or o n a vir u s -2 ( C o V - 2) ( m e a n E C9 0 0. 5 M). 
A T -5 2 7 h a s b e e n e v al u at e d i n t w o 
c o m pl et e d cli ni c al st u di e s i n h e alt h y v ol u nt e er s a n d p ati e nt s i nf e ct e d wit h h e p atiti s C 
vir u s ( H C V). I n t h e r e c e ntl y c o m pl et e d P h a s e II st u d y A T -0 1 B -0 0 2 i n H C V -i nfe ct e d 
p ati e nt s, A T -5 2 7 w a s w ell -t ol er at e d f or d ur ati o n s u p t o 1 2 w e e k s a n d a c hi e v e d a hi g h 
r at e of a nti vir al effi c a c y wit h n o s af et y i s s u e s.
D e s pit e t h e r e c e nt a p pr o v al of v a c ci n e s f or t h e pr e v e nti o n of s e v er e a c ut e r e s pir at or y 
s y n dr o m e c or o n a vir u s -2 ( S A R S -C o V - 2) i nf e cti o n a n d t h e r e c e nt e m er g e n c y u s e 
a ut h ori z ati o n ( E U A) f or m o n o cl o n al a nti b o d y t h er a pi e s f or mil d t o m o d er at e C O VI D-1 9, 
t h er e r e m ai n s a si g nifi c a nt a n d ur g e nt u n m et m e di c al n e e d t o d e v el o p n e w t h er a pi e s f or 
C O VI D -1 9. L o gi sti c al c h all e n g e s t o wi d e s pr e a d v a c ci n ati o n gl o b all y ar e li k el y t o r e m ai n 
i n t h e n e ar f utur e a n d t h er e will b e p o p ul ati o n s w h o c a n n ot b e s af el y v a c ci n at e d or f or 
w h o m v a c ci n ati o n m a y off er i n s uffi ci e nt pr ot e cti o n.
C urr e ntl y a v ail a bl e tr e at m e nt s, 
r e m d e si vir a n d d e x a m et h a s o n e, h a v e d e m o n str at e d b e n efit o nl y i n h o s pit ali z e d p ati e nt s 
wit h C O VI D - 1 9, a n d t h e r e c e ntl y a ut h ori z e d m o n o cl o n al a nti b o d y t h er a pi e s f or mil d t o 
m o d er at e C O VI D -1 9 h a v e t o b e a d mi ni st er e d b y i ntr a v e n o u s i nf u si o n, m a ki n g t h e m 
u n s uit a bl e f or u s e i n t h e o ut p ati e nt s etti n g . T h er e r e m ai n s, t h er ef or e, a n ur g e nt u n m et 
m e di c al n e e d t o
d e v el o p n e w t h er a pi e s f or C O VI D -1 9.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
9
1. 1
O B J E C TI V E S A N D E N D P O I N T S
T a bl e 1  
O bj e cti v e s a n d C orr e s p o n di n g E n d p oi nt s
Pri m ar y O bj e cti v e
C orr e s p o n di n g E n d p oi nt

T o e v al u at e t h e a nti vir al 
a cti vit y of A T -5 2 7 c o m p ar e d 
wit h pl a c e b o

C h a n g e fr o m b a s eli n e i n a m o u nt of S A R S -C o V -2 vir u s 
R N A a s m e a s ur e d b y R T -P C R at s p e cifi e d ti m e p oi nt s
S e c o n d ar y O bj e cti v e s
C orr e s p o n di n g E n d p oi nt s

T o e v al u at e t h e a nti vir al 
a cti vit y of A T -5 2 7 c o m p ar e d 
wit h pl a c e b o

Ti m e  t o c e s s ati o n of S A R S-C o V -2 vir al s h e d di n g a s 
m e a s ur e d b y R T -P C R 

Ti m e  t o s u st ai n e d n o n-d et e ct a bl e S A R S -C o V -2 vir u s 
R N A

Pr o p orti o n of p ati e nt s p o siti v e f or S A R S -C o V -2 vir u s 
R N A b y R T -P C R at s p e cifi e d ti m e p oi nt s

Ar e a u n d er t h e c ur v e i n t h e a m o u nt of S A R S -C o V -2 vir u s 
R N A a s m e a s ur e d b y R T -P C R
●
T o e v al u at e t h e s af et y of 
A T -5 2 7 c o m p ar e d wit h 
pl a c e b o

I n ci d e n c e a n d s e v erit y of a d v er s e e v e nt s, wit h s e v erit y 
d et er mi n e d a c c or di n g t o N CI C T C A E v 5. 0 

C h a n g e fr o m b a s eli n e i n t ar g et e d vit al si g n s, i n cl u di n g 
S p O 2

C h a n g e fr o m b a s eli n e i n t ar g et e d cli ni c al l a b or at or y t e st 
r e s ult s

T o c h ar a ct eri z e t h e P K 
pr ofil e of A T -5 1 1 (fr e e b a s e 
f or m of A T-5 2 7) a n d it s 
m a j or m et a b olit e s

Pl a s m a c o n c e ntr ati o n of A T -5 1 1, A T -5 5 1, A T -2 2 9, a n d 
A T -2 7 3 ( s urr o g at e f or t h e i ntr a c ell ul ar c o n c e ntr ati o n of 
t h e a cti v e tri p h o s p h at e m et a b olit e A T-9 0 1 0) at s p e cifi e d 
ti me p oi nt s

T o e v al u at e t h e effi c a c y  of 
A T -5 2 7 c o m p ar e d wit h 
pl a c e b o

Ti m e  t o all e vi ati o n or i m pr o v e m e nt of C O VI D-1 9 
s y m p t o m s (It e m s 1-1 2 of t h e C O VI D -1 9 s y m p t o m di ar y) 
m a i nt ai n e d f or a d ur ati o n of 2 1. 5 h o ur s, d efi n e d a s 
f oll o w s:
-
F or n e w s y m pt o m s: ti m e fr o m st art of tr e at m e nt t o t h e 
all e vi ati o n of C O VI D -1 9 s y m pt o m s (i. e., a s c or e of 0 
[ n o n e] or 1 [ mil d] o n t h e C O VI D-1 9 S y m p t o m Di ar y)
-
F or pr e -e xi sti n g s y m p t o m s: ti m e fr o m st art of tr e at m e nt 
t o w h e n a p ati e nt’ s s ym p t o m s h a v e b e e n m ai nt ai n e d 
or i m pr o v e d ( n ot e: im p r o v e d r e q uir e s at l e a st a si n gl e 
c at e g or y i m pr o v e m e nt fr o m b a s eli n e o n t h e Li k ert 
s c al e.)

Ti m e  t o all e vi ati o n or i m pr o v e m e nt of C O VI D-1 9 
s y m p t o m s (It e m s 1-1 2 of t h e C O VI D -1 9 S y m pt o m D i ar y) 
m a i nt ai n e d f or a d ur ati o n of 4 3 h o ur s, d efi n e d a s f oll o w s:
-
F or n e w s y m pt o m s: ti m e fr o m st art of tr e at m e nt t o t h e 
all e vi ati o n of C O VI D -1 9 s y m pt o m s (i. e., a s c or e of 0 
[ n o n e] or 1 [ mil d] o n t h e C O VI D-1 9 S y m p t o m Di ar y)
-
F or pr e -e xi sti n g s y m p t o m s: ti m e fr o m st art of tr e at m e nt 
t o w h e n a p ati e nt’ s s ym p t o m s h a v e b e e n m ai nt ai n e d 
or i m pr o v e d ( n ot e: i m pr o v e d r e q uir e s at l e a st a si n gl e 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 0
T a bl e 1
O bj e cti v e s a n d C orr e s p o n di n g E n d p oi nt s ( c o nt.)
S e c o n d ar y O bj e cti v e s
C orr e s p o n di n g E n d p oi nt s

T o e v al u at e t h e effi c a c y  of 
A T -5 2 7 c o m p ar e d wit h 
pl a c e b o ( c o nt d..)
c at e g or y i m pr o v e m e nt fr o m b a s eli n e o n t h e Li k ert s c al e.)

Ti m e  t o all e vi ati o n of C O VI D-1 9 s y m p t o m s, d efi n e d a s 
t h e l e n gt h of ti m e t a k e n fr o m st art of tr e at m e nt t o t h e 
p oi nt at w hi c h t h e f oll o wi n g crit eri o n i s m et a n d 
m a i nt ai n e d f or at l e a st 2 1. 5 h o ur s: S c or e of 0 or 1 o n 
It e m s 1- 1 2 of t h e C O VI D-1 9 S y m p t o m Di ar y ( wit h o ut 
c o n si d er ati o n f or pr e s e n c e of pr e -e xi sti n g s y m p t o m s)

Ti m e  t o all e vi ati o n of C O VI D-1 9 s y m p t o m s, d efi n e d a s 
t h e l e n gt h of ti m e t a k e n fr o m st art of tr e at m e nt t o t h e 
p oi nt at w hi c h t h e f oll o wi n g crit eri o n i s m et a n d 
m a i nt ai n e d f or at l e a st 4 3 h o ur s: S c or e of 0 or 1 o n 
It e m s 1- 1 2 of t h e C O VI D-1 9 S y m p t o m Di ar y ( wit h o ut 
c o n si d er ati o n f or pr e s e n c e of pr e -e xi sti n g s y m p t o m s)

D ur ati o n of f e v er, d efi n e d a s t h e ti m e t o r et ur n t o a n 
af e bril e st at e (t e m p er at ur e 3 7. 5° C) m ai nt ai n e d f or at 
l e a st 2 1. 5 h o ur s

Fr e q u e n c y of C O VI D -1 9 -r el at e d c o m pli c ati o n s ( d e at h, 
h o s pit ali z ati o n, r a di ol o gi c all y c o nfir m e d p n e u m o ni a, 
a c ut e r e s pir at or y f ail ur e, s e p si s, c o a g ul o p at h y, 
p eri c ar diti s, m y o c ar diti s, c ar di a c f ail ur e) 

Ti m e  t o all e vi ati o n of a n i n di vi d u al sy m pt o m, d efi n e d a s 
t h e ti m e t a k e n fr o m t h e st art of tr e at m e nt t o t h e p oi nt at 
w hi c h t h e f oll o wi n g crit eri o n i s m et a n d m a i nt ai n e d (f or 
e a c h i n di vi d u al s ym p t o m) f or at l e a st 2 1. 5 h o ur s: 
– S c or e of 0 or 1 f or It e m s 1 -1 2 of t h e C O VI D -1 9 
S y m p t o m Di ar y 
– S c or e of 0 f or It e m s 1 3 a n d 1 4 of t h e C O VI D -1 9 
S y m p t o m Di ar y
E x pl or at or y O bj e cti v e s
C orr e s p o n di n g E n d p oi nt s

T o e v al u at e t h e a nti vir al 
a cti vit y of A T -5 2 7 c o m p ar e d 
wit h pl a c e b o

Tr e at m e nt -e m er g e nt a mi n o a ci d s u b stit uti o n s i n S A R S -
C o V -2 vir al g e n e s ( n s p 1 2 a n d p ot e nti all y ot h er g e n e s) 

A nti -S A R S -C o V -2 a nti b o d y st at u s/tit er at s p e cifi e d 
ti me p oi nt s

C h a n g e fr o m b a s eli n e i n S A R S -C o V -2 vir u s tit er at 
s p e cifi e d ti m e p oi nt s

Ti m e  t o c e s s ati o n of S A R S-C o V -2 vir al s h e d di n g a s 
m e a s ur e d b y vir u s tit er 

Pr o p orti o n of p ati e nt s wit h p o siti v e S A R S -C o V -2 vir u s 
tit er at s p e cifi e d ti m e p oi nt s 

Ar e a u n d er t h e c ur v e of S A R S -C o V -2 vir u s tit er 

Dr u g s u s c e pti bilit y i n p ati e nt s wit h e v al u a bl e vir u s at 
s p e cifi e d ti m e p oi nt s

T o e v al u at e t h e r el ati o n s hi p 
b et w e e n dr u g e x p o s ur e a n d 
a nti vir al a cti vit y of A T -5 2 7

R el ati o n s hi p b et w e e n pl a s m a c o n c e ntr ati o n of A T -2 7 3 
a n d a nti -vir al a cti vit y


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 1
T a bl e 1
O bj e cti v e s a n d C orr e s p o n di n g E n d p oi nt s ( c o nt.)
E x pl or at or y O bj e cti v e s
C orr e s p o n di n g E n d p oi nt s

T o e v al u at e p ati e nt -r e p ort e d 
C O VI D -1 9 s y m p t o m s e v erit y

P ati e nt’ s gl o b al i m pr e s si o n of s e v erit y of C O VI D -1 9 
s y m p t o m s a s a s s e s s e d t hr o u g h t h e u s e of P GI S at D a y 
1 4 a n d D a y 2 8

T o i d e ntif y a n d/ or e v al u at e 
bi o m ar k er s t h at ar e 
pr e di cti v e of r e s p o n s e t o 
A T -5 2 7 (i. e., pr e di cti v e 
bi o m ar k er s), ar e e arl y 
s urr o g at e s of effi c a c y , ar e 
a s s o ci at e d wit h pr o gr e s si o n 
t o a m or e s e v er e di s e a s e 
st at e (i. e., pr o g n o sti c 
b i o mar k er s), c a n pr o vi d e 
e vi d e n c e of A T -5 2 7 a cti vit y 
(i. e., p h ar m a c o d y n a mi c 
bi o m ar k er s), or c a n i n cr e a s e 
t h e k n o wl e d g e a n d 
u n d er st a n di n g of di s e a s e 
bi ol o g y a n d dr u g s af et y

R el ati o n s hi p b et w e e n bi o m ar k er s i n bl o o d, s ali v a, 
n a s o p h ar y n g e al s w a b, a n d n a s o s or pti o n s a m pl e s (li st e d 
i n S e cti o n 4. 5. 5 of t h e st u d y pr ot o c ol ) a n d effi c a c y, 
s af et y, P K, or ot h er bi o m ar k er e n d p oi nt s
C O VI D -1 9 c or o n a vir u s di s e a s e 2 0 1 9; N CI C T C A E N ati o n al C a n c er I n stit ut e C o m m o n 
T er mi n ol o g y Crit eri a f or A d v er s e E v e nt s; n s p 1 2 n o n -str u ct ur al pr ot ei n 1 2 ; P GI S P ati e nt Gl o b al 
I m pr e s si o n of S e v erit y; P K p h ar m a c o ki n eti c ; R T -P C R r e v er s e-tr a n s cri pti o n p ol y m e r a s e c h ai n 
r e a cti o n; S A R S -C o V - 2 s e v er e a c ut e r e s pir at or y s y n dr o m e c or o n a vir u s -2; S p O 2 p eri p h er al 
c a pill ar y o x y g e n s at ur ati o n .
1. 2
S T U D Y D E SI G N
T hi s i s a P h a s e II, r a n d o mi z e d, d o u bl e -bli n d, pl a c e b o -c o ntr oll e d st u d y t o e v al u at e t h e 
a nti vir al a cti vit y, s af et y, p h ar m a c o ki n eti c s, a n d effi c a c y of s el e ct e d d o s e r e gi m e n s of 
A T -5 2 7 c o m p ar e d wit h pl a c e b o i n n o n -h o s pit ali z e d a d ult p ati e nt s wit h mil d or m o d er at e 
C O VI D -1 9.
If all p ot e nti al c o h ort s ar e f ull y e nr oll e d, t h e st u d y will e nr oll u p t o 
a p pr o xi m at el y 2 2 0 p ati e nt s at a p pr o xi m at el y 5 2 sit e s gl o b all y.
P ati e nt s will b e s cr e e n e d u p t o 7 2 h o ur s pri or t o r a n d o mi z ati o n. P ati e nt s w h o d o n ot 
m e et t h e crit eri a f or p arti ci p ati o n i n t hi s st u d y ( s cr e e n f ail ur e) c a n n ot b e r e -s cr e e n e d. 
T h e i n v e sti g at or will r e c or d r e a s o n s f or s cr e e n f ail ur e i n t h e s cr e e ni n g l o g. 
Eli gi bl e p ati e nt s will b e e nr oll e d s e q u e nti all y i nt o o n e of u p t o fi v e p o s si bl e tr e at m e nt 
c o h ort s ( C o h ort s A E). Si xt y p ati e nt s will b e e nr oll e d i nt o C o h ort A; C o h ort s B E will 
e nr oll 4 0 p ati e nt s e a c h. P ati e nt s w h o wit h dr a w fr o m t h e st u d y or w h o di s c o nti n u e st u d y 
tr e at m e nt will n ot b e r e pl a c e d. H o w e v er, p ati e nt s w h o wit h dr a w fr o m t h e st u d y aft er 
s cr e e ni n g, b ut b ef or e r e c ei vi n g t h e fir st d o s e, will b e r e pl a c e d.
H o w e v er, t h e y m a y n ot 
r e c ei v e t h e s a m e tr e at m e nt a s t h e p ati e nt t h e y ar e r e pl a ci n g.
I n C o h ort A, p ati e nt s will b e r a n d o mi z e d i n a 1: 1 r ati o t o r e c ei v e eit h er A T -5 2 7 5 5 0 m g 
t a bl et s ( or pl a c e b o) t wi c e a d a y (BI D ) o n D a y s 1 5, wit h a s s e s s m e nt vi sit s o n D a y s 3, 5, 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 2
a n d 7. Aft er 3 0 p ati e nt s ( 5 0 % e nr ol m e nt) i n C o h ort A h a v e c o m pl et e d a s s e s s m e nt s 
t hr o u g h D a y 1 0, an i nt eri m r e vi e w of s af et y d at a will b e c o n d u ct e d t o d et er mi n e t h e 
A T -5 2 7 d o s e a n d r e gi m e n f or C o h ort B. 
I n C o h ort s BE, p ati e nt s will b e r a n d o mi z e d i n a 3: 1 r ati o t o r e c ei v e eit h er A T -5 2 7 or 
pl a c e b o o n D a y s 1 – 5, wit h a s s e s s m e nt vi sit s o n D a y s 3, 5 a n d 7.
D o s e r e gi m e n 
d e ci si o n s f or C o h ort s C E will b e m a d e b y t h e S p o n s or st u d y t e a m f oll o wi n g u n bli n d e d 
r e vi e w of s af et y d at a b y a n I nt er n al M o nit ori n g C o m mitt e e (I M C) af t er 2 0 p ati e nt s
( a p pr o xi m at el y 1 5 a cti v e a n d 5 pl a c e b o) e nr oll e d i n t h e pr e vi o u s c o h ort h a v e c o m pl et e d 
a s s e s s m e nt s t hr o u g h D a y 1 0. T h e m a xi m u m d o s e t o b e t e st e d i n t h e st u d y will n ot 
e x c e e d A T -5 2 7 1 1 0 0 m g BI D f or 5 d a y s.
D e p e n di n g o n e m er gi n g d at a, t h e S p o n s or 
m a y al s o e v al u at e r e gi m e n s wit h d o s e s of A T -5 2 7 l o w er t h a n 5 5 0 m g BI D.
C o h ort s 
e v al u ati n g s u c h l o w er d o s e s m a y b e i niti at e d at a n y ti m e f oll o wi n g t h e C o h ort A i nt eri m 
s af et y r e vi e w a n d will n ot r e q uir e I M C o v er si g ht.
F or all c o h ort s, vi sit s m a y b e c o n d u ct e d i n cli ni c or b y m o bil e n ur si n g. W h er e l o c al 
p oli ci e s a n d l o c al sit e l o gi sti c s p er mit, p ati e nt s m a y al s o b e c o nfi n e d i n cli ni c d uri n g
D a y s 1 – 7. W h er e tr e at m e nt o c c ur s i n t h e i n p ati e nt s etti n g, t h e p ur p o s e of 
h o s pit ali z ati o n m u st n ot b e f or s e v er e C O VI D -1 9 r e q uiri n g i n p ati e nt tr e at m e nt.  A s af et y 
f oll o w-u p t el e p h o n e c all will b e c o n d u ct e d o n D a y 1 4 a n d a n e n d of st u d y s af et y 
f oll o w-u p t el e p h o n e c all o n D a y 3 3. T h e t ot al st u d y d ur ati o n f or e a c h p ati e nt will b e 
3 3 d a y s.
F or all c o h ort s, a s el e cti o n of diff er e nt s a m pl e s will b e c oll e ct e d t o a s s e s s S A R S -C o V -2 
vir al st at u s at v ari o u s ti m e p oi nt s. T o e v al u at e t h e P K pr o p erti e s of A T -5 2 7, P K s a m pl e s 
will b e c oll e ct e d at v ari o u s ti m e p oi nt s. P ati e nt s will b e cl o s el y m o nit or e d f or C O VI D -1 9 
si g n s a n d s y m pt o m s a n d a d v er s e e v e nt s ( A E s); A E s will b e gr a d e d a c c or di n g t o 
N ati o n al C a n c er I n stit ut e C o m m o n T er mi n ol o g y Crit eri a f or A d v er s e E v e nt s 
( N CI C T C A E) v 5. 0. 
D uri n g C o h ort s B E, a n I M C will pr o vi d e a d diti o n al s af et y o v er si g ht f or c o h ort s 
e v al u ati n g r e gi m e n s wit h A T -5 2 7 d o s e s hi g h er t h a n 5 5 0 m g BI D (r ef er t o S e cti o n 1. 2. 2
f or d et ail s). 
T h e st u d y s c h e m a i s s h o w n i n Fi g ur e 1 .




A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 4
t h eir j o b r ol e s d uri n g a cli ni c al tri al. T h e s e r ol e s i n cl u d e t h e u n bli n di n g gr o u p 
r e s p o n si bl e, cli ni c al s u p pl y c h ai n m a n a g ers, s a m pl e h a n dli n g st aff, o p er ati o n al a s s a y 
gr o u p p er s o n n el, I x R S s er vi c e pr o vi d er, a n d I M C m e m b er s.
S u p p orti n g bi o m etri c s st aff
(i n d e p e n d e nt of t h e pr oj e ct t e a m) will h a v e a c c e s s t o t h e u n bli n d e d d at a t o all o w f or d at a 
tr a n sf er, u n bli n di n g, a n d s u m m ari zin g of s af et y d at a f or I M C r e vi e w. 
W h il e P K s a m pl e s m u st b e c oll e ct e d fr o m p ati e nt s a s si g n e d t o t h e pl a c e b o gr o u p t o 
m ai nt ai n t h e bli n di n g of tr e at m e nt a s si g n m e nt, P K a s s a y r e s ult s f or t h e s e p ati e nt s ar e 
g e n er all y n ot n e e d e d f or t h e s af e c o n d u ct or pr o p er i nt er pr et ati o n of t h e st u d y d at a.
L a b or at ori e s r e s p o n si bl e f or p erf or mi n g st u d y dr u g P K a s s a y s will b e u n bli n d e d t o 
p ati e nt tr e at m e nt a s si g n m e nt s t o i d e ntif y a p pr o pri at e s a m pl e s f or a n al y si s. P K s a m pl e s 
fr o m p ati e nt s a s si g n e d t o t h e pl a c e b o gr o u p will n ot b e a n al y z e d f or st u d y dr u g P K 
c o n c e ntr ati o n e x c e pt b y r e q u e st ( e. g., t o e v al u at e a p o s si bl e err or i n d o si n g). 
If u n bli n di n g i s n e c e s s ar y f or a m e di c al e m er g e n c y ( e. g., i n t h e c a s e of a s eri o u s 
a d v er s e e v e nt (S A E ) f or w hi c h p ati e nt m a n a g e m e nt mi ght b e aff e ct e d b y k n o wl e d g e of 
tr e at m e nt a s si g n m e nt), t h e i n v e sti g at or will b e a bl e t o br e a k t h e tr e at m e nt c o d e b y 
c o nt a cti n g t h e I x R S. T h e tr e at m e nt c o d e s h o ul d n ot b e br o k e n e x c e pt i n e m er g e n c y 
sit u ati o n s. T h e i n v e sti g at or i s n ot r e q uir e d t o c o nt a ct t h e M e di c al M o nit or pri or t o 
br e a ki n g t h e tr e at m e nt c o d e.
H o w e v er, t h e i n v e sti g at or s h o ul d c o nt a ct t h e M e di c al 
M o nit or t o di s c u s s e m er g e n c y u n bli n di n g aft er t h e tr e at m e nt c o d e h a s b e e n br o k e n. 
If t h e i n v e sti g at or wi s h e s t o k n o w t h e i d e ntit y of t h e st u d y dru g f or a n y r e a s o n ot h er t h a n 
a m e di c al e m er g e n c y, h e or s h e s h o ul d c o nt a ct t h e M e di c al M o nit or dir e ctl y. T h e 
i n v e sti g at or s h o ul d d o c u m e nt a n d pr o vi d e a n e x pl a n ati o n f or a n y n o n-e m er g e n c y 
u n bli n di n g. If t h e M e di c al M o nit or a gr e e s t o p ati e nt u n bli n di n g, t h e i n v e sti g at or will b e 
a bl e t o br e a k t h e tr e at m e nt c o d e b y c o nt a cti n g t h e I x R S. 
A s p er h e alt h a ut h orit y r e p orti n g r e q uir e m e nt s, t h e S p o n s or' s Dr u g S af et y r e pr e s e nt ati v e 
will br e a k t h e tr e at m e nt c o d e f or all s eri o u s, u n e x p e ct e d s u s p e ct e d a d v er s e r e a cti o n s 
t h at ar e c o n si d er e d b y t h e i n v e sti g at or or S p o n s or t o b e r el at e d t o a n i n v e sti g ati o n al 
m e di ci n al pr o d u ct (I M P) . T h e p ati e nt m a y c o nti n u e t o r e c ei v e tr e at m e nt, a n d t h e 
i n v e sti g at or, p ati e nt, a n d S p o n s or p er s o n n el, wit h t h e e x c e pti o n of t h e Dr u g S af et y 
r e pre s e nt ati v e a n d p er s o n n el w h o m u st h a v e a c c e s s t o p ati e nt tr e at m e nt a s si g n m e nt s t o 
f ulfill t h eir r ol e s ( a s d efi n e d a b o v e), will r e m ai n bli n d e d t o tr e at m e nt a s si g n m e nt.
1. 2. 2
D at a M o nit ori n g
D uri n g C o h ort s B E, a n I M C will pr o vi d e a d diti o n al s af et y o v er si g ht f or c o h ort s 
e v al u ati n g r e gi m e n s wit h A T -5 2 7 d o s e s hi g h er t h a n 5 5 0 m g BI D. T h e I M C will i n cl u d e 
r e pr e s e nt ati v e s fr o m Cli ni c al S ci e n c e a n d Cli ni c al S af et y w h o ar e i n d e p e n d e nt of t h e 
S p o n s or st u d y t e a m , a n d a Bi o st ati sti c i a n w h o d o e s n ot h a v e r e g ul ar c o nt a ct wit h t h e 
sit e s . I n a d diti o n t o t h e o n g oi n g a s s e s s m e nt of t h e i n ci d e n c e, n at ur e, a n d s e v erit y of 
A E s, S A E s , d e at h s, a n d vit al si g ns a n d l a b or at or y a b n or m aliti e s p erf or m e d b y t h e 




A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 6
2 7 p ati e nt s p er tr e at m e nt gr o u p ( a cti v e or pl a c e b o) i n t h e m o difi e d i nt e nt-t o-tr e at i nf e ct e d 
(mI T Ti ; d efi n e d i n T a bl e 2 ) p o p ul ati o n will r e s ult i n at l e a st 8 0 % p o w er t o d et e ct a m e a n 
r e d u cti o n i n c h a n g e fr o m b a s eli n e of b et w e e n 0. 7 a n d 1. 1 l og 1 0 c o pi e s u si n g a 
t w o-s a m pl e t -t e st f or c o m p ari s o n of m e a n s, a s s u mi n g a st a n d ar d d e vi ati o n of b et w e e n 
1. 2 a n d 1. 8 5 ( R e g e n er o n 2 0 2 0 ) a n d b a s e d o n a 1-si d e d 1 0 % al p h a. T h e s a m pl e si z e 
h a s b e e n a dj u st e d t o 3 0 p ati e nt s p er tr e at m e nt gr o u p t o a c c o u nt f or a n esti m at e d 9 0 % 
S A R S -C o V -2 p o siti v e r at e a n d i s b a s e d o n a si n gl e -c o h ort c o m p ari s o n of A T -5 2 7 v er s u s 
pl a c e b o.
4.
A N A L Y SI S S E T S
Di s p o siti o n s u m m ari e s will b e b a s e d o n t h e i nt e nt -t o-tr e at (I T T) p o p ul ati o n. All 
r a n d o mi z e d p ati e nt s will b e i n cl u d e d i n t h e I T T p o p ul ati o n, a n d d at a will b e s u m m ari z e d 
a c c or di n g t o t h e r a n d o mi z e d tr e at m e nt a s si g n m e nt.
All pri m ar y a n d s e c o n d ar y vir ol o g y a n d effi c a c y o ut c o m e s will b e a n al y z e d i n t h e mI T Ti 
p o p ul ati o n. T h e mI T Ti p o p ul ati o n i s d efi n e d a s all p ati e nt s r a n d o mi z e d i n t h e st u d y w h o 
r e c ei v e d a n y a m o u nt of st u d y dr u g a n d h a d at l e a st o n e p o siti v e S A R S -C o V -2 R T -P C R 
t e st r e s ult a b o v e or e q u al t o t h e li mit of q u a ntifi c ati o n ( L O Q) d uri n g t h e st u d y , wit h 
p ati e nt s gr o u p e d a c c or di n g t o t h e tr e at m e nt a s si g n m e nt at r a n d o mi z ati o n. 
S af et y a n al y s e s will b e p erf or m e d o n t h e s af et y e v al u a bl e p o p ul ati o n, w hi c h c o n si st s of 
all p ati e nt s w h o r e c ei v e a n y a m o u nt of st u d y dr u g. I n all s af et y a n al y s e s, p ati e nt s will b e 
gr o u p e d a c c or di n g t o t h e tr e at m e nt t h at t h e p ati e nt s a ct u all y r e c ei v e d r at h er t h a n t h e 
tr e at m e nt a s si g n e d at r a n d o mi z ati o n. P ati e nt s w h o r e c ei v e d a n y d o s e of A T -5 2 7 will b e 
s u m m ari z e d i n t h e A T -5 2 7 gr o u p.
P h ar m a c o ki n eti c a n al y s e s will b e p erf or m e d o n t h e P K a n al y si s p o p ul ati o n, w hi c h will 
c o n si st of all p ati e nt s i n t h e I T T p o p ul ati o n w h o h a d at l e a st o n e p o st -d o s e dr u g 
c o n c e ntr ati o n m e a s ur e m e nt at a s c h e d ul e d vi sit ti m e p oi nt. 
T h e a n al y si s p o p ul ati o n s ar e d efi n e d i n T a bl e 2 .


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 7
T a bl e 2
A n al y si s S et s
P o p ul ati o n
D efi niti o n
I T T
All r a n d o mi z e d p ati e nt s , w h et h er or n ot t h e p ati e nt r e c ei v e d t h e 
a s si g n e d tr e at m e nt.
S af et y -e v al u a bl e
All p ati e nt s w h o r e c ei v e d at l e a st o n e d o s e of st u d y tr e at m e nt.
mI T Ti
All p ati e nt s r a n d o mi z e d i n t h e st u d y t h at r e c ei v e d a n y a m o u nt of 
st u d y dr u g a n d h a d at l e a st o n e p o siti v e c e ntr al S A R S -C o V -2 
R T - P C R t e st r e s ult a b o v e or e q u al t o t h e L O Q ( b y 
n a s o p h ar y n g e al s w a b) d uri n g t h e st u d y , wit h p ati e nt s gr o u p e d 
a c c or di n g t o t h e tr e at m e nt a s si g n m e nt at r a n d o mi z ati o n
P K p o p ul ati o n
All p ati e nt s i n t h e I T T p o p ul ati o n w h o h a d at l e a st o n e p o st - d o s e 
dr u g c o n c e ntr ati o n m e a s ur e m e nt at a s c h e d ul e d vi sit ti m e p oi nt
I T Ti nt e nt-t o-tr e at; mI T Ti m o difi e d i nt e nt-t o-tr e at i nf e ct e d; L O Q li mit of q u a ntifi c ati o n; 
P K p h ar m a c o ki n eti c ; R T -P C R r e v er s e-tr a n s cri pti o n p ol ym e r a s e c h ai n r e a cti o n;
S A R S -C o V - 2s e v er e a c ut e r e s pir at or y s y n dr o m e c or o n a vir u s - 2.
5.
S T A TI S TI C A L A N A L Y S E S
5. 1
G E N E R A L C O N SI D E R A TI O N
All vir ol o g y a n d effi c a c y a n al y s e s will b e p erf or m e d o n t h e mI T Ti p o p ul ati o n.
All pri m ar y a n d s e c o n d ar y vir ol o g y e n d p oi nt s will b e pr o d u c e d u si n g t h e n a s o p h ar y n g e al 
s w a b s a m pl e s. A d diti o n al d e s cri pti v e a n al y s e s f or s ali v a a n d s er u m s a m pl e s will b e 
p erf or m e d o n a n e x pl or at or y b a si s f or t h e pri m ar y a n d s e c o n d ar y vir ol o g y e n d p oi nt s, a s 
r e q uir e d. A s u m m ar y of t h e s a m pli n g diff er e n c e s b et w e e n c o h ort s i s pr o vi d e d i n 
T a bl e 3 .  R ef er t o A p p e n di x 1 a n d A p p e n di x 2 of t h e st u d y pr ot o c ol f or f urt h er d et ail s.
N o al p h a a dj u st m e nt s f or m ulti pl e c o m p ari s o n s ar e pl a n n e d.
F or all c o h ort s, t h e pri m ar y vir ol o g y a n al y si s will b e p erf or m e d a s p art of a D a y 1 0 
R e vi e w ( a c c o m p a ni e d wit h k e y s af et y r e vi e w if d e e m e d n e c e s s ar y, s e e S e cti o n 5. 7. 1 ) 
w h i c h i s t o b e c o m pl et e d aft er all p ati e nt s e nr oll e d i n t h e c urr e nt c o h ort h a v e c o m pl et e d 
a s s e s s m e nt s t hr o u g h D a y 1 0. Ot h er e n d p oi nt s will b e a n al y z e d at t h e c o m pl eti o n of 
e a c h f ull c o h ort or at t h e c o m pl eti o n of t h e st u d y.
All a n al y s e s at t h e D a y 1 0 r e vi e w or at 
t h e c o m pl eti o n of e a c h c o h ort will c o m p ar e e a c h A T-5 2 7 d o s e gr o u p a n d a c o m bi n e d 
pl a c e b o gr o u p, i n cl u di n g all pl a c e b o p ati e nt s e nr oll e d a cr o s s c o h ort s u p t o t h e c o h ort 
b ei n g a n al y z e d, w hil e a n al y s e s p erf or m e d at t h e c o m pl eti o n of t h e st u d y will c o m p ar e 
e a c h A T -5 2 7 d o s e gr o u p a n d a c o m bi n e d pl a c e b o gr o u p fr o m all c o h ort s.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 8
T a bl e 3
Diff er e n c e s i n Vir ol o g y  S a m pli n g B et w e e n C o h ort s
A s s e s s m e nt
C o h ort A
C o h ort s B E
N a s o p h ar y n g e al s w a b 
s a m pl e f or C O VI D -1 9 
vir ol o g y
O n c e a d a y o n D a y s 1, 3, 5, 
a n d 7
O n c e a d a y o n D a y s 1, 3, 5, 
a n d 7
S ali v a s a m pl e f or C O VI D -
1 9 vir ol o g y
N A
O n c e a d a y o n D a y s 1, 3, 5, 
a n d 7
S er u m s a m pl e f or 
a nti -S A R S -C o V -2 
a nti b o di e s a n d vir al R N A 
O n c e a d a y o n D a y s 1 a n d 7
O n c e a d a y  o n D a y s 1, 3, 5, 
a n d 7
C O VI D -1 9 c or o n a vir u s di s e a s e 2 0 1 9 ; N A n ot a p pli c a bl e; S A R S -C o V - 2 s e v er e a c ut e 
r e s pir at ory s y n dr o m e c or o n a vir u s - 2.
F or vir ol o g y e n d p oi nt s, t h e ti m e wi n d o w s f or e a c h a s s e s s m e nt ar e gi v e n i n T a bl e 4 . T h e 
ti m e wi n d o w s will b e u s e d f or all vir ol o g y e n d p oi nt s e x c e pt t h e ti m e-t o-e v e nt e n d p oi nt s.
T a bl e 4
Vir ol o g y  A s s e s s m e nt Ti m e Wi n d o w s
S c h e d ul e d Ti m e p oi nt a, b , d
A c c e pt a bl e Ti m e Wi n d o w
B a s eli n e ( D a y 1 pr e - d o s e)
D a y 1 pr e -d o s e c
D a y 3
D a y 2 – D a y  3
D a y 5
D a y 4 – D a y  5
D a y 7
D a y 6 – D a y  8
a A n u n s c h e d ul e d vi sit r e pr e s e nt s a vi sit t h at i s n ot s p e cifi e d b y t h e pr ot o c ol b ut i s d et er mi n e d t o 
b e n e c e s s ar y b y t h e i n v e sti g at or or S p o n s or ( e. g., f or e v al u ati o n of a n a d v er s e e v e nt). 
A s s e s s m e nt s (i n cl u di n g P K s a m pl e c oll e cti o n) s h o ul d b e p erf or m e d a s c li ni c all y i n di c at e d. F or 
u n s c h e d ul e d vi sit s o c c urri n g aft er D a y 7, P K s a m pl e c oll e cti o n i s n ot r e q uir e d.
b P ati e nt s w h o di s c o nti n u e st u d y dr u g pr e m at ur el y will c o nti n u e t o c o m pl et e a s s e s s m e nt s a s 
i n di c at e d u ntil t h e e n d of t h e st u d y. P ati e nt s w h o di s c o n ti n u e fr o m st u d y p arti ci p ati o n will h a v e
a n e arl y t er mi n ati o n vi sit 7 ( 2) d a y s aft er t h eir fi n al d o s e of st u d y dr u g. P ati e nt s w h o 
di s c o nti n u e fr o m t h e st u d y aft er D a y 1 4 will n ot b e r e q uir e d t o c o m pl et e a n e arl y t er mi n ati o n 
vi sit.
c If n o pr e-d o s e s a m pl e i s a v ail a bl e, a s a m pl e t a k e n u p t o 2 h o ur s p o st -d o s e c a n b e u s e d a s 
b a s eli n e.
d N o u n s c h e d ul e d vi sit or e arl y t er mi n ati o n s er u m s a m pl e t o b e t a k e n f or C o h ort A.
F or vit al si g n s, i n cl u di n g o x y g e n s at ur ati o n, t h e ti m e wi n d o w s f or e a ch a s s e s s m e nt ar e 
gi v e n i n T a bl e 5 .


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
1 9
T a bl e 5
Vit al Si g n s (I n cl u di n g O x y g e n S at ur ati o n) Ti m e Wi n d o w s
S c h e d ul e d Ti m e p oi nt a, b , d
A c c e pt a bl e Ti m e Wi n d o w
B a s eli n e ( D a y 1 pr e - d o s e)
D a y 1 pr e -d o s e c
D a y 3
D a y 2 – D a y  3 
D a y 5
D a y 4 – D a y  5 
D a y 7
D a y 6 – D a y  8
a A n u n s c h e d ul e d vi sit r e pr e s e nt s a vi sit t h at i s n ot s p e cifi e d b y t h e pr ot o c ol b ut i s d et er mi n e d t o 
b e n e c e s s ar y b y t h e i n v e sti g at or or S p o n s or ( e. g., f or e v al u ati o n of a n a d v er s e e v e nt). 
A s s e s s m e nt s (i n cl u di n g P K s a m pl e c oll e cti o n) s h o ul d b e p erf or m e d a s cli ni c all y i n di c at e d.  
F or u n s c h e d ul e d vi sit s o c c urri n g aft er D a y 7, P K s a m pl e c oll e cti o n i s n ot r e q uir e d.
b P ati e nt s w h o di s c o nti n u e st u d y dr u g pr e m at ur el y will c o nti n u e t o c o m pl et e a s s e s s m e nt s a s 
i n di c at e d u ntil t h e e n d of t h e st u d y.  P ati e nt s w h o di s c o nti n u e fr o m st u d y p arti ci p ati o n will h a v e
a n e arl y t er mi n ati o n vi sit 7 ( ± 2) d a y s aft er t h eir fi n al d o s e of st u d y dr u g.  P ati e nt s w h o 
di s c o nti n u e fr o m t h e st u d y aft er D a y 1 4 will n ot b e r e q uir e d t o c o m pl et e a n e arl y t er mi n ati o n 
vi sit.
c B a s eli n e i s d efi n e d a s t h e l a st a s s e s s m e nt pri or t o tr e at m e nt. 
d T h e s e ti m e wi n d o w s d o n ot a p pl y t o t e m p er at ur e. T e m p er at ur e i s c oll e ct e d a s p art of t h e 
C O VI D -1 9 S y m p t o m Di ar y (t wi c e a d a y o n D a y s 11 4; o n c e a d a y o n D a y s 1 5 2 8).
F or l a b p ar a m et er s ( h e m at ol o g y, c h e mi str y), t h e ti m e wi n d o w s f o r e a c h a s s e s s m e nt ar e 
gi v e n i n T a bl e 6 .
T a bl e 6
L a b or at or y  ( H e m at ol o g y, C h e mi str y) Ti m e Wi n d o w s
S c h e d ul e d Ti m e p oi nt a
A c c e pt a bl e Ti m e Wi n d o w
B a s eli n e ( D a y 1 pr e - d o s e)
D a y 1 pr e -d o s e b
D a y 3
D a y 2 – D a y  4 
D a y 7
D a y 5 – D a y  9
a A n u n s c h e d ul e d vi sit r e pr e s e nt s a vi sit t h at i s n ot s p e cifi e d b y t h e pr ot o c ol b ut i s d et er mi n e d t o 
b e n e c e s s ar y b y t h e i n v e sti g at or or S p o n s or ( e. g., f or e v al u ati o n of a n a d v er s e e v e nt). 
A s s e s s m e nt s (i n cl u di n g P K s a m pl e c oll e cti o n) s h o ul d b e p erf or m e d a s cli ni c all y i n di c at e d.  
F or u n s c h e d ul e d vi sit s o c c urri n g aft er D a y 7, P K s a m pl e c oll e cti o n i s n ot r e q uir e d.
b B a s eli n e i s d efi n e d a s t h e l a st a s s e s s m e nt pri or t o tr e at m e nt.
U n s c h e d ul e d vi sit a n d e arl y t er mi n ati o n vi sit d at a will al s o b e  m a p p e d a c c or di n g t o t h e 
a c c e pt a bl e ti m e wi n d o w s p er T a bl e 4 , T a bl e 5 , a n d T a bl e 6 . W h er e m ulti pl e 
m e a s ur e m e nt s wit hi n a vi sit wi n d o w ar e a v ail a bl e f or a p ati e nt , t h e v al u e obt ai n e d 
cl o s e st t o t h e t ar g et ti m ep oi nt (c e nt er of t h e a c c e pt a bl e ti m e wi n d o w) will b e u s e d. If t w o 
m e a s ur e m e nt s c oll e ct e d wit h t h e s a m e ti m e d e vi ati o n e xi st b ef or e a n d aft er t h e t ar g et 
ti m ep oi nt, t h e m e a s ur e m e nt o bt ai n e d b ef or e t h e t ar g et ti m ep oi nt wil l b e a d o pt e d f or 
a n al y si s.
H o w e v er, pr ef er e n c e will al w a y s b e gi v e n t o m e a s ur e m e nt s c oll e ct e d o n t h e 
d a y s p e cifi e d i n t h e s c h e d ul e d ti m e p oi nt.
T h e a s s e s s m e nt ti m ep oi nt h a vi n g n o 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 0
m e a s ur e m e nt s wit hi n t h e c orr e s p o n di n g a c c e pt a bl e ti m e wi n d o w will b e c o n si d e r e d a s 
mi s si n g a n d will n ot b e i n cl u d e d i n t h e a n al y si s f or t h e ti m e p oi nt i n q u e sti o n.
5. 2
P A R TI CI P A N T DI S P O SI T I O N
Di s p o siti o n s u m m ari e s will b e b a s e d o n t h e I T T p o p ul ati o n.
T h e n u m b er of p ati e nt s w h o e nr oll, di s c o nti n u e, or c o m pl et e t h e st u d y will b e 
s u m m ari z e d b y tr e at m e nt gr o u p a n d p o ol e d pl a c e b o gr o u p. S u m m ari e s m a y al s o b e 
pr o d u c e d f or e a c h i n di vi d u al pl a c e b o gr o u p . R e a s o n s f or pr e m at ur e st u d y wit h dr a w al 
will b e li st e d a n d s u m m ari z e d b y tr e at m e nt gr o u p . M aj or pr ot o c ol d e vi ati o n s ( P D s) will 
b e li st e d a n d e v al u at e d f or t h eir p ot e nti al eff e ct s o n t h e i nt er pr et ati o n of st u d y r e s ult s.
P ati e nt s will n ot b e e x cl u d e d fr o m t h e a n al y si s p o p ul ati o n s b a s e d o n m aj or P D s u nl e s s 
t h e y d o n ot ot h er wi s e m e et t h e d efi niti o n s f or e a c h p o p ul ati o n. S e n siti vit y a n al y s e s 
e v al u ati n g t h e i m p a ct of m aj or P D s m a y b e c o n d u ct e d if a l ar g e n u m b er of m aj or P D' s 
ar e o b s er v e d d uri n g t h e st u d y.
5. 3
P RI M A R Y E N D P OI N T A N A L Y SI S
5. 3. 1
D efi niti o n of Pri m ar y  Vir ol o g y E n d p oi nt
T h e pri m ar y o bj e cti v e of t hi s st u d y i s t o e v al u at e t h e a nti vir al a cti vit y of A T -5 2 7 
c o m p ar e d wit h pl a c e b o o n t h e b a si s of t h e c h a n g e fr o m b a s eli n e i n a m o u nt of 
S A R S -C o V -2 vir u s R N A a s m e a s ur e d b y R T -P C R a n d b a s e d o n t h e l o g -1 0 s c al e at 
s p e cifi e d ti m e p oi nt s . 
T h e pri m ar y a n al y si s will u s e t h e n a s o p h ar y n g e al s w a b d at a.
F or all C o h ort s, t h e 
pri m ar y a n al y si s will b e c o m p ar e d at D a y s 3, 5, a n d 7 a n d will b e p erf or m e d a s p art of 
t h e D a y 1 0 R e vi e w ( S e cti o n 5. 7. 1 ).
All c o h ort s will u s e a p o ol e d pl a c e b o gr o u p i n cl u di n g all p ati e nt s u p t o t h e c o h ort b ei n g 
a n al y z e d. At t h e e n d of t h e st u d y, s e n siti vit y a n al y si s will b e p erf or m e d f or e a c h c o h ort 
wit h a c o m bi n e d pl a c e b o gr o u p fr o m all c o h ort s ( S e cti o n 5. 3. 3 ).
T h e pri m ar y a n al y si s f or e a c h c o h ort will b e t e st e d at a o n e -si d e d 1 0 % al p h a ( e q ui v al e nt 
t o a t w o-si d e d 2 0 % al p h a) . 
5. 3. 2
M ai n A n al y ti c al A p pr o a c h f or Pri m ar y  Vir ol o g y E n d p oi nt
T h e pri m ar y vir ol o g y e n d p oi nt a n al y s e s will b e p erf or m e d o n t h e mI T Ti p o p ul ati o n u si n g 
t h e n a s o p h ar y n g e al s w a b d at a. 
F or e a c h c o h ort, t h e c h a n g e fr o m b a s eli n e i n t h e a m o u nt of S A R S -C o V -2 vir u s R N A will 
b e c o m p ar e d b e t w e e n t h e A T-5 2 7 gr o u p a n d t h e p o ol e d pl a c e b o gr o u p (m e a ni n g
all 
pl a c e b o p ati e nt s u p t o a n d i n cl u di n g t h e c o h ort b ei n g a n al y z e d will b e u s e d t o f or m t h e 
pl a c e b o c o m p ar at or gr o u p ) at D a y s 3, 5, a n d 7 u si n g a n al y si s of c o v ari a n c e (A N C O V A )
wit h b a s eli n e vir al l o a d a s a c o v ari at e. 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 1
T h e l e a st s q u ar e s m e a n ( L S M) c h a n g e a n d it s st a n d ar d err or ( S E) of m e a n s i n e a c h 
gr o u p, t h e diff er e n c e b et w e e n t w o gr o u p s i n L S M c h a n g e, S E, a n d 8 0 % CI, a n d p -
v al u e s will b e pr e s e nt e d . T h e L S M c h a n g e will b e pr e s e nt e d gr a p hi c all y o v er ti m e.
A d diti o n all y, d e s cri pti v e s u m m ari e s f or t h e c h a n g e fr o m b a s eli n e will al s o b e pr e s e nt e d 
b y tr e at m e nt gr o u p. T h e c h a n g e fr o m b a s eli n e a n d t h e a m o u nt of S A R S -C o V -2 vir u s 
R N A will al s o b e pr e s e nt e d gr a p hi c all y o v er ti m e .
B a s eli n e i s d efi n e d a s t h e D a y 1 ( pr e -d o s e) n a s o p h ar y n g e al s w a b ( T a bl e 4 ).
If t h e d at a ar e n ot n or m all y di stri b ut e d, a n o n-p ar a m etri c alt er n ati v e m et h o d will b e u s e d 
( e. g., M a n n -W h it n e y U t e st) t o c o m p ar e di stri b uti o n s.
T h e q u alit ati v e r e s ult of t h e S A R S -C o V -2 R T -P C R t e st i s d et er mi n e d u si n g c y cl e 
t hr e s h ol d ( Ct) v al u e s. If t h e q u alit ati v e r e s ult i s p o siti v e, t h e n a n a s s o ci at e d q u a ntit ati v e 
r e s ult i s al s o pr o vi d e d. T h e q u a nt it ati v e r e s ult i s eit h er n u m eri c al or b el o w t h e li mit of 
q u a ntifi c ati o n ( B L Q).
T h e li mit of q u a ntifi c ati o n ( L O Q) f or t h e vir u s R N A i s 
1 2 0 c o pi e s/ ml. If t h e vir u s R N A s a m pl e h a s a p o siti v e q u alit ati v e r e s ult, b ut a 
q u a ntit ati v e r e s ult B L Q, vir u s R N A wil l b e i m p ut e d a s L O Q – 1 ( 1 1 9 c o pi e s / m L).
N e g ati v e q u alit ati v e s a m pl e s will b e i m p ut e d a s L O Q/ 2 ( 6 0 c o pi e s/ ml) b ef or e b ei n g 
tr a n sf or m e d t o t h e l o g 1 0 s c al e.
S a m pl e s r e p ort e d a s p o siti v e, b ut n ot q u a ntifi a bl e, will 
c o ntri b ut e t o q u alit ati v e s u m m ari e s, b ut w ill b e tr e at e d a s mi s si n g ( n ot i m p ut e d) f or 
q u a ntit ati v e s u m m ari e s.
Mi s si n g d at a will n ot b e i m p ut e d. 
A n y mi s si n g d at a will n ot b e i n cl u d e d i n t h e a n al y s e s.
5. 3. 3
S e n siti vit y A n al y s e s f or Pri m ar y  Vir ol o g y E n d p oi nt
A s e n siti vit y a n al y si s m a y b e p erf or m e d , w h er e b y o nl y d at a o bt ai n e d at t h e n o mi n al 
ti m e p oi nt i s u s e d. T hi s m e a n s t h at t h e ti m e wi n d o w s i n T a bl e 4 w o ul d n ot b e a p pli c a bl e ; 
o nl y s a m pl e s c oll e ct e d o n t h e s c h e d ul e d ti m e p oi nt s ( D a y s 3, 5, a n d 7) w o ul d b e 
i n cl u d e d i n t h e a n al y si s.
At t h e e n d of t h e st u d y, s e n siti vit y a n al y s e s will al s o b e p erf or m e d f or e a c h c o h ort wit h a 
c o m bi n e d pl a c e b o gr o u p fr o m all c o h ort s.
5. 3. 4
S u p pl e m e nt ar y  An al y s e s f or Pri m ar y  Vir ol o g y E n d p oi nt
T o s u p pl e m e nt t h e m ai n a n al y si s, a n e x pl or at or y ti m e-w ei g ht e d a v er a g e c h a n g e fr o m 
b a s eli n e m a y al s o b e p erf or m e d . T hi s will b e c al c ul at e d a s t h e A U C of t h e c h a n g e fr o m 
b a s eli n e vir al l o a d di vi d e d b y it s t ot al ti m e i nt er v al (ti m e of l a st o b s er v ati o n mi n u s ti m e of 
fir st o b s er v ati o n).


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 2
5. 3. 5
S u b gr o u p A n al y s e s f or Pri m ar y  Vir ol o g y E n d p oi nt
T h e c h a n g e fr o m b a s eli n e i n t h e a m o u nt of S A R S-C o V -2 vir u s R N A m a y b e c o m p ar e d 
b et w e e n t h e tr e at m e nt gr o u p s a n d p o ol e d pl a c e b o gr o u p f or t h e f oll o wi n g s u b gr o u p s: 

B a s eli n e vir al l o a d (f or e x a m pl e: hi g h, l o w; b a s e d o n m e di a n b a s eli n e vir al l o a d )

B a s eli n e a nti -S A R S -C o V -2 a nti b o d y ( s pi k e pr ot ei n) st at u s ( p o siti v e, n e g ati v e)

Ti m e fr o m s y m pt o m o n s et t o tr e at m e nt ( 3 d a y s, 3 d a y s)

A n y u n d erl yi n g h e alt h c o n diti o n s ( y e s, n o)
S u b gr o u p a n al y s e s will b e a n al y z e d d e s cri pti v el y at e a c h ti m e p oi nt a n d m a y b e pl ott e d 
o v er ti m e.
5. 4
S E C O N D A R Y E N D P OI N T S A N A L Y S E S
All s e c o n d ar y e n d p oi nt s will b e a n al y z e d d e s cri pti v el y a n d s u m m ar y st ati sti c s w ill b e 
pr e s e nt e d.
D e s cri pti v e c o m p ari s o n s will b e m a d e f or e a c h A T -5 2 7 gr o u p a n d a p o ol e d 
pl a c e b o gr o u p c o nt ai ni n g p ati e nt s fr o m all c o h ort s. F or ti m e t o e v e nt e n d p oi nt s, a 
K a pl a n -M e i er pl ot a n d t h e m e di a n ti m e t o r e s p o n s e will b e pr e s e nt e d al o n g wit h t h e 
8 0 % CI. F or pr o p orti o n, fr e q u e n c y a n d i n ci d e n c e e n d p oi nt s, t h e n u m b er, pr o p orti o n a n d 
diff er e n c e i n pr o p orti o n s al o n g wit h 8 0 % CI s will b e pr e s e nt e d.
F or ar e a u n d er t h e c ur v e 
( A U C) e n d p oi nt s, s u m m ar y st atisti c s will b e pr e s e nt e d.
5. 4. 1
P ot e nti al F urt h er St ati sti c al A n al y s e s
If r e q uir e d, i n a d diti o n t o t h e d e s cri pti v e a n al y s e s, f or m al st ati sti c al a n al y si s m a y al s o b e 
pr e s e nt e d f or s e c o n d ar y e n d p oi nt s. 
Ti m e t o e v e nt s e c o n d ar y vir ol o g y a n d effi c a c y e n d p oi nt s m a y b e a n al y z e d u si n g t h e 
g e n er ali z e d W il c o x o n t e st or l o g -r a n k t e st ( a s a p pr o pri at e), w hi c h m a y b e str atifi e d f or 
a p pr o pri at e c o v ari at e s . S e c o n d ar y pr o p orti o n, fr e q u e n c y a n d i n ci d e n c e e n d p oi nt s f or 
vir ol o g y a n d effi c a c y m a y b e a n al y z e d u si n g t h e Fi s h er’ s E x a ct t e st. A U C a n d d ur ati o n 
s e c o n d ar y e n d p oi nt s m a y b e a n al y z e d u si n g t h e M a n n W h it n e y U t e st, w h er e A U C i s 
c al c ul at e d u si n g t h e tr a p e z oi d al m et h o d. 
5. 4. 2
S e c o n d ar y  E n d p oi nt s
5. 4. 2. 1
S e c o n d ar y  E n d p oi nt s ( Vir ol o g y)
All s e c o n d ar y vir ol o g y a n al y s e s will b e p erf or m e d o n t h e mI T Ti p o p ul ati o n.
All vir ol o g y a n al y s e s will b e p erf or m e d u si n g t h e n a s o p h a r y n g e al s w a b d at a. 
D e s cri pti v e a n al y s e s of s ali v a a n d s er u m s a m pl e s will b e p erf or m e d o n a n e x pl or at or y 
b a si s f or t h e pri m ar y a n d s e c o n d ar y vir ol o g y e n d p oi nt s, a s r e q uir e d.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 3
Ti m e t o e v e nt vir ol o g y  s e c o n d ar y e n d p oi nt s
F or ti m e t o e v e nt vir ol o g y s e c o n d ar y e n d p oi nt s, ti m e will b e c al c ul at e d i n h o ur s .

Ti m e t o c e s s ati o n of S A R S -C o V -2 vir al s h e d di n g a s m e a s ur e d b y  R T-P C R
–
Ti m e t o c e s s ati o n of vir al s h e d di n g b y R T -P C R, i n h o ur s , i s d efi n e d a s t h e ti m e 
b et w e e n t h e i niti ati o n of a n y st u d y tr e at m e nt a n d fir st ti m e w h e n a n e g ati v e or 
B L Q t e st r e s ult b y R T-P C R i s o bt ai n e d . P ati e nt s w h o d o n ot r e c ei v e a n e g ati v e
or B L Q t e st r e s ult b y R T -P C R b y t h e l a st o b s er v ati o n ti m ep oi nt will b e tr e at e d a s 
c e n s or e d at t h e fi n al ti m e p oi nt o n D a y 7.

Ti m e t o s u st ai n e d n o n -d et e ct a bl e S A R S -C o V - 2 vir u s R N A
–
Ti m e t o s u st ai n e d n o n -d et e ct a bl e S A R S - C o V-2 vir u s R N A, i n h o ur s , i s d efi n e d 
a s t h e ti m e b et w e e n t h e i niti ati o n of a n y st u d y tr e at m e nt a n d fir st ti m e w h e n a 
n e g ati v e o r B L Q t e st r e s ult b y R T-P C R i s o bt ai n e d aft er w hi c h n o p o siti v e t e st
a b o v e or e q u al t o t h e L O Q w a s r e p ort e d.
P ati e nt s w h o d o n ot m e et t hi s 
e n d p oi nt b y t h e l a st o b s er v ati o n ti m ep oi nt will b e tr e at e d a s c e n s or e d at t h e fi n al 
ti m e p oi nt o n D a y 7 . 
T h e s e ti m e -t o-e v e nt e n d p oi nt s will b e s u m m ari z e d u si n g d e s cri pti v e st ati sti c s b y 
tr e at m e nt, a s w ell a s K a pl a n -M e i er pl ot s. T h e m e di a n ti m e t o r e s p o n s e
fr o m t h e 
K a pl a n -M e i er pl ot s will b e pr e s e nt e d al o n g wit h t h e 8 0 % CI. If r e q uir e d, a h a z ar d r ati o
m a y b e pr o d u c e d a dj u sti n g f or b a s eli n e vir al l o a d u si n g a C o x pr o p orti o n al h a z ar d s 
m o d el.
F or all c o h ort s, t h e vir ol o g y ti m e -t o-e v e nt e n d p oi nt s will b e d e s cri b e d f or t h e A T -5 2 7 
gr o u p a n d t h e p o ol e d pl a c e b o gr o u p t hr o u g h D a y 7 u si n g t h e mI T Ti p o p ul ati o n.
F or vir ol o g y ti m e t o e v e nt e n d p oi nt s, d e at h s will b e ri g ht c e n s or e d at D a y 7 . 
C o n s e q u e ntl y, f or t h e s e e n d p oi nt s, p arti ci p a nt s c e n s or e d o n t h e fi n al d a y r efl e ct t w o 
diff er e nt st at e s, d e at h or f ail ur e t o m e et t h e i m pr o v e m e nt o ut c o m e crit eri o n. T h er ef or e, 
it i s i m p ort a nt t o u n d er st a n d t h e o ut c o m e i n t h e c ont e xt of t h e n u m b er a n d ti mi n g of 
d e at h s b y tr e at m e nt gr o u p .
I nt er c urr e nt e v e nt s ar e t h o s e t h at o c c ur aft er tr e at m e nt i niti ati o n a n d eit h er pr e cl u d e
o b s er v ati o n of t h e v ari a bl e or aff e ct it s i nt er pr et ati o n. I nt er c urr e nt e v e nt s a n d mi s si n g 
d at a will b e a c c o u nt e d f or t hr o u g h c e n s ori n g r ul e s, a s d e s cri b e d i n T a bl e 7 b el o w.




A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 5
F or t h e vir ol o g y A U C e n d p oi nt, t h e A U C of t h e a m o u nt of vir u s R N A ( R T-P C R) will b e 
c o m p ar e d b et w e e n t h e A T -5 2 7 gr o u p a n d a c o m bi n e d pl a c e b o gr o u p. F or all c o h ort s,
s u m m ar y st ati sti c s will b e pr e s e nt e d t o D a y 7 u si n g t h e f ull c o m bi n e d pl a c e b o gr o u p.
Mi s si n g d at a will b e tr e at e d a s s u c h a n d n ot i n cl u d e d i n t h e a n al y si s.
If t h e vir u s R N A s a m pl e h a s a p o siti v e q u alit ati v e r e s ult, b ut a q u a ntit ati v e r e s ult b el o w 
t h e B L Q, vir u s R N A will b e i m p ut e d a s L O Q – 1 ( 1 1 9 c o pi e s/ m L).
N e g ati v e q u alit ati v e 
s a m pl e s will b e i m p ut e d a s L O Q/ 2 ( 6 0 c o pi e s/ ml) b ef or e b ei n g tr a n sf or m e d t o t h e l o g 1 0 
s c al e.
5. 4. 2. 2
S e c o n d ar y E n d p oi nt s ( S af et y )
T h e s af et y o bj e cti v e f or t hi s st u d y i s t o e v al u at e t h e s af et y of A T -5 2 7 c o m p ar e d wit h 
pl a c e b o.
T h e s af et y p o p ul ati o n will b e u s e d f or all s af et y a n al y s e s. P ati e nt s will b e a n al y z e d 
a c c or di n g t o t h e tr e at m e nt t h e y a ct u all y r e c ei v e d.
S af et y a n al y s e s will b e pr e s e nt e d b y e a c h A T -5 2 7 d o s e a n d a c o m bi n e d pl a c e b o gr o u p 
c o nt ai ni n g p ati e nt s fr o m all c o h ort s. S af et y will b e a s s e s s e d t hr o u g h s u m m ari e s of 
e x p o s ur e t o st u d y tr e at m e nt, A E s , c h a n g e s i n l a b or at or y t e st r e s ult s, a n d c h a n g e s i n 
vit al si g n s a n d E C G s. If a l o w n u m b er of e v e nt s i s o b s er v e d, a li sti n g m a y b e pr o d u c e d 
i n pl a c e of a s u m m ar y t a bl e. A li sti n g of pr e g n a n ci e s will al s o b e pr o d u c e d .
St u d y tr e at m e nt e x p o s ur e ( s u c h a s tr e at m e nt d ur ati o n a n d t ot al d o s e r e c ei v e d) will b e 
s u m m ari z e d wit h d e s cri pti v e st ati sti c s.

I n ci d e n c e a n d s e v erit y of A E s , wit h s e v erit y d et er mi n e d a c c or di n g t o 
N CI C T C A E  v5. 0
All v er b ati m A E t er m s will b e m a p p e d t o M e di c al Di cti o n ar y f or R e g ul at or y A cti viti e s
( M e d D R A) t h e s a ur u s t er m s a n d will b e cl a s sifi e d b y S y st e m O r g a n C l a s s ( S O C) a n d 
pr ef err e d t er m. A E s e v erit y will b e gr a d e d a c c or di n g t o N CI C T C A E v 5. 0. F or A E s of 
v ar y i n g s e v erit y, t h e hi g h e st gr a d e will b e u s e d i n t h e s u m m ari e s. D e at h s a n d c a u s e of 
d e at h will b e li st e d.
O nl y tr e at m e nt -e m er g e nt A E s will b e s u m m ari z e d. Tr e at m e nt -e m er g e nt A E s ar e 
d ef i n e d a s t h o s e A E s wit h o b s er v e d or i m p ut e d o n s et d at e o n or aft er t h e st art d at e of 
tri al tr e at m e nt. O nl y w h er e t h e m o st e xtr e m e i nt e n sit y i s gr e at er t h a n t h e i niti al i nt e n sit y 
( or if m o st e xtr e m e i nt e n sit y i s n ot mi s si n g a n d i niti al i nt e n sit y i s mi s si n g) will e v e nt s wit h 
a n o n s et d at e pri or t o t h e st art of st u d y tr e at m e nt b e c o n si d er e d tr e at m e nt -e m er g e nt.
A n A E wit h a c o m pl et el y mi s si n g st art d at e will b e a s s u m e d t o b e tr e at m e nt -e m er g e nt
u nl e s s t h e A E h a s a c o m pl et e n o n -i m p ut e d e n d d at e t h at i s pri or t o st u d y D a y 1.
A E s
will b e c o d e d a n d t a b ul at e d b y S O C a n d/ or P r ef err e d T e r m s (P T s) . I n t a b ul ati o n s, P T s 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 6
a n d t h eir a s s o ci at e d S O C will b e pr e s e nt e d i n or d er of d e s c e n di n g fr e q u e n c y s u m m e d
a cr o s s t h e tr e at m e nt gr o u p s . 
T h e f oll o wi n g will b e s u m m ari z e d f or e a c h A T -5 2 7 gr o u p a n d a p o ol e d pl a c e b o gr o u p , 
a n d li sti n g s pr o d u c e d w h er e r e q uir e d:

A E s

S A E s

A E s r el at e d t o st u d y tr e at m e nt

A E s l e a di n g t o d e at h

A E s l e a di n g t o wit h dr a w al of st u d y dr u g

A E s l e a di n g t o wit h dr a w al fr om st u d y

A E s o c c urri n g i n 5 % of p ati e nt s i n at l e a st o n e tr e at m e nt gr o u p

A E s o c c urri n g i n 1 0 % of p ati e nt s i n at l e a st o n e tr e at m e nt gr o u p

A E s of N CI C T C A E G r a d e 3 or hi g h er

A E s b y m o st e xtr e m e N CI C T C A E gr a d e

A E s a n d S A E s b y o ut c o m e

A E s a n d S A E s b y ti m e of o n s et a c c or di n g t o t h e f oll o wi n g c at e g ori e s:
–
W e e k 1 ( D a y s 1 -7)
–
W e e k 2 ( D a y s 8 -1 4)
–
D a y s 1 5
All a d v er s e e v e nt s of s p e ci al i nt er e st ( A E SI) will b e pr e s e nt e d b y tr e at m e nt gr o u p. A E SI
ar e a s f oll o w s f or t hi s st u d y:

C a s e s of p ot e nti al dr u g -i n d u c e d li v er i nj ur y t h at i n cl u d e a n el e v at e d al a ni n e 
tr a n s a mi n a s e (A L T ) or a s p art at e a mi n otr a n sf er a s e (A S T ) i n c o m bi n ati o n wit h eit h er 
a n el e v at e d bilir u bi n or cli ni c al j a u n di c e, a s d efi n e d b y H y' s L a w ( a s d et ail e d i n 
pr ot o c ol) 

S u s p e ct e d tr a n s mi s si o n of a n i nf e cti o u s a g e nt b y t h e st u d y dr u g, a s d efi n e d b el o w 
A n y or g a ni s m, vir u s, or i nf e cti o u s p arti cl e ( e. g., pri o n pr ot ei n tr a n s mitti n g 
tr a n s mi s si bl e s p o n gif or m e n c e p h al o p at h y), p at h o g e ni c or n o n-p at h o g e ni c, i s 
c o n si d er e d a n i nf e cti o u s a g e nt. A tr a n s mi s si o n of a n i nf e cti o u s a g e nt m a y b e 
s u s p e ct e d fr o m cli ni c al s y m pt o m s or l a b or at or y fi n di n g s t h at i n di c at e a n i nf e cti o n i n 
a p ati e nt e x p o s e d t o a m e di ci n al pr o d u ct. T hi s t er m a p pli e s o nl y w h e n a 
c o nt a mi n ati o n of t h e st u d y dr u g i s s u s p e ct e d .
D et ail s of a n y d e at h s will b e pr e s e nt e d i n t h e f or m of a n i n di vi d u al p ati e nt li sti n g, a s w ell 
a s i n a fr e q u e n c y t a bl e b y tr e at m e nt gr o u p .


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 7

C h a n g e fr o m b a s eli n e i n t ar g et e d vit al si g n s, i n cl u di n g p eri p h er al c a pill ar y  
o x y g e n s at ur ati o n ( S p O 2 )
F or e a c h of t h e vit al si g n s ( p ul s e r at e, r e s pir at or y r at e, bl o o d pr e s s ur e, p eri p h er al 
c a pill ar y o x y g e n s at ur ati o n [S p O 2 ], a n d t e m p er at ur e), s u m m ar y st ati sti c s o n a b s ol ut e 
v al u e a n d t h e c h a n g e fr o m b a s eli n e will b e pr e s e nt e d o v er ti m e. F or all c o h ort s, t hi s will 
b e pr e s e nt e d b y tr e at m e nt gr o u p at all ti m e p oi nt s u si n g a c o m bi n e d pl a c e b o gr o u p 
c o nt ai ni n g p ati e nt s fr o m all c o h ort s.
A d diti o n all y, f or all c o h ort s, a gr a p hi c al r e pr e s e nt ati o n of m e a n s o v er ti m e of 
t e m p er at ur e ( d ail y t o D a y 2 8 ) will b e pr e s e nt e d. S u m m ari e s of ot h er t e m p er at ur e 
r el at e d s e c o n d ar y effi c a c y e n d p oi nt ar e d e s cri b e d i n S e cti o n 5. 4. 2. 3 .
B a s eli n e i s d efi n e d a s t h e l a st a s s e s s m e nt pri or t o tr e at m e nt.

C h a n g e fr o m b a s eli n e i n t ar g et e d cli ni c al l a b or at or y  t e st r e s ult s
F or e a c h of t h e h e m at ol o gi c al a n d bi o c h e mi c al t e st p ar a m et er s, s u m m ar y st ati sti c s of
o b s er v e d a n d c h a n g e fr o m b a s eli n e v al u e s at e a c h ti m ep oi nt will b e pr e s e nt e d b y
tr e at m e nt gr o u p f or e a c h s c h e d ul e d ti m ep oi nt. B a s eli n e i s d efi n e d a s t h e l a st 
a s s e s s m e nt pri or t o tr e at m e nt.
A d diti o n all y, s hift t a bl e s of  s el e ct e d l a b or at or y t e st s will b e u s e d t o s u m m ari z e t h e 
b a s eli n e a n d m a xi m u m p o st -b a s eli n e s e v erit y gr a d e.
N CI C T C A E v 5. 0 gr a di n g will b e 
u s e d wit h a n i n di c ati o n of t h e dir e cti o n of t h e a b n or m alit y ( Hi g h, L o w). A s u m m ar y of t h e 
n u m b er a n d p er c e nt a g e of p ati e nt s wit h a b n or m al l a b or at or y o ut c o m e s will b e pr o d u c e d 
b y tr e at m e nt gr o u p a n d p o ol e d pl a c e b o gr o u p f or e a c h p ar a m et er f or e a c h s c h e d ul e d 
ti m e p oi nt.
T h e n u m b er a n d pr o p orti o n of p ati e nt s w h o m e e t t h e pr e-s p e cifi e d crit eri a s h o w n i n 
T a bl e 8 will b e pr e s e nt e d b y tr e at m e nt gr o u p d uri n g t h e st u d y.
T a bl e 8
Pr e -s p e cifi e d Tr e at m e nt -E m er g e nt A b n or m al L a b or at or y  Crit eri a
A S T ( U/ L) or A L T ( U/ L) a n d T ot al bilir u bi n ( m g/ d L)
A S T ( U/ L) or A L T ( U/ L) 3 B a s eli n e
A S T ( U/ L) or A L T ( U/ L) 5 B a s eli n e
A S T ( U/ L) or A L T ( U/ L) 3 B a s eli n e a n d T ot al bilir u bi n ( m g/ d L) 2 U L N
A L T a l a ni n e a m i n otr a n sf er a s e; A S Ta s p art at e a mi n otr a n sf er a s e; U L N u p p er li mit of n or m al.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 8
5. 4. 2. 3
S e c o n d ar y  E n d p oi nt s ( Effi c a c y)
Ti m e t o e v e nt a n d d ur ati o n effi c a c y s e c o n d ar y e n d p oi nt s i n cl u d e:

Ti m e t o all e vi ati o n or i m pr o v e m e nt of C O VI D -1 9 s y m pt o m s
(It e m s 11 2 of t h e 
C O VI D -1 9 S y m pt o m D i ar y) m ai nt ai n e d f or a d ur ati o n of 2 1. 5 h o ur s
–
Ti m e t o all e vi ati o n or i m pr o v e m e nt i s d efi n e d a s t h e l e n gt h of ti m e ( h o ur s) t a k e n 
fr o m st art of tr e at m e nt t o t h e p oi nt at w hi c h all of t h e f oll o wi n g t hr e e crit eri a ar e 
m et a n d m ai nt a i n e d f or a c o n c urr e nt d ur ati o n of at l e a st 2 1. 5 h o ur s:
o
All e vi ati o n of all n e w C O VI D -1 9 s y m pt o m s, d efi n e d a s a s c or e of 0 [ n o n e] 
or 1 [ mil d] of t h e C O VI D-1 9 S y m pt o m Di ar y
o
I m pr o v e m e nt of all pr e-e xi sti n g s y m pt o m s t h at h a d w or s e n e d d u e t o 
C O VI D -1 9 , d efi n e d a s at l e a st a si n gl e c at e g or y i m pr o v e m e nt fr o m 
b a s eli n e o n t h e Li k ert s c al e. F or e x a m pl e, a s y m pt o m cl a s s e d a s s e v er e 
at b a s eli n e m u st i m pr o v e t o m o d er at e, mil d, or n o n e, a n d a s y m pt o m 
cl a s s e d a s m o d er at e at b a s eli n e m u st i m pr o v e t o mil d or n o n e .
o
M a i nt ai n/i m pr o v e m e nt of all pr e -e xi sti n g s y m pt o m s t h at h a d n ot w or s e n e d 
d u e t o C O VI D -1 9 , d efi n e d a s eit h er r e m ai ni n g t h e s a m e s c or e or at l e a st 
a si n gl e c at e g or y i m pr o v e m e nt fr o m b a s eli n e o n t h e Li k ert s c al e.

Ti m e t o all e vi ati o n or i m pr o v e m e nt of C O VI D -1 9 s y m pt o m s (It e m s 11 2 of t h e 
C O VI D -1 9 S y m pt o m D i ar y) mai nt ai n e d f or a d ur ati o n of 4 3 h o ur s
–
Ti m e t o all e vi ati o n or i m pr o v e m e nt i s d efi n e d a s t h e l e n gt h of ti m e ( h o ur s) t a k e n 
fr o m st art of tr e at m e nt t o t h e p oi nt at w hi c h all of t h e f oll o wi n g t hr e e crit eri a ar e 
m et a n d m ai nt ai n e d f or a c o n c urr e nt d ur ati o n of at l e a st 4 3 h o ur s:
o
All e vi ati o n of all n e w C O VI D -1 9 s y m pt o m s, d efi n e d a s a s c or e of 0 [ n o n e] 
or 1 [ mil d] of t h e C O VI D-1 9 S y m pt o m Di ar y
o
I m pr o v e m e nt of all pr e-e xi sti n g s y m pt o m s t h at h a d w or s e n e d d u e t o 
C O V I D-1 9 , d efi n e d a s at l e a st a si n gl e c at e g or y i m pr o v e m e nt fr o m 
b a s eli n e o n t h e Li k ert s c al e.  F or e x a m pl e, a s y m pt o m cl a s s e d a s s e v er e 
at b a s eli n e m u st i m pr o v e t o m o d er at e, mil d, or n o n e, a n d a s y m pt o m 
cl a s s e d a s m o d er at e at b a s eli n e m u st i m pr o v e t o mil d or n o n e.
o
M a i nt ai n/i m pr o v e m e nt of all pr e-e xi sti n g s y m pt o m s t h at h a d n ot w or s e n e d 
d u e t o C O VI D -1 9 , d efi n e d a s eit h er r e m ai ni n g t h e s a m e s c or e or at l e a st 
a si n gl e c at e g or y i m pr o v e m e nt fr o m b a s eli n e o n t h e Li k ert s c al e.
T h e effi c a c y e n d p oi nt d efi niti o n i n cl u d e s b ot h all e vi ati o n of n e w C O VI D -1 9 s y m pt o m s 
a n d m ai nt e n a n c e/i m pr o v e m e nt of pr e -e xi sti n g C O VI D -1 9 s y m pt o m s t o all o w f or t h e 
p o s si bilit y t h at s o m e p ati e nt s m a y h a v e u n d erl yi n g h e alt h c o n diti o n s wit h s y m pt o m s 
si mil ar t o t h o s e o b s er v e d wit h C O VI D -1 9 ( e. g., c o u g h i n a p ati e nt wit h c hr o ni c 
o b str u cti v e p ul m o n ar y di s e a s e).  At s cr e e ni n g, p ati e nt s will b e a s s e s s e d wit h a 1 4 -it e m 
C O VI D -1 9 s y m pt o m s e v erit y a s s e s s m e nt t o i d e ntif y pr e -e xi sti n g s y m pt o m s ( wit hi n t h e 
pri or 3 0 d a y s), a n d a s s e s s if t h e y w or s e n e d d u e t o C O VI D -1 9.  S y m pt o m s t h at ar e n ot 
pr e -e xi sti n g ar e c o n si d er e d t o b e n e w s y m pt o m s a n d n e e d t o a c hi e v e s u st ai n e d 
all e vi ati o n ( s c or e of 0 or 1) t o m e et t h e e n d p oi nt, a s d e s cri b e d a b o v e.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
2 9

Ti m e t o all e vi ati o n of C O VI D -1 9 si g n s a n d s y m pt o m s m ai nt ai n e d f or a 
d ur ati o n of 2 1. 5 h o ur s
–
Ti m e t o all e vi ati o n of C O VI D -1 9 s y m pt o m s i s d efi n e d a s t h e l e n gt h of ti m e 
( h o ur s) t a k e n fr o m st art of tr e at m e nt t o t h e p oi nt at w hi c h t h e f oll o wi n g crit eri o n 
i s m et a n d m ai nt ai n e d f or at l e a st 2 1. 5 h o ur s: S c or e of 0 or 1 o n It e m s 11 2 o f 
t h e C O VI D-1 9 S y m pt o m Di ar y , r e g ar dl e s s of if t h e s y m pt o m i s pr e-e xi sti n g or 
n e w.

Ti m e t o all e vi ati o n of C O VI D -1 9 si g n s a n d s y m pt o m s m ai nt ai n e d f or a 
d ur ati o n of 4 3 h o ur s
–
Ti m e t o all e vi ati o n of C O VI D -1 9 s y m pt o m s i s d efi n e d a s t h e l e n gt h of ti m e 
( h o ur s) t a k e n fr o m st art of tr e at m e nt t o t h e p oi nt at w hi c h t h e f oll o wi n g crit eri o n 
i s m et a n d m ai nt ai n e d f or at l e a st 4 3 h o ur s: S c or e of 0 or 1 o n It e m s 1 1 2 of t h e 
C O VI D -1 9 S y m pt o m Di ar y, r e g ar dl e s s of if t h e s y m pt o m i s pr e-e xi sti n g or n e w.

D ur ati o n of f e v er
–
D ur ati o n of f e v er i s d efi n e d a s t h e ti m e fr o m st art of tr e at m e nt t o r et ur n t o a n 
af e bril e st at e (t e m p er at ur e ≤3 7. 5° C) m ai nt ai n e d f or at l e a st 2 1. 5 h o ur s.

Ti m e t o all e vi ati o n of a n i n di vi d u al s y m pt o m
–
Ti m e t o all e vi ati o n of a n i n di vi d u al s y m pt o m i s d efi n e d a s t h e l e n gt h of ti m e
( h o ur s) t a k e n fr o m t h e st art of tr e at m e nt t o t h e p oi nt at w hi c h t h e f oll o wi n g 
crit eri o n i s m et a n d m ai nt ai n e d (f or e a c h i n di vi d u al s y m pt o m) f or at l e a st 
2 1. 5 h o ur s: 
o
S c or e of 0 or 1 f or It e m s 1 1 2 of t h e C O VI D -1 9 S y m pt o m Di ar y
o
S c or e of 0 f or It e m s 1 3 a n d 1 4 of t h e C O VI D -1 9 S y m pt o m Di ar y
F or e a c h of t h e s e e n d p oi nt s, t h e ti m e at w hi c h t h e e n d p oi nt i s m et i s t h e ti m e of t h e st art 
of  t h e p eri o d w h e n t h e crit eri o n i s m et.
T h e s e e n d p oi nt s will b e s u m m ari z e d u si n g d e s cri pti v e st ati sti c s b y tr e at m e nt gr o u p , a s 
w e ll a s K a pl a n-M ei er pl ot s
w h er e a p pr o pri at e . T h e m e di a n ti m e t o r e s p o n s e will b e 
pr e s e nt e d al o n g wit h t h e 8 0 % CI. F or all c o h ort s, t h e effi c a c y ti m e t o e v e nt e n d p oi nt s 
will b e d e s cri b e d t hr o u g h D a y 2 8 b et w e e n t h e A T -5 2 7 gr o u p a n d t h e c o m bi n e d pl a c e b o 
gr o u p fr o m all a v ail a bl e c o h ort s u si n g t h e mI T Ti p o p ul ati o n.
A s u m m ar y of t h e s y m pt o m s e v erit y f or e a c h s y m pt o m i n t h e C O VI D -1 9 s y m pt o m di ar y
will b e pr o vi d e d at b a s eli n e, D a y 1 4 a n d D a y 2 8 f or e a c h tr e at m e nt gr o u p a n d p o ol e d 
pl a c e b o gr o u p. D a y 1 4 ( m or ni n g) a s s e s s m e nt s ar e t o b e u s e d f or t h e D a y 1 4 s u m m ar y. 
If t h e m or ni n g s a m pl e i s mi s si n g, t h e e v e ni n g s a m pl e will b e u s e d.
F or effi c a c y ti m e t o e v e nt e n d p oi nt s, d e at h s will b e ri g ht c e n s or e d at D a y 2 8. 
C o n s e q u e ntl y, f or t h e s e e n d p oi nt s, p arti ci p a nt s c e n s or e d o n D a y 2 8 r efl e ct t w o diff er e nt 
st at e s, d e at h a n d f ail ur e t o m e et t h e i m pr o v e m e nt o ut c o m e crit eri o n. T h er ef or e, it i s 


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 0
i m p ort a nt t o u n d er st a n d t h e o ut c o m e i n t h e c o nt e xt of t h e n u m b er a nd ti mi n g of d e at h s 
b y tr e at m e nt gr o u p .
I nt er c urr e nt e v e nt s ar e t h o s e t h at o c c ur aft er tr e at m e nt i niti ati o n a n d eit h er pr e cl u d e
o b s er v ati o n of t h e v ari a bl e or aff e ct it s i nt er pr et ati o n.
I nt er c urr e nt e v e nt s a n d mi s si n g 
d at a will b e a c c o u nt e d f or t hr o u g h c e n s ori n g r ul e s, a s d e s cri b e d i n T a bl e 9 b el o w.
T a bl e 9
Effi c a c y  Ti m e t o E v e nt C e n s ori n g
E v e nt
C e n s or
D at e a n d Ti m e
D e at h pri or t o m e eti n g 
e n d p oi nt
Y e s
Fi n al ti m e p oi nt o n D a y  2 8
Di s c o nti n u ati o n or l o st t o 
f oll o w-u p u p t o D a y 2 8 f or 
a n y r e a s o n pri or t o m e eti n g 
e n d p oi nt
Y e s
L a st o b s er v e d C O VI D -1 9 
s y m p t o m di ar y a s s e s s m e nt
D o n ot m e et t h e e n d p oi nt
Y e s
Fi n al ti m e p oi nt o n D a y  2 8
Fr e q u e n c y effi c a c y e n d p oi nt s i n cl u d e:

Fr e q u e n c y  of C O VI D-1 9 r el at e d c o m pli c ati o n s 
–
C O VI D -1 9 -r el at e d c o m pli c ati o n s i n cl u d e: d e at h, h o s pit ali z ati o n, r a di ol o gi c all y 
c o nfir m e d p n e u m o ni a, a c ut e r e s pir at or y f ail ur e, s e p si s, c o a g ul o p at h y, 
p eri c ar diti s, m y o c ar diti s,
a n d c ar di a c f ail ur e .
F or fr e q u e n c y effi c a c y e n d p oi nt s, t h e n u m b er, pr o p orti o n a n d diff er e n c e i n pr o p orti o n s 
b et w e e n t h e A T -5 2 7 gr o u p a n d t h e p o ol e d pl a c e b o gr o u p fr o m all a v ail a bl e c o h ort s, 
al o n g wit h 8 0 % CI s will b e pr e s e nt e d b y tr e at m e nt gr o u p .
5. 4. 2. 4
S e c o n d ar y  E n d p oi nt ( P h ar m a c o ki n eti c s)

Pl a s m a c o n c e ntr ati o n of A T- 5 1 1, A T- 5 5 1, A T- 2 2 9, a n d A T- 2 7 3 at s p e cifi e d 
ti m e p oi nt s
T h e P K a n al y si s p o p ul ati o n will c o n si st of p ati e nt s wit h s uffi ci e nt d at a t o e n a bl e 
e sti m ati o n of k e y p ar a m et er s (i n cl u di n g, b ut n ot li mit e d t o, m a xi m u m c o n c e ntr ati o n [ C
m a x ]
a n d mi ni m u m c o n c e ntr ati o n), wit h p ati e nt s gr o u p e d a c c or di n g t o tr e at m e nt r e c ei v e d. 
D u e t o s p ar s e s a m pli n g, n o n -c o m p art m e nt al a n al y si s will n ot b e p erf or m e d . 
S a m pl e s t a k e n f or P K a n al y si s will b e pr o c e s s e d t o pl a s m a a n d c o n c e ntr ati o n s of 
A T -5 1 1 (fr e e b a s e f or m of A T -5 2 7) a n d it s m aj or m et a b olit e s A T -5 5 1, A T -2 2 9, a n d 
A T -2 7 3, will b e q u a ntifi e d b y a v ali d at e d li q ui d c hr o m at o gr a p h y -t a n d e m m a s s 
s p e ctr o m etr y m et h o d.
F or A T -5 1 1, A T -5 5 1, A T -2 2 9, a n d A T -2 7 3 pl a s m a c o n c e ntr ati o n -ti m e pr ofil e s will b e 
pl ott e d

B y c o h ort,


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 1
–
O v erl a yi n g arit h m eti c m e a n a n d i n di vi d u al v al u e s ( l o g c o n c e ntr ati o n s c al e)
–
O v erl a yi n g arit h m eti c m e a n ( + S D) a n d i n di vi d u al v al u e s (li n e ar c o n c e ntr ati o n 
s c al e )
–
O v erl a yi n g i n di vi d u al pl ot s ( li n e ar a n d l o g co n c e ntr ati o n s c al e )

Gr o u p b y c o h ort
–
O v erl a yi n g arit h m eti c m e a n (l o g c o n c e ntr ati o n s c al e)
–
O v erl a yi n g arit h m eti c m e a n ( + S D) (li n e ar c o n c e ntr ati o n s c al e)
I n di vi d u al P K c o n c e ntr ati o n d at a will b e li st e d b y c o h ort.
D e s cri pti v e s u m m ar y st ati sti c s t a bl e s f or P K c o n c e ntr ati o n d at a will b e pr o vi d e d b y 
c o h ort a n d vi sit/ s a m pli n g ti m ep oi nt. S u m m ar y st ati sti c s will i n cl u d e m e a n ( arit h m eti c 
a n d g e o m etri c), S D, C V ( arit h m eti c a n d g e o m etri c), m e di a n, mi ni m u m, a n d m a xi m u m. 
C o n c e ntr ati o n s b el o w t h e l o w er li mit of q u a ntific ati o n ( L L O Q ) will b e tr e at e d a s z er o i n 
s u m m ar y st ati sti c s a n d f or P K p ar a m et er c al c ul ati o n s. 
N o nli n e ar mi x e d eff e ct s ( N L M E) m o d eli n g m a y b e u s e d t o a n al y z e t h e d o s e -
c o n c e ntr ati o n -ti m e d at a of A T-5 1 1 a n d A T -2 7 3 i n pl a s m a.
P o p ul ati o n a n d i n di vi d u al P K 
p ar a m et er s ( e. g., C L/ F a n d V s s/ F) will b e e sti m at e d a n d t h e i nfl u e n c e of v ari o u s 
c o v ari at e s ( s u c h a s a g e, g e n d er a n d b o d y w ei g ht) o n t h e s e p ar a m et er s will b e 
i n v e sti g at e d. T h e d at a c oll e ct e d d uri n g t hi s st u d y m a y b e p o ol e d wi t h d at a c oll e ct e d i n 
ot h er cli ni c al st u di e s ( pr e vi o u s P h a s e I a n d/ or P h a s e II st u d y i n h e alt h y v ol u nt e er s a n d 
H C V -i nf e ct e d p ati e nt s) a s a p pr o pri at e t o b uil d t h e p h ar m a c o ki n eti c m o d el. S e c o n d ar y 
P K p ar a m et er s s u c h a s A U C a n d C m a x m a y b e d eri v e d fr o m t h e i n di vi d u al p o st -h o c 
pr e di cti o n s. R e s ult s of t h e N L M E P K a n al y si s will b e r e p ort e d i n a st a n d al o n e d o c u m e nt 
s e p ar at e fr o m t h e Cli ni c al St u d y R e p ort ( C S R). 
A d diti o n al P K a n al y s e s m a y b e c o n d u ct e d a s a p pr o pri at e. T h e P K d at a a n d p ar a m et er s 
d eri v e d fr o m t h e s e a n al y s e s m a y b e u s e d f or e x pl or at or y gr a p hi c al a n al y s e s of t h e 
p h ar m a c o d y n a mi c ( P D) d at a a n d p ar a m et er s.
5. 4. 2. 5
S e n siti vit y A n al y s e s f or S e c o n d ar y  E n d p oi nt s
D u e t o pr a cti c al c o n str ai nt s, p ati e nt s m a y r e c ei v e fir st st u d y tr e at m e nt a d a y p o st 
r a n d o mi z ati o n. S e n siti vit y a n al y s e s m a y
b e p erf or m e d o n t h e f oll o wi n g ti m e -t o-e v e nt 
vir ol o g y a n d effi c a c y s e c o n d ar y e n d p oi nt s, d efi n e d a s t h e ti m e fr o m r a n d o mi z ati o n t o 
m e e ti n g t h e e n d p oi nt:

Ti m e t o c e s s ati o n of S A R S -C o V -2 vir al s h e d di n g a s m e a s ur e d b y R T -P C R

Ti m e t o s u st ai n e d n o n -d et e ct a bl e S A R S -C o V -2 vir u s R N A

Ti m e t o all e vi ati o n or i m pr o v e m e nt of C O VI D -1 9 s y m pt o m s (It e m s 1 1 2 of t h e 
C O VI D -1 9 s y m pt o m di ar y) 

Ti m e t o all e vi ati o n of C O VI D -1 9 si g n s a n d s y m pt o m s


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 2
S e n siti vit y a n al y s e s m a y al s o b e p erf or m e d f or t h e f oll o wi n g ti m e -t o-e v e nt vir ol o g y 
s e c o n d ar y e n d p oi nt s w h er e r e s ult s r e p ort e d a s B L Q ar e tr e at e d a s p o siti v e (i n st e a d of 
n e g ati v e) :

Ti m e t o c e s s ati o n of S A R S -C o V -2 vir al s h e d di n g a s m e a s ur e d b y R T -P C R

Ti m e t o s u st ai n e d n o n -d et e ct a bl e S A R S -C o V -2 vir u s R N A
5. 5
E X P L O R A T O R Y E N D P OI N T S A N A L Y SI S
E x pl or at or y  Vir ol o g y E n d p oi nt A n al y s e s
T h e f oll o wi n g vir ol o g y e x pl or at or y e n d p oi nt s will b e c o m p ar e d b et w e e n e a c h A T -5 2 7 
d o s e gr o u p a n d t h e p o ol e d pl a c e b o gr o u p: 

Tr e at m e nt -e m er g e nt a mi n o a ci d s u b stit uti o n s i n S A R S -C o V -2 vir al g e n e s 
( n s p 1 2 a n d p ot e nti all y ot h er g e n e s)  

A nti -S A R S -C o V -2 a nti b o d y st at u s/tit er at s p e cifi e d ti m e p oi nt s

C h a n g e fr o m b a s eli n e i n S A R S -C o V -2 vir u s tit er at s p e cifi e d ti m e p oi nt s 

Ti m e t o c e s s ati o n of S A R S -C o V -2 vir al s h e d di n g a s m e a s ur e d b y vir u s tit er 

Pr o p orti o n of p ati e nt s wit h p o siti v e S A R S -C o V -2 vir u s tit er at s p e cifi e d 
ti m e p oi nt s 

A U C of S A R S -C o V -2 vir u s tit er 

Dr u g s u s c e pti bil it y i n p ati e nt s wit h e v al u a bl e vir u s at s p e cifi e d ti m e p oi nt s
P ol y m or p hi c a n d t r e at m e nt-e m er g e nt s u b stit uti o n s i n n s p 1 2 a n d p ot e nti all y ot h er g e n e s
will b e r e p ort e d d e s cri pti v el y, a n d t h e p er c e nt a g e of p ati e nt s wit h t h o s e vir al m ut ati o n s 
will b e c al c ul at e d.
E x pl or at or y e n d p oi nt s d efi n e d b y vir u s tit er will b e s u m m ari z e d u si n g d e s cri pti v e 
st ati sti c s si mil ar a s s p e cifi e d f or t h e s e c o n d ar y e n d p oi nt s d efi n e d b y S A R S - C o V-2 vir u s 
R N A. 
Dr u g s u s c e pti bilit y will b e r e p ort e d a s E C 5 0 v al u e s, a n d r e s p e cti v e f ol d-c h a n g e v al u e s 
(r ati o of E C5 0 s a m pl e / E C 5 0 r ef er e n c e) will b e c al c ul at e d fr o m t h o s e. A s u m m ar y of dr u g 
s u s c e pti bilit y wit h s u m m ar y st ati sti c s will b e pr o d u c e d at b a s eli n e ( a n d ot h er ti m e p oi nt s, 
if r e q uir e d), t o g et h er wit h a n i n di vi d u al p ati e nt li stin g of dr u g s u s c e pti bilit y.
E x pl or at or y  P h ar m a c o ki n eti c E n d p oi nt An al y s e s
T h e e x p o s ur e -r e s p o n s e pr ofil e of A T-5 1 1 a n d it s m aj or m et a b olit e s will b e e x pl or e d 
( e. g., r el ati o n s hi p b et w e e n pl a s m a c o n c e ntr ati o n of A T-2 7 3 a n d a nti vir al a cti vit y) a n d will 
b e r e p ort e d i n a st a n d al o n e d o c u m e nt s e p ar at e fr o m t h e C S R.
R e s pir at or y  C oi nf e cti o n s ( Bi ofir e)
All b a s eli n e ( n a s o p h ar y n g e al) s a m pl e s will b e t e st e d f or r e s pir at or y p at h o g e n s u si n g t h e 
q u alit ati v e P C R -b a s e d F D A cl e ar e d Bi o Fir e Fil m Arr a y ® R e s pir at or y P a n el 2 a s s a y. T hi s 




A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 4
F or all c o h ort s, if t h e d at a ar e a v ail a bl e i n a ti m el y m a n n er, t h e c h a n g e fr o m b a s eli n e i n 
S A R S -C o V -2 vir u s tit er ( S e cti o n 5. 5 ) will al s o b e d e s cri b ed.
D e m o gr a p hi c (i n cl u di n g, b ut n ot li mit e d t o, a g e, s e x a n d B MI) will b e s u m m ari z e d a s 
d e s cri b e d i n S e cti o n 5. 7. 3 .  A s u m m ar y will b e pr e s e nt e d b y tr e at m e nt gr o u p (i ncl u di n g a 
p o ol e d pl a c e b o gr o u p u p t o t h e c o h ort b ei n g a n al y z e d) a n d will b e pr e s e nt e d f or t h e 
mI T Ti p o p ul ati o n a n d m a y, i n a d diti o n, b e pr e s e nt e d f or t h e s af et y p o p ul ati o n. 
I n a d diti o n, s u m m ari e s of t h e pl a c e b o gr o u p s fr o m e a c h i n di vi d u al c o h ort u p t o t h e
c o h ort b ei n g a n al y z e d m a y
b e pr e s e nt e d.
If d e e m e d n e c e s s ar y, th e f oll o wi n g k e y s af et y d at a will b e pr o vi d e d f or t h e c urr e nt 
A T -5 2 7 gr o u p a n d a p o ol e d pl a c e b o gr o u p u p t o t h e c o h ort b ei n g a n al y z e d : 

All A E s

S eri o u s A E s

A E s l e a di n g t o d e at h

L a b or at or y a b n or m aliti e s
I n or d er t o a v oi d t h e ri s k of u n bli n di n g at p ati e nt l e v el b y t h e a n al y si s of i n di vi d u al s af et y 
d at a, s af et y r e pr e s e nt ati v es i n d e p e n d e nt t o t h e st u d y will b e d el e g at e d t o r e vi e w a n y 
s af et y li sti n g s.
5. 7. 2 
S u m m ari e s of C o n d u ct of St u d y
T h e n u m b er of p ati e nt s w h o ar e r a n d o mi z e d, e nr oll, di s c o nti n u e, or c o m pl et e t h e st u d y
will b e s u m m ari z e d. R e a s o n s f or pr e m at ur e st u d y di s c o nti n u ati o n will b e li st e d a n d
s u m m ari z e d u si n g a p o ol e d pl a c e b o gr o u p. T h e p o ol e d pl a c e b o gr o u p m a y al s o b e s plit 
b y c o h ort, if r e q uir e d.
Eli gi bilit y crit eri a a n d ot h er m aj or P D s will b e li st e d a n d s u m m ari z e d b y tr e at m e nt gr o u p.
5. 7. 3
S u m m ari e s of D e m o gr a p hi c s a n d B a s eli n e C h ar a ct eri sti c s
D e m o gr a p hi c a n d b a s eli n e c h ar a ct eri sti c s (i n cl u di n g, b ut n ot li mit e d t o, a g e, s e x, B MI , 
s elf -r e p ort ed r a c e/ et h ni cit y, o n s et of s y m pt o m s , b a s eli n e s y m pt o m s e v erit y , pr e s e n c e of 
u n d erl yi n g c o n diti o n s, a n d pr e -e xi sti n g s y m pt o m s ) will b e s u m m ari z e d u si n g m e a n s, 
S D s , m e di a n s, a n d r a n g e s f or c o nti n u o u s v ari a bl e s a n d pr o p orti o n s f or c at e g ori c al 
v ari a bl e s, a s a p pr o pri at e. A s u m m ar y will b e pr e s e nt e d b y tr e at m e nt gr o u p (i n cl u di n g a 
p o ol e d pl a c e b o gr o u p) a n d will b e pr e s e nt e d f or t h e mI T Ti p o p ul ati o n a n d m a y, i n 
a d diti o n , b e pr e s e nt e d f or t h e s af et y p o p ul ati o n. 
I n a d diti o n, s u m m ari e s of t h e pl a c e b o gr o u ps fr o m e a c h i n di vi d u al c o h ort will b e 
pr e s e nt e d t o all o w f or a hi g h -l e v el c o m p ari s o n of t h e p ati e nt s t o b e p o ol e d.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 5
M e di c al hi st or y d at a, i n cl u di n g s ur g er y a n d pr o c e d ur e s,
a n d b a s eli n e c o n diti o n s, will b e 
li st e d u si n g t h e s af et y p o p ul ati o n. Pr e vi o u s a n d c o n c o mit a nt tr e at m e nt s will b e 
s u m m ari z e d d e s cri pti v el y b y tr e at m e nt gr o u p.
Li sti n g s will al s o b e pr o vi d e d.
I n a d diti o n, t h er e will b e a s u m m ar y a n d li sti n g of all tr e at m e nt s wit h t h e i n di c ati o n gi v e n 
a s ‘ C O VI D -1 9’.
5. 8
I N T E RI M AN A L Y S E S 
5. 8. 1
Pl a n n e d I nt eri m A n al y s e s
A n i nt eri m s af et y a n al y si s i s pl a n n e d f or C o h ort A aft er t h e fir st 3 0 p ati e nt s h a v e 
c o m pl et e d a s s e s s m e nt s t hr o u g h D a y 1 0 t o all o w d et er mi n ati o n of t h e A T -5 2 7 d o s e a n d 
r e gi m e n f or C o h ort B. N o ot h er i nt eri m a n al y s e s ar e pl a n n e d.
T h e f oll o wi n g k e y s af et y d at a will b e pr o vi d e d f or t h e A T -5 2 7 gr o u p a n d pl a c e b o gr o u p: 

All A E s

S eri o u s A E s

A E s l e a di n g t o d e at h

L a b or at or y a b n or m aliti e s
I n or d er t o a v oi d t h e ri s k of u n bli n di n g at p ati e nt l e v el b y t h e a n al y si s of i n di vi d u al s af et y 
d at a, s af et y r e pr e s e nt ati v es i n d e p e n d e nt t o t h e st u d y will b e d el e g at e d t o r e vi e w t h e 
s af et y li sti n g s.
5. 8. 2
O pti o n al I nt eri m A n al y s e s
Gi v e n t h e h y p ot h e si s -g e n er ati n g n at ur e of t hi s st u d y, t h e S p o n s or m a y c h o o s e t o 
c o n d u ct a d diti o n al i nt eri m a n al y s e s (i. e., b e y o n d w h at i s s p e cifi e d i n t h e pr ot o c ol).  T h e 
d e ci si o n t o c o n d u ct a n o pti o n al i nt eri m a n al y si s a n d t h e ti mi n g of t h e a n al y si s will b e 
d o c u m e nt e d i n t h e S p o n s or' s tri al m a st er fil e p ri or t o t h e c o n d u ct of t h e i nt eri m a n al y si s.  
T h e i nt eri m a n al y si s will b e p erf or m e d a n d i nt er pr et e d b y m e m b er s of t h e S p o n s or ’ s
st u d y t e a m a n d a p pr o pri at e s e ni or m a n a g e m e nt p er s o n n el, w h o will b e u n bli n d e d at t h e 
tr e at m e nt gr o u p l e v el.  A c c e s s t o tr e at m e nt a s si g n m e nt i nf or m ati o n will f oll o w t h e 
S p o n s or' s st a n d ar d pr o c e d ur e s.
6.
S U P P O R TI N G D O C U M E N T A TI O N
A p p e n di x 1
C h a n g e s t o Pr ot o c ol -Pl a n n e d A n al y s e s
T hi s s e cti o n i s n ot a p pli c a bl e, si n c e t h er e ar e n o c h a n g e s t o pr ot o c ol -pl a n n e d a n al y s e s.


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 6
A p p e n di x 2
C O VI D -1 9 S y m pt o m Di ar y  a n d P ati e nt Gl o b al 
I m pr e s si o n of S e v erit y
D o n ot r e pr o d u c e or di stri b ut e .  T h e S p o n s or will pr o vi d e sit e s wit h 
all i n str u m e nt s t o b e c o m pl et e d i n t hi s st u d y .
N ot e t h at t h e f oll o wi n g i s a s a m pl e.  Sit e s will b e pr o vi d e d wit h s e p ar at e v er si o n s of t h e 
di ar y f or D a y s 11 4 ( m or ni n g v s. e v e ni n g, i n cl u di n g r e c or di n g of t e m p er at ur e) a n d D a y s 
1 5 2 8 ( e v e ni n g, i n cl u di n g r e c or di n g of t e m p er at ur e).
T o d a y' s d at e: _ _ _ _ _ _ _ _ _ _ _   Ti m e c o m pl eti n g: _ _ _ _ _ _ _ _ _ _ _
C O VI D -1 9 E v e ni n g S y m pt o m Di ar y
T hi s di ar y will k e e p tr a c k of y o ur C O VI D -1 9 s y m pt o m s a n d t e m p er at ur e d uri n g t h e st u d y. 
Pl e a s e c o m pl et e t hi s di ar y b ef or e y o u g o t o b e d e a c h e v e ni n g. F or e a c h s y m pt o m, 
pl e a s e ti c k t h e b o x t h at b e st d e s cri b e s y o ur e x p eri e n c e.
Pl e a s e r at e t h e s e v erit y of e a c h s y m pt o m at it s w or st si n c e y o u g ot u p t hi s m or ni n g.
N o n e
Mil d
M o d er at e
S e v er e
1. N a s al c o n g e sti o n or r u n n y n o s e
2. S or e t hr o at
3. C o u g h
4. S h ort n e s s of br e at h
( diffi c ult y br e at hi n g)
5. A c h e s a n d p ai n s
6. F ati g u e (tir e d n e s s)
7. H e a d a c h e
8. C hill s/ S w e at s 
9. F e eli n g h ot or f e v eri s h
1 0. N a u s e a ( w a nti n g t o t hr o w u p)
1 1. V o miti n g (t hr o w n u p)
1 2. Di arr h e a ( m o stl y  or c o m pl et el y 
li q ui d b o w el m o v e m e nt s)


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 7
A p p e n di x 2
C O VI D -1 9 S y m pt o m Di ar y  a n d P ati e nt Gl o b al 
I m pr e s si o n of S e v erit y ( c o nt.)
S a m e a s u s u al / n o c h a n g e 
N ot a s g o o d a s u s u al / 
n o s e n s e
1 3. R at e y o ur s e n s e of s m ell si n c e 
y o u g ot u p t hi s m or ni n g.
1 4. R at e y o ur s e n s e of t a st e si n c e 
y o u g ot u p t hi s m or ni n g.
P ati e nt Gl o b al I m pr e s si o n of S e v erit y
Pl e a s e r at e y o ur o v er all C O VI D -1 9 s y m pt o m s at t h eir w or st si n c e y o u g ot u p t hi s 
m or ni n g.
☐
N o n e
☐
Mil d
☐
M o d er at e 
☐
S e v er e


A T -5 2 7 — F. H off m a n n -L a R o c h e Lt d a n d At e a P h ar m a c e uti c al s, I n c.
St ati sti c al A n al y si s Pl a n W V 4 3 0 4 2
3 8
7.
R E F E R E N C E S
Fi s c h er W A, Er o n J J, H ol m a n W , et al. M ol n u pir a vir, a n Or al A nti vir al Tr e at m e nt f or 
C O VI D -1 9. m e d R xi v ; 2 0 2 1 . d oi: htt p s:// d oi. or g/ 1 0. 1 1 0 1/ 2 0 2 1. 0 6. 1 7. 2 1 2 5 8 6 3 9.